MALT1 modulators and uses thereof
By designing specific compounds to regulate the activity of MALT1 protein, it solves the problem of difficult to effectively treat autoimmune and inflammatory diseases and related cancers in the prior art, and provides an effective treatment plan.
Patent Information
- Application Number
- CN202380030626.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-31
- Filing Date
- 2023-03-30
- Publication Date
- 2024-11-26
AI Technical Summary
The prior art is difficult to effectively regulate the activity of the MALT1 protein, resulting in challenges in the treatment of autoimmune and inflammatory diseases and related cancers.
A class of compounds is designed to regulate their activity by acting on MALT1 for the treatment of autoimmune and inflammatory diseases, as well as related cancers. These compounds include specific chemical structures, such as compounds represented by formula (I), formula (Ia) and formula (Ib) and their salts, for administration as pharmaceutical compositions.
These compounds can effectively regulate the activity of the MALT1 protein and are used to treat autoimmune and inflammatory diseases, as well as related cancers, providing potential therapeutic options.
Smart Images

Figure BDA0005061276580000011 
Figure BDA0005061276580000021 
Figure BDA0005061276580000022
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 63 / 325,852, filed on March 31, 2022, the entire disclosure of which is hereby incorporated by reference in its entirety for all purposes. Background Art
[0003] Mucosa-associated lymphoid tissue lymphoma transporter 1 (MALT1) is an intracellular signaling protein known to be derived from innate immune cells (e.g., natural killer cells NK, dendritic cells DC and mast cells) and adaptive immune cells (e.g., T cells and B cells). MALT1 plays an important role in influencing immune responses. For example, in T cell receptor signaling, MALT1 mediates nuclear factor κΒ (NFKB) signaling, thereby causing T cell activation and proliferation. Therefore, MALT1 is meaningful in the mechanisms of autoimmunity and inflammatory pathology. In addition, constitutive (dysregulated) MALT1 activity is associated with cancers such as MALT lymphoma and activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL). Regulators of MALT1 activity can be used as potential therapeutic agents. Summary of the invention
[0004] Provided herein are compounds designed to act as MALT1 modulators. In some embodiments, it is contemplated that such compounds may be used as therapeutic agents for the treatment of autoimmune and inflammatory diseases, disorders or conditions, or cancer.
[0005] In one aspect, provided herein are compounds represented by formula (I):
[0006]
[0007] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0008] R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where R 1 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0009] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ;
[0010] R 3 is hydrogen or C 1-3 alkyl;
[0011] R 1a is independently hydroxyl or -OC 1-3 alkyl;
[0012] R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl;
[0013] Z is -C(H)(R A )-、-SO 2 -or-NR A -;
[0014] R A Yes-C(O)C 1-6 Alkyl, -C(O)OH or 5-6 membered heteroaryl;
[0015] m is 0 or 1; and
[0016] n is 0 or 1.
[0017] In another aspect, provided herein is a compound represented by formula (Ia)
[0018]
[0019] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0020] R 1 Selected from C 1-6 Alkyl, C 1-3 A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0021] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a;
[0022] R 1a is independently hydroxyl or -OC 1-3 Alkyl; and
[0023] R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl.
[0024] In another aspect, provided herein is a compound represented by formula (Ib)
[0025]
[0026] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0027] R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0028] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0029] m is 0 or 1; and
[0030] n is 0 or 1.
[0031] In another aspect, provided herein is a compound represented by formula (Ic)
[0032]
[0033] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0034] R 1 It is C 1-6 Alkyl or C 1-3 haloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0035] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0036] R 4 is -C(O)OH or a 5-6 membered heteroaryl;
[0037] m is 0 or 1; and
[0038] n is 0 or 1.
[0039] In some embodiments, the compounds provided herein are selected from the compounds shown in Table 1 or a pharmaceutically acceptable salt thereof.
[0040] In another aspect, provided herein is a pharmaceutical composition comprising a compound disclosed herein and a pharmaceutically acceptable carrier.
[0041] In another aspect, provided herein is a method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound or stereoisomer and / or pharmaceutical composition disclosed herein.
[0042] In another aspect, provided herein is a method of treating an autoimmune or inflammatory disorder or disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound or pharmaceutical composition disclosed herein. DETAILED DESCRIPTION
[0043] As generally described herein, the present invention provides compounds designed, for example, to act as MALT1 modulators. In certain embodiments, it is contemplated that such compounds may be used as therapeutic agents for the treatment of autoimmune and inflammatory diseases, disorders or conditions, or cancer.
[0044] definition
[0045] Chemical Definition
[0046] The definitions of specific functional groups and chemical terms are described in more detail below. Chemical elements are identified according to the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75th edition, inside cover, and specific functional groups are generally defined as described herein. In addition, general principles of organic chemistry as well as specific functional moieties and reactivities are described in Thomas Sorrell, Organic Chemistry, University Science Books, Sausalito, 1999; Smith and March, March's Advanced Organic Chemistry, 5th ed., John Wiley & Sons, Inc., New York, 2001; Larock, Comprehensive Organic Transformations, VCH Publishers, Inc., New York, 1989; and Carruthers, Some Modern Methods of Organic Synthesis, 3rd ed., Cambridge University Press, Cambridge, 1987.
[0047] It is understood that compounds having the same molecular formula but differing in the nature or order of bonding of their atoms or in the spatial arrangement of their atoms are referred to as "isomers". Isomers with different spatial arrangements of atoms are referred to as "stereoisomers". Stereoisomers that are not mirror images of each other are referred to as "diastereomers", while stereoisomers that are non-superimposable mirror images of each other are referred to as "enantiomers". When a compound has an asymmetric center, for example, bonded to four different groups, a pair of enantiomers is possible. An enantiomer can be characterized by the absolute configuration of its asymmetric center and described by the R- and S-sequencing rules of Cahn and Prelog, or by the way in which the molecule rotates the plane of polarized light and is designated as right-handed or left-handed (i.e., (+) or (-)-isomers, respectively). Chiral compounds can exist as individual enantiomers or as mixtures thereof. A mixture containing equal proportions of enantiomers is referred to as a "racemic mixture".
[0048] The compounds described herein may include one or more asymmetric centers and may therefore exist in various isomeric forms, e.g., enantiomers and / or diastereomers. For example, the compounds described herein may be in the form of individual enantiomers, diastereomers, or geometric isomers, or may be in the form of stereoisomer mixtures, including racemic mixtures and mixtures enriched in one or more stereoisomers. Isomers may be separated from mixtures by methods known to those skilled in the art, including chiral high pressure liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers may be prepared by asymmetric synthesis. See, e.g., Jacques et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen et al., Tetrahedron 33:2725 (1977); Eliel, Stereochemistry of Carbon Compounds (McGraw-Hill, NY, 1962); and Eliel, Tables of Resolving Agents and Optical Resolutions, p. 268 (EL Eliel, ed., Univ. of Notre Dame Press, Notre Dame, IN 1972). The present invention additionally encompasses the compounds described herein as individual isomers substantially free of other isomers and alternatively as mixtures of various isomers.
[0049] As used herein, a pure enantiomer compound is substantially free of other enantiomers or stereoisomers of the compound (i.e., enantiomeric excess). In other words, the "S" form of the compound is substantially free of the "R" form of the compound, and is therefore in enantiomeric excess relative to the "R" form. The term "enantiomerically pure" or "pure enantiomer" means that the compound includes more than 75% by weight, more than 80% by weight, more than 85% by weight, more than 90% by weight, more than 91% by weight, more than 92% by weight, more than 93% by weight, more than 94% by weight, more than 95% by weight, more than 96% by weight, more than 97% by weight, more than 98% by weight, more than 98.5% by weight, more than 99% by weight, more than 99.2% by weight, more than 99.5% by weight, more than 99.6% by weight, more than 99.7% by weight, more than 99.8% by weight, or more than 99.9% by weight of the enantiomer. In certain embodiments, weights are based on the total weight of all enantiomers or stereoisomers of the compound.
[0050] In the compositions provided herein, enantiomerically pure compounds may be present with other active or inactive ingredients. For example, a pharmaceutical composition comprising an enantiomerically pure R-compound may include, for example, about 90% excipients and about 10% enantiomerically pure R-compounds. In certain embodiments, the enantiomerically pure R-compound in such a composition may, for example, include at least about 95% by weight of the R-compound and up to about 5% by weight of the S-compound by total weight of the compound. For example, a pharmaceutical composition comprising an enantiomerically pure S-compound may include, for example, about 90% excipients and about 10% enantiomerically pure S-compounds. In certain embodiments, the enantiomerically pure S-compound in such a composition may, for example, include at least about 95% by weight of the S-compound and up to about 5% by weight of the R-compound by total weight of the compound. In certain embodiments, the active ingredient may be formulated with little or no excipient or carrier.
[0051] The compounds described herein may also include one or more isotopic substitutions. For example, H may be in any isotopic form, including 1 H. 2 H (D or deuterium) and 3 H (T or tritium); C can be in any isotopic form, including 12 C. 13 C and 14 C; O can be in any isotopic form, including 16 O and 18 O; F can be in any isotopic form, including 18 F and 19 F; etc.
[0052] The following terms are intended to have the meaning presented below, and can be used to understand the description and expected scope of the present invention. When describing the present invention, the present invention may include compounds and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such compounds, and methods of using such compounds and compositions, unless otherwise specified, the following terms, if present, have the following meanings. It should also be understood that when described herein, any part defined below can be substituted by various substituents, and the corresponding definition is intended to include such substituted parts within its scope as described below. Unless otherwise specified, the term "substituted" will be defined as described below. It should also be understood that when used in this article, the term "group (group / radical)" can be considered interchangeable. The article "a / an" can be used herein to refer to one or more than one (i.e., at least one) grammatical object of the article. As an example, "analog" means an analog or more than one analog.
[0053] When a range of values is listed, it is intended to include every value and sub-range within the range. For example, "C 1–6 The term "alkyl" is intended to encompass C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 1–6 , C 1–5 , C 1–4 , C 1–3 , C 1–2 , C 2–6 , C 2–5 , C 2–4 , C 2–3 , C 3–6 , C 3–5 , C 3–4 , C 4–6 , C 4–5 and C 5–6 alkyl.
[0054] As used herein, "alkyl" refers to, for example, a straight or branched chain saturated hydrocarbon group ("C 1–20 In some embodiments, an alkyl group has 1 to 10 carbon atoms (“C 1-10 In some embodiments, an alkyl group has 1 to 9 carbon atoms (“C 1-9 In some embodiments, an alkyl group has 1 to 8 carbon atoms (“C 1-8 In some embodiments, an alkyl group has 1 to 7 carbon atoms (“C 1-7 In some embodiments, an alkyl group has 1 to 6 carbon atoms (“C 1-6In some embodiments, an alkyl group has 1 to 5 carbon atoms (“C 1-5 In some embodiments, an alkyl group has 1 to 4 carbon atoms (“C 1-4 In some embodiments, an alkyl group has 1 to 3 carbon atoms (“C 1-3 In some embodiments, an alkyl group has 1 to 2 carbon atoms (“C 1-2 In some embodiments, an alkyl group has 1 carbon atom (“C 1 C 1–6 Examples of the alkyl group include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, hexyl and the like.
[0055] As used herein, "alkenyl" refers to a straight or branched chain hydrocarbon group ("C-carbon" or "C-carbon-carbon-alkyl") having 2 to 20 carbon atoms, one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds), and optionally one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds). 2–20 In some embodiments, an alkenyl group does not contain any triple bonds. In some embodiments, an alkenyl group has 2 to 10 carbon atoms (“C 2-10 In some embodiments, an alkenyl group has 2 to 9 carbon atoms (“C 2-9 In some embodiments, an alkenyl group has 2 to 8 carbon atoms (“C 2-8 In some embodiments, an alkenyl group has 2 to 7 carbon atoms (“C 2-7 In some embodiments, an alkenyl group has 2 to 6 carbon atoms (“C 2-6 In some embodiments, an alkenyl group has 2 to 5 carbon atoms (“C 2-5 In some embodiments, an alkenyl group has 2 to 4 carbon atoms (“C 2-4 In some embodiments, an alkenyl group has 2 to 3 carbon atoms (“C 2-3 In some embodiments, an alkenyl group has 2 carbon atoms (“C 2 The one or more carbon-carbon double bonds may be internal (such as in 2-butenyl) or terminal (such as in 1-butenyl). 2-4 Examples of alkenyl groups include vinyl (C 2 ), 1-propenyl (C 3 ), 2-propenyl (C 3 ), 1-butenyl (C 4 ), 2-butenyl (C 4 ), butadiene (C 4 ) etc. 2-6 Examples of alkenyl groups include the aforementioned C2-4 Alkenyl and pentenyl (C 5 ), pentadienyl (C 5 ), hexenyl (C 6 ) etc. Other examples of alkenyl groups include heptenyl (C 7 ), octenyl (C 8 ), octatrienyl (C 8 )wait.
[0056] As used herein, "alkynyl" refers to a straight or branched chain hydrocarbon group ("C alkyl" or "alkynyl") having 2 to 20 carbon atoms, one or more carbon-carbon triple bonds (e.g., 1, 2, 3, or 4 carbon-carbon triple bonds), and optionally one or more carbon-carbon double bonds (e.g., 1, 2, 3, or 4 carbon-carbon double bonds). 2–20 In some embodiments, an alkynyl group does not contain any double bonds. In some embodiments, an alkynyl group has 2 to 10 carbon atoms (“C 2-10 In some embodiments, an alkynyl group has 2 to 9 carbon atoms (“C 2-9 In some embodiments, an alkynyl group has 2 to 8 carbon atoms (“C 2-8 In some embodiments, an alkynyl group has 2 to 7 carbon atoms (“C 2-7 In some embodiments, an alkynyl group has 2 to 6 carbon atoms (“C 2-6 In some embodiments, an alkynyl group has 2 to 5 carbon atoms (“C 2-5 In some embodiments, an alkynyl group has 2 to 4 carbon atoms (“C 2-4 In some embodiments, an alkynyl group has 2 to 3 carbon atoms (“C 2-3 In some embodiments, an alkynyl group has 2 carbon atoms (“C 2 The one or more carbon-carbon triple bonds may be internal (such as in 2-butynyl) or terminal (such as in 1-butynyl). 2-4 Examples of alkynyl groups include, but are not limited to, ethynyl (C 2 ), 1-propynyl (C 3 ), 2-propynyl (C 3 ), 1-butynyl (C 4 ), 2-butynyl (C 4 ) etc. 2-6 Examples of alkenyl groups include the aforementioned C 2-4 Alkynyl and pentynyl (C 5 ), hexynyl (C 6 ) and the like. Other examples of alkynyl groups include heptynyl (C 7 ), octynyl (C 8 )wait.
[0057] As used herein, "alkylene," "alkenylene," "alkynylene," "cycloalkylene," "heterocyclylene," "heteroarylene," and "phenylene" refer to divalent radicals of alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl (e.g., saturated and partially saturated), heteroaryl, and phenyl, respectively.
[0058] When a range or number of carbons is provided for a particular "alkylene," "alkenylene," or "alkynylene," it is understood that the range or number refers to the range or number of carbons in a linear carbon divalent chain. "Alkylene," "alkenylene," and "alkynylene" may be substituted or unsubstituted with one or more substituents as described herein.
[0059] As used herein, "aryl" refers to a group having 6 to 14 ring carbon atoms and zero heteroatoms provided in the aromatic ring system, a monocyclic or polycyclic (e.g., bicyclic or tricyclic) 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π electrons in common in the ring array) ("C 6–14 In some embodiments, an aryl group has six ring carbon atoms (“C 6 In some embodiments, an aryl group has ten ring carbon atoms (“C 10 In some embodiments, an aryl group has fourteen ring carbon atoms (“C 14 Typical aryl groups include, but are not limited to, groups derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, hexabenzophenone, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as-indacene, s-indacene, indane, indene, naphthalene, octacene, o-indacene, oct ... The aryl groups include phenyl, naphthyl and indenyl.
[0060] As used herein, "heteroaryl" refers to a radical of a 5-10 membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6 or 10 electrons shared in the ring array) having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen and sulfur ("5-10 membered heteroaryl"). In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom when valence permits. Heteroaryl bicyclic ring systems can contain one or more heteroatoms in one or both rings. "Heteroaryl" also includes ring systems in which a heteroaryl ring as defined above is fused to one or more aryl groups, wherein the point of attachment is on the aryl or heteroaryl ring, and in this case, the number of ring members refers to the number of ring members in the fused (aryl / heteroaryl) ring system. For bicyclic heteroaryl groups in which one ring does not contain heteroatoms (e.g., indolyl, quinolyl, carbazolyl, etc.), the point of attachment can be on either ring, i.e., the ring with the heteroatom (e.g., 2-indolyl) or the ring without the heteroatom (e.g., 5-indolyl).
[0061] In some embodiments, heteroaryl is a 5-10 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-10 membered heteroaryl”). In some embodiments, heteroaryl is a 5-8 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heteroaryl”). In some embodiments, heteroaryl is a 5-6 membered aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms provided in the aromatic ring system, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heteroaryl”). In some embodiments, 5-6 membered heteroaryl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, 5-6 membered heteroaryl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heteroaryl has 1 ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0062] Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thienyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl, and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl. Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepine, oxacycloheptenyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazole, benzothiazolyl, benzisothiazole, benzothiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, piperidinyl, quinolyl, isoquinolyl, quinolyl, quinoxalinyl, phthalazinyl, and quinazolinyl.
[0063] Examples of representative heteroaryl groups include the following:
[0064]
[0065] wherein each Z is selected from carbonyl, N, NR 65 , O and S; and R 65 are independently hydrogen, C 1-8 Alkyl, C 3-10 Carbocyclic group, 4-10 membered heterocyclic group, C 6 -C 10 Aryl and 5-10 membered heteroaryl.
[0066] As used herein, "carbocyclyl" or "carbocycle" refers to a non-aromatic ring system having 3 to 10 ring carbon atoms ("C 3–10 In some embodiments, the carbocyclyl group has 3 to 8 ring carbon atoms ("C 3-8 In some embodiments, a carbocyclyl group has 3 to 7 ring carbon atoms (“C 3-7 In some embodiments, a carbocyclyl group has 3 to 6 ring carbon atoms (“C 3-6 In some embodiments, a carbocyclyl group has 5 to 10 ring carbon atoms (“C 5-10 Exemplary C 3–6Carbocyclic groups include but are not limited to cyclopropyl (C 3 ), cyclobutyl (C 4 ), cyclobutenyl (C 4 ), cyclopentyl (C 5 ), cyclopentenyl (C 5 ), cyclohexyl (C 6 ), cyclohexenyl (C 6 ), cyclohexadienyl (C 6 ) etc. Exemplary C 3-8 Carbocyclic groups include but are not limited to the aforementioned C 3-6 Carbocyclic groups, and cycloheptyl (C 7 ), cycloheptenyl (C 7 ), cycloheptadienyl (C 7 ), cycloheptatrienyl (C 7 ), cyclooctyl (C 8 ), cyclooctenyl (C 8 ), bicyclo[2.2.1]heptyl(C 7 ), bicyclo[2.2.2]octyl(C 8 ) etc. Exemplary C 3–10 Carbocyclic groups include but are not limited to the above C 3–8 Carbocyclic and cyclononyl (C 9 ), cyclononenyl (C 9 ), cyclodecyl (C 10 ), cyclodecenyl (C 10 ), octahydro-1H-indenyl (C 9 ), decahydronaphthyl (C 10 ), spiro[4.5]decyl (C 10 ) etc. As illustrated by the foregoing examples, in certain embodiments, the carbocyclyl is a monocyclic ring ("monocyclic carbocyclyl") or contains a fused, bridged or spiro ring system, such as a bicyclic ring system ("bicyclic carbocyclyl") and can be saturated or can be partially unsaturated.
[0067] The term "cycloalkyl" refers to a monovalent saturated cyclic, bicyclic or bridged cyclic (e.g., adamantyl) hydrocarbon group having 3-12, 3-8, 4-8 or 4-6 carbon atoms, such as a "C" alkyl group derived from a cycloalkane. 4-8 Exemplary cycloalkyl groups include, but are not limited to, cyclohexane, cyclopentane, cyclobutane, and cyclopropane.
[0068] As used herein, “C 3-6 "Monocyclic cycloalkyl" or "monocyclic C 3-6"Cycloalkyl" refers to a saturated 3- to 7-membered monocyclic hydrocarbon ring system. 3- to 7-membered monocyclic cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. When specified as optionally substituted or unsubstituted, the substituents on the cycloalkyl group (e.g., in the case of optionally substituted cycloalkyl groups) may be present at any substitutable position, and include, for example, the position at which the cycloalkyl group is attached.
[0069] As used herein, "heterocyclyl" or "heterocycle" refers to a radical of a 3- to 10-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus and silicon ("3-10 membered heterocyclyl"). In heterocyclyls containing one or more nitrogen atoms, the point of attachment may be a carbon or nitrogen atom when valence permits. A heterocyclyl may be a monocyclic ring ("monocyclic heterocyclyl") or a fused, bridged or spirocyclic ring system, such as a bicyclic ring system ("bicyclic heterocyclyl"), and may be saturated or may be partially unsaturated. Heterocyclyl bicyclic ring systems may contain one or more heteroatoms in one or both rings. "Heterocyclyl" also includes ring systems in which a heterocyclyl ring as defined above is fused to one or more carbocyclyls, wherein the point of attachment is on the carbocyclyl or heterocyclyl ring; or a heterocyclyl ring as defined above is fused to one or more aryl or heteroaryl groups, wherein the point of attachment is on the heterocyclyl ring, and in such cases the number of ring members continues to refer to the number of ring members in the heteroaryl ring system. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" may be used interchangeably.
[0070] In some embodiments, heterocyclyl is a 4-7 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“4-7 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-10 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon (“5-10 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-8 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-8 membered heterocyclyl”). In some embodiments, heterocyclyl is a 5-6 membered non-aromatic ring system having ring carbon atoms and 1-4 ring heteroatoms, wherein each heteroatom is independently selected from nitrogen, oxygen, and sulfur (“5-6 membered heterocyclyl”). In some embodiments, 5-6 membered heterocyclyl has 1-3 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has 1-2 ring heteroatoms selected from nitrogen, oxygen, and sulfur. In some embodiments, the 5-6 membered heterocyclyl has one ring heteroatom selected from nitrogen, oxygen, and sulfur.
[0071] Exemplary 3-membered heterocyclic groups containing one heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclic groups containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclic groups containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, dihydrothienyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione. Exemplary 5-membered heterocyclic groups containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclic groups containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclic groups containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclic groups containing two heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclic groups containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 8-membered heterocyclic groups containing one heteroatom include, but are not limited to, azocanyl, oxecanyl, and thiocanyl. 6 Exemplary 5-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 5,6-bicyclic heterocycle) include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, benzoxazolinonyl, etc. Exemplary 6-membered heterocyclyl groups fused to an aryl ring (also referred to herein as a 6,6-bicyclic heterocycle) include, but are not limited to, tetrahydroquinolinyl, tetrahydroisoquinolinyl, etc.
[0072] Examples of such saturated or partially unsaturated heterocyclyl groups include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, pyrrolidinyl, pyridonyl, pyrrolidinonyl, piperidinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, morpholinyl, dihydrofuranyl, dihydropyranyl, dihydropyridinyl, tetrahydropyridinyl, dihydropyrimidinyl, oxetanyl, azetidinyl, and tetrahydropyrimidinyl. When specified as optionally substituted or unsubstituted, the substituents on the heterocyclyl group (e.g., in the case of an optionally substituted heterocyclyl group) may be present at any substitutable position, and include, for example, the position at which the heterocyclyl group is attached.
[0073] When used to describe a compound or a group present on a compound, "hetero" means that one or more carbon atoms in the compound or group have been replaced by nitrogen, oxygen or sulfur atoms. Hetero can be applied to any of the above hydrocarbon groups, such as alkyl, for example heteroalkyl; carbocyclic, for example heterocyclic; aryl, for example heteroaryl; and similar groups having 1 to 5, especially 1 to 3 heteroatoms.
[0074] As used herein, "cyano" refers to -CN.
[0075] As used herein, the term "halo" and "halogen" refer to an atom selected from fluorine (fluoro, -F), chlorine (chloro, -Cl), bromine (bromo, -Br) and iodine (iodo, -I). In certain embodiments, the halo group is fluorine or chlorine.
[0076] As used herein, the term "alkoxy" refers to an alkyl group attached to another moiety through an oxygen atom (-O(alkyl)). Non-limiting examples include, for example, methoxy, ethoxy, propoxy, and butoxy.
[0077] "Haloalkoxy" is a haloalkyl group attached to another moiety through an oxygen atom, such as but not limited to -OCHF 2 or -OCF 3 .
[0078] The term "haloalkyl" includes monohaloalkyl, polyhaloalkyl and perhaloalkyl substituted with one or more halogen atoms, wherein the halogen is independently selected from fluorine, chlorine, bromine and iodine. 1-4 Halogenated alkyl-OC 1-4 Alkyl, the point of attachment occurs on the halogenated alkyl portion.
[0079] As used herein, "oxo" refers to -C=O.
[0080] In general, the term "substituted", whether or not preceded by the term "optionally", means that at least one hydrogen present on a group (e.g., a carbon or nitrogen atom) is replaced with a permissible substituent, such as a substituent that, upon substitution, results in a stable compound, such as a compound that does not spontaneously undergo transformation (e.g., by rearrangement, cyclization, elimination, or other reaction). Unless otherwise specified, a "substituted" group has a substituent at one or more substitutable positions of the group, and when more than one position in any given structure is substituted, the substituent may be the same or different at each position.
[0081] The nitrogen atoms may be substituted or unsubstituted where valence permits, and include primary, secondary, tertiary, and quaternary nitrogen atoms. Exemplary nitrogen atom substituents include, but are not limited to, hydrogen, -OH, -OR aa , –N(R cc ) 2 、–CN、–C(=O)R aa , –C(=O)N(R cc ) 2 , –CO 2 R aa ,–SO 2 R aa , –C(=NR bb )R aa , –C(=NR cc )OR aa , –C(=NR cc )N(R cc ) 2 ,–SO 2 N(R cc ) 2 ,–SO 2 R cc ,–SO 2 OR cc , –SOR aa , –C(=S)N(R cc ) 2 、–C(=O)SR cc , –C(=S)SR cc , –P(=O) 2 R aa , –P(=O)(R aa ) 2 , –P(=O) 2 N(R cc ) 2 , –P(=O)(NR cc ) 2 , C 1–10 Alkyl, C 1-10 Perhaloalkyl, C 2-10 Alkenyl, C2-10 Alkynyl, C 3-10 Carbocyclic group, 3-14 membered heterocyclic group, C 6-14 Aryl and 5-14 membered heteroaryl, or two R groups connected to the nitrogen atom cc The groups are connected to form a 3-14 membered heterocyclyl or 5-14 membered heteroaryl ring, wherein each alkyl, alkenyl, alkynyl, carbocyclyl, heterocyclyl, aryl and heteroaryl group is independently substituted by 0, 1, 2, 3, 4 or 5 R dd group substituted, and wherein R aa , R bb , R cc and R dd As defined above.
[0082] These and other exemplary substituents are described in more detail in the Detailed Description, Examples, and Claims.The present invention is not intended to be limited in any way by the exemplary list of substituents set forth above.
[0083] Other definitions
[0084] As used herein, "pharmaceutically acceptable carrier" refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound formulated with it. Pharmaceutically acceptable carriers, adjuvants or vehicles that can be used in the compositions described herein include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances, such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulosic substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene glycol-polyoxypropylene block polymers, polyethylene glycol and lanolin.
[0085] As used herein, "pharmaceutically acceptable salts" refer to those salts suitable for contact with tissues of humans and lower animals without excessive toxicity, irritation, allergic response, etc. and commensurate with a reasonable benefit / risk ratio within the scope of reasonable medical judgment. Pharmaceutically acceptable salts are well known in the art. For example, Berge describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds of the present invention include salts derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts formed of amino groups with inorganic acids (such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid) or organic acids (such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid), or salts formed by using other methods used in the art (such as ion exchange). Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Pharmaceutically acceptable salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 alkyl) 4 Salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. Additional pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium and amine cations formed using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, lower alkyl sulfonates and aryl sulfonates, where appropriate.
[0086] As used herein, a "subject" to which administration is contemplated includes, but is not limited to, humans (i.e., males or females of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or non-human animals, e.g., mammals, such as primates (e.g., cynomolgus monkeys, rhesus monkeys), cattle, pigs, horses, sheep, goats, rodents, cats, and / or dogs. In certain embodiments, the subject is a human. In certain embodiments, the subject is a non-human animal. The terms "human," "patient," and "subject" are used interchangeably herein.
[0087] Disease, disorder and condition are used interchangeably herein.
[0088] As used herein, and unless otherwise indicated, the terms "treat," "treating," and "treatment" contemplate actions taken while a subject has a specified disease, disorder, or condition to reduce the severity of the disease, disorder, or condition, or to delay or slow the progression of the disease, disorder, or condition ("therapeutic treatment"), and also contemplate actions taken before a subject begins to have a specified disease, disorder, or condition ("prophylactic treatment").
[0089] As used herein, an "effective amount" of a compound refers to an amount sufficient to elicit a desired biological response. As will be appreciated by one of ordinary skill in the art, the effective amount of a compound of the invention may vary depending on factors such as the desired biological endpoint, the pharmacokinetics of the compound, the disease being treated, the mode of administration, and the age, health, and condition of the subject. An effective amount encompasses both therapeutic and prophylactic treatments.
[0090] As used herein, and unless otherwise indicated, a "therapeutically effective amount" of a compound is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or an amount sufficient to delay or minimize one or more symptoms associated with a disease, disorder, or condition. A therapeutically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of a disease, disorder, or condition. The term "therapeutically effective amount" can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0091] Compound
[0092] In one aspect, provided herein are compounds represented by formula (I):
[0093]
[0094] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0095] R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where R 1 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0096] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ;
[0097] R 3 is hydrogen or C 1-3 alkyl;
[0098] R 1a is independently hydroxyl or -OC 1-3 alkyl;
[0099] R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl;
[0100] Z is -C(H)(R A )-、-SO 2 -or-NR A -;
[0101] R A Yes-C(O)C 1-6 Alkyl, -C(O)OH or 5-6 membered heteroaryl;
[0102] m is 0 or 1; and
[0103] n is 0 or 1.
[0104] In some embodiments, the compound is represented by formula (I'):
[0105]
[0106] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0107] R 1 Select from the group consisting of: C1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where R 1 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0108] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ;
[0109] R 3 is hydrogen or C 1-3 alkyl;
[0110] R 1a is independently hydroxyl or -OC 1-3 alkyl;
[0111] R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl;
[0112] Z is -C(H)(R A )-、-SO 2 -or-NR A -;
[0113] R A Yes-C(O)C 1-6 Alkyl, -C(O)OH or 5-6 membered heteroaryl;
[0114] m is 0 or 1; and
[0115] n is 0 or 1.
[0116] In some embodiments, R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -OC 1-3 Alkyl substitution.
[0117] In some embodiments, R 1 Select from the group consisting of: C1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -O-CH 3 replace.
[0118] In some embodiments, R 1 Selected from the group consisting of: -CH(CH 3 ) 2 CF 3 , cyclopropyl, phenyl,
[0119] In some embodiments, R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, C 1-6 Alkyl or -OC 1-3 Alkyl substitution.
[0120] In some embodiments, R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0121] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0122] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0123] In some embodiments, R 2 It is C 1-6 Alkyl or aryl, where C 1-6 Alkyl and aryl groups are replaced by hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0124] In some embodiments, R 2 It is C 1-6 Alkyl or phenyl, where C 1-6 Alkyl or phenyl groups are replaced by hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0125] In some embodiments, R 2 Select from the group consisting of:
[0126] In some embodiments, R 2 Select from the group consisting of:
[0127] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0128] In some embodiments, R 3 is hydrogen or CH 3 In some embodiments, R 3 Yes CH 3 .
[0129] In some embodiments, Z is -SO 2 -.
[0130] In some embodiments, m is 1 and n is 1.
[0131] In some embodiments, Z is -NR A -.
[0132] In some embodiments, m is 0 and n is 0. In some embodiments, m is 1 and n is 1.
[0133] In some embodiments, R A Yes-C(O)C 1-6In some embodiments, R A is -C(O)CH 3 .
[0134] In some embodiments, Z is -C(H)(R A )-.
[0135] In some embodiments, m is 0 and n is 0.
[0136] In some embodiments, R A It is -C(O)OH.
[0137] In some embodiments, m is 1 and n is 1.
[0138] In some embodiments, R A is -C(O)OH or a 5-6 membered heteroaryl. A Yes -C(O)OH
[0139]
[0140] In another aspect, provided herein is a compound represented by formula (Ia):
[0141]
[0142] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0143] R 1 Selected from C 1-6 Alkyl, C 1-3 A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0144] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ;
[0145] R 1a is independently hydroxyl or -OC 1-3 Alkyl; and
[0146] R 2aindependently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl.
[0147] In some embodiments, the compound is represented by formula (Ia'):
[0148]
[0149] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0150] R 1 Selected from C 1-6 Alkyl, C 1-3 A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ;
[0151] R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ;
[0152] R 1a is independently hydroxyl or -OC 1-3 Alkyl; and
[0153] R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl.
[0154] In some embodiments, R 1 It is C 1-6 Alkyl, C 1-3 A halogenated alkyl or aryl group, wherein C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -OC 1-3 Alkyl substitution.
[0155] In some embodiments, R 1 It is C 1-6 Alkyl, C 1-3 A halogenated alkyl or aryl group, wherein C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -O-CH 3 replace.
[0156] In some embodiments, R 1 Selected from the group consisting of: -CH(CH 3 ) 2 CF 3 , phenyl,
[0157] In some embodiments, R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, C 1-6 Alkyl or -OC 1-3 Alkyl substitution.
[0158] In some embodiments, R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0159] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0160] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0161] In some embodiments, R 2 It is C 1-6 Alkyl or aryl, where C 1-6 Alkyl and aryl groups are replaced by hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0162] In some embodiments, R 2 It is C 1-6 Alkyl or phenyl, where C 1-6 Alkyl or phenyl groups are replaced by hydroxyl, cyano, CH 3 or -O-CH 3 replace.
[0163] In some embodiments, R 2 Select from the group consisting of:
[0164] In some embodiments, R 2 Select from the group consisting of:
[0165] In some embodiments, R 2 Selected from the group consisting of: CH 3 , cyclopropyl, -C(H)(CH 3 ) 2 、-CH 2 C(CH 3 ) 3 , phenyl,
[0166] In another aspect, provided herein is a compound represented by formula (Ib):
[0167]
[0168] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0169] R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0170] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0171] m is 0 or 1; and
[0172] n is 0 or 1.
[0173] In some embodiments, the compound is represented by formula (Ib'):
[0174]
[0175] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0176] R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0177] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0178] m is 0 or 1; and
[0179] n is 0 or 1.
[0180] In some embodiments, R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein C 1-6 The alkyl group may be optionally replaced by -O-CH 3 replace.
[0181] In some embodiments, R 1 Selected from the group consisting of: -CH(CH 3 ) 2 CF 3 , cyclopropyl and
[0182] In some embodiments, R 2 is phenyl or wherein the phenyl group is optionally substituted by a cyano group.
[0183] In some embodiments, R 2 Selected from the group consisting of: phenyl,
[0184] In some embodiments, R 2 yes In some embodiments, R 2 yes In some embodiments, R 2 Selected from the group consisting of: phenyl,
[0185] In some embodiments, m is 0 and n is 0. In some embodiments, m is 1 and n is 1.
[0186] In another aspect, provided herein is a compound represented by formula (Ic):
[0187]
[0188] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0189] R 1 It is C 1-6 Alkyl or C 1-3 haloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0190] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0191] R 4 is -C(O)OH or a 5-6 membered heteroaryl;
[0192] m is 0 or 1; and
[0193] n is 0 or 1.
[0194] In some embodiments, the compound is represented by formula (Ic'):
[0195]
[0196] or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein:
[0197] R 1 It is C 1-6 Alkyl or C 1-3 haloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution;
[0198] R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano;
[0199] R 4 is -C(O)OH or a 5-6 membered heteroaryl;
[0200] m is 0 or 1; and
[0201] n is 0 or 1.
[0202] In some embodiments, R 1 It is C 1-6 Alkyl or C 1-3 A haloalkyl group, wherein C 1-6 The alkyl group may be optionally replaced by -O-CH3 replace.
[0203] In some embodiments, R 1 It is CF 3 or
[0204] In some embodiments, R 2 It is phenyl, wherein the phenyl group is optionally substituted by a cyano group.
[0205] In some embodiments, R 2 Selected from the group consisting of: phenyl,
[0206] In some embodiments, R 2 yes In some embodiments, R 2 yes In some embodiments, R 2 Selected from the group consisting of: phenyl,
[0207] In some embodiments, m is 0 and n is 0.
[0208] In some embodiments, R 4 It is -C(O)OH.
[0209] In some embodiments, the compound is selected from any compound listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0210] Table 1. List of compounds.
[0211]
[0212]
[0213]
[0214]
[0215]
[0216]
[0217] Pharmaceutical compositions and routes of administration
[0218] The compound provided according to the present invention is usually applied in the form of a pharmaceutical composition. Therefore, the present invention provides a pharmaceutical composition containing the following as an active ingredient: one or more compounds described or their pharmaceutically acceptable salts or esters and one or more pharmaceutically acceptable excipients, carriers (including inert solid diluents and fillers), diluents (including sterile aqueous solutions and various organic solvents), penetration enhancers, solubilizers and adjuvants. The pharmaceutical composition can be applied alone or in combination with other therapeutic agents. Such compositions are prepared in a manner known in the medical field (see, for example, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa., 17th edition (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd edition (editor: GS Banker and CT Rhodes).
[0219] The pharmaceutical compositions can be administered in single or multiple doses by any of the accepted modes of pharmaceutical administration having similar utility, e.g., as described in those patents and patent applications incorporated by reference, including rectal, buccal, intranasal, and transdermal routes, by intraarterial injection, intravenous, intraperitoneal, parenteral, intramuscular, subcutaneous, oral, topical administration, as an inhalant, or, for example, by impregnated or coated devices such as stents, or arterial inserted cylindrical polymers.
[0220] A mode of administration is parenteral, particularly by injection. The novel composition of the present invention may be incorporated to include aqueous or oil suspensions or emulsions with sesame oil, corn oil, cottonseed oil or peanut oil and elixirs, mannitol, dextrose or sterile aqueous solutions and similar pharmaceutical vehicles in the form of injection. Saline solutions are also commonly used for injection, but are not preferably used in the context of the present invention. Ethanol, glycerol, propylene glycol, liquid polyethylene glycols, etc. (and their suitable mixtures), cyclodextrin derivatives and vegetable oils may also be used. Suitable fluidity may be maintained, for example, by using coatings such as lecithin, by maintaining the desired particle size in the case of dispersions, and by using a surfactant. Prevention of the effects of microorganisms may be provided by a variety of antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, etc.
[0221] Sterile injectable solutions are prepared by incorporating the desired amount of the compound according to the invention into a suitable solvent as needed with the various other ingredients listed above, followed by filtration sterilization. Typically, dispersions are prepared by incorporating various sterilized active ingredients into a sterile vehicle containing a basic dispersion medium and other ingredients required from those listed above. In the case of sterile powders for the preparation of sterile injectable solutions, preferred preparation methods are vacuum drying and freeze drying techniques that produce a powder of the active ingredient plus any additional desired ingredients from its previous sterile filtered solution.
[0222] Oral administration is another route of administration of the compound according to the present invention. It can be administered by capsules or enteric coated tablets, etc. In the process of manufacturing a pharmaceutical composition comprising at least one compound described herein, the active ingredient is usually diluted by an excipient and / or encapsulated in such a carrier that can be in the form of a capsule, a sachet, paper or other container. When an excipient is used as a diluent, it can be in the form of a solid, semisolid or liquid material (as described above), which serves as a medium, carrier or medium for the active ingredient. Therefore, the composition can be in the form of tablets, pills, powders, lozenges, medicine bags, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as solids or in liquid media), ointments containing, for example, up to 10% by weight of active compounds, soft gelatin capsules and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders.
[0223] Some examples of suitable excipients include lactose, glucose, sucrose, sorbitol, mannitol, starch, gum arabic, calcium phosphate, alginate, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup and methylcellulose. The formulation may additionally include: lubricants such as talc, magnesium stearate and mineral oil; wetting agents; emulsifiers and suspending agents; preservatives such as methyl and propyl hydroxybenzoates; sweeteners; and flavoring agents.
[0224] The compositions of the present invention can be formulated so as to provide rapid, sustained or delayed release of the active ingredient after being applied to the patient using procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolution systems, which include polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patents No. 3,845,770; No. 4,326,525; No. 4,902,514; and No. 5,616,345. Another formulation for use in the method of the present invention uses a transdermal delivery device ("patch"). Such transdermal patches can be used to provide continuous or discontinuous infusions of the compounds of the present invention in controlled amounts. The construction and use of transdermal patches for delivering medicaments are well known in the art. See, for example, U.S. Patents No. 5,023,252, No. 4,992,445, and No. 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
[0225] The composition is preferably formulated in unit dosage form. The term "unit dosage form" refers to a physically discrete unit suitable as a unit dose for human subjects and other mammals, each unit containing a predetermined amount of active material calculated to produce the desired therapeutic effect and a suitable pharmaceutical excipient (e.g., tablet, capsule, ampoule). The compound is generally administered in a pharmaceutically effective amount. However, it should be understood that the actual amount of the compound administered will generally be determined by the doctor in view of the relevant circumstances, including the condition to be treated; the selected route of administration; the actual administered compound and its relative activity; the age, weight and response of the individual patient; the severity of the patient's symptoms, etc.
[0226] For preparing solid compositions such as tablets, the main active ingredient is mixed with a pharmaceutical excipient to form a solid preformulated composition containing a homogeneous mixture of the compound of the present invention. When referring to these preformulated compositions as homogeneous, it is meant that the active ingredient is generally dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
[0227] Tablet of the present invention or pill can be coated or otherwise mixed to provide dosage form, which has the advantage of long action time or protection from the effect of the acidic conditions of the stomach.For example, tablet or pill can include inner dosage component and outer dosage component, and the latter adopts the form of coating on the former.Two kinds of components can be separated by enteric layer, and described enteric layer is used to resist the disintegration in the stomach and allows inner component to be transmitted into the duodenum intact or delayed release.Multiple materials can be used for this type of enteric layer or coating, and this type of material comprises many polymeric acids and polymeric acids and the mixture of materials such as shellac, hexadecanol and cellulose acetate.
[0228] Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof and powders. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described above. Preferably, the composition is administered by oral or nasal respiratory route for local or systemic effect. Compositions preferably in pharmaceutically acceptable solvents may be atomized by the use of an inert gas. Atomized solutions may be inhaled directly from an atomizing device, or the atomizing device may be connected to a mask holder or an intermittent positive pressure breathing machine. Solutions, suspensions or powder compositions may be preferably administered orally or nasally from a device that delivers the formulation in an appropriate manner.
[0229] In some embodiments, a pharmaceutical composition includes a disclosed compound, or a stereoisomer and / or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
[0230] How to use
[0231] The compounds and compositions described herein are generally useful for modulating MALT1, and can be used to treat diseases or conditions, particularly those susceptible to modulation of the proteolytic and / or autoproteolytic activity of MALT1. In some embodiments, the compounds and compositions described herein can be used to inhibit MALT1. In some embodiments, it is contemplated that the compounds and compositions of the invention can be used to treat diseases, disorders, or conditions characterized by dysregulated NF-kB activation, such as autoimmune or immune and inflammatory disorders, allergic disorders, respiratory disorders, and neoplastic disorders.
[0232] In typical embodiments, the present invention is intended to encompass the compounds disclosed herein, as well as pharmaceutically acceptable salts, pharmaceutically acceptable esters, tautomeric forms, polymorphs, and prodrugs of such compounds. In some embodiments, the present invention comprises pharmaceutically acceptable addition salts, pharmaceutically acceptable esters, solvates (e.g., hydrates) of addition salts, tautomeric forms, polymorphs, enantiomers, mixtures of enantiomers, stereoisomers, or mixtures of stereoisomers (pure or as racemic or non-racemic mixtures) of the compounds described herein (e.g., compounds of Formula I, Ia, Ib, or Ic).
[0233] In some embodiments, the autoimmune and inflammatory disorders are selected from arthritis, ankylosing spondylitis, inflammatory bowel disease, ulcerative colitis, gastritis, pancreatitis, Crohn's disease, celiac disease, multiple sclerosis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, rheumatic fever, gout, organ or transplant rejection, acute or chronic graft-versus-host disease, chronic allograft rejection, Behcet's disease, uveitis, psoriasis, psoriatic arthritis, BENTA disease, polymyositis, dermatitis, atopic dermatitis, dermatomyositis, acne vulgaris, myasthenia gravis, hidradenitis suppurativa, Grave's disease, Hashimoto thyroiditis, Sjogren's syndrome, and blistering disorders (e.g., pemphigus vulgaris), antibody-mediated vasculitis syndromes including ANCA-associated vasculitis, Henoch-Schonlein purpura, and inflammatory bowel disease. Purpura), and immune complex vasculitis (primary or secondary to infection or cancer).
[0234] In some embodiments, the autoimmune or inflammatory disorder or disease is selected from the group consisting of acute graft versus host disease, chronic graft versus host disease, lupus, scleroderma, psoriatic arthritis, primary sclerosing cholangitis, rheumatoid arthritis, and inflammatory bowel disease.
[0235] In some embodiments, the neoplastic disorder is selected from carcinoma, sarcoma, lymphoma, leukemia and germ cell tumors, adenocarcinoma, bladder cancer, clear cell carcinoma, skin cancer, brain cancer, cervical cancer, colon cancer, colorectal cancer, endometrial cancer, brain tumors, breast cancer, stomach cancer, germ cell tumors, glioblastoma, hepatic adenoma, Hodgkin's lymphoma, liver cancer, kidney cancer, lung cancer, pancreatic cancer, head / neck / throat cancer, ovarian cancer, dermal tumors, prostate cancer, renal cell carcinoma, gastric cancer, blood cancer, medulloblastoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma (DLBCL), activated B-cell-like diffuse large B-cell lymphoma (ABC-DLBCL), mantle cell lymphoma, marginal zone lymphoma, T-cell lymphoma, in particular Sezary syndrome (Sezary syndrome syndrome), mycosis fungoides, cutaneous T-cell lymphoma, T-cell acute lymphoblastic leukemia, melanoma, mucosa-associated lymphoid tissue (MALT) lymphoma, multiple myeloma, plasma cell neoplasms, lentigo maligna melanoma, acral lentigo melanoma, squamous cell carcinoma, chronic myeloid leukemia, myeloid leukemia, superficial spreading melanoma, acral lentigo melanoma, mucosal melanoma, nodular melanoma, polypoid melanoma, desmoplastic melanoma, amelanotic melanoma, soft tissue melanoma, melanoma with small nevus-like cells, melanoma with Spitz nevus nevus-like features, uveal melanoma, precursor T-cell, leukemia / lymphoma, acute myeloid leukemia, chronic myeloid leukemia, acute lymphocytic leukemia, follicular lymphoma, chronic lymphocytic leukemia / lymphoma, Burkitt's lymphoma, mycosis fungoides, peripheral T-cell lymphoma, nodular sclerosis type of Hodgkin lymphoma, mixed cell type of Hodgkin lymphoma, non-small cell lung cancer, large cell carcinoma, and small cell lung cancer.
[0236] In certain embodiments, the tumor disorder is a cancer in the form of a tumor or blood-derived cancer. In certain embodiments, the tumor is a solid tumor. In certain embodiments, the tumor is malignant and / or metastatic. In certain embodiments, the tumor is selected from adenoma, adenocarcinoma, blastoma (e.g., hepatoblastoma, glioblastoma, neuroblastoma and retinoblastoma), cancer (e.g., colorectal cancer or hepatocellular carcinoma, pancreatic cancer, prostate cancer, gastric cancer, esophageal cancer, cervical cancer and head and neck cancer and adenocarcinoma), desmoid tumor, desmoplastic small round cell tumor, endocrine tumor, germ cell tumor, lymphoma, leukemia, sarcoma (e.g., Ewing sarcoma, osteosarcoma, rhabdomyosarcoma or any other soft tissue sarcoma), Wilms tumor (Wilms tumor), lung tumor, colon tumor, lymphoma, breast tumor or melanoma.
[0237] In some embodiments, the allergic condition is selected from contact dermatitis, celiac disease, asthma, hypersensitivity to house dust mites, pollens and related allergens, and berylliosis.
[0238] In some embodiments, the respiratory disorder is selected from asthma, bronchitis, chronic obstructive pulmonary disease (COPD), cystic fibrosis, pulmonary edema, pulmonary embolism, pneumonia, pulmonary sarcoidosis, silicosis, pulmonary fibrosis, respiratory failure, acute respiratory distress syndrome, primary pulmonary hypertension, and emphysema.
[0239] In some embodiments, the compounds and compositions of the invention can be used to treat rheumatoid arthritis, systemic lupus erythematosus, vasculitic conditions, allergic diseases, asthma, chronic obstructive pulmonary disease (COPD), acute or chronic transplant rejection, graft-versus-host disease, cancers of hematopoietic origin or solid tumors, chronic myeloid leukemia, myeloid leukemia, non-Hodgkin's lymphoma or other B-cell lymphomas.
[0240] Combination therapy
[0241] The compounds of the compositions described herein may be administered in combination with another agent or therapy.The subject to whom the compounds disclosed herein are to be administered may have a disease, disorder or condition, or a symptom thereof, that would benefit from treatment with another agent or therapy.
[0242] In some embodiments, the compounds of the compositions described herein can be administered simultaneously with one or more other therapeutic agents or before or after one or more other therapeutic agents. In some embodiments, the compounds of the compositions described herein can be administered alone by the same or different administration routes as other agents, or can be administered together with other agents in the same pharmaceutical composition.
[0243] In some embodiments, the compounds described herein can be administered as the sole active ingredient, or in combination with (e.g., as an adjuvant to) other drugs (e.g., immunosuppressants or immunomodulators or other anti-inflammatory agents) or chemotherapeutic agents (e.g., malignant cell antiproliferative agents), for example, for the treatment or prevention of acute or chronic rejection of allografts or xenografts, or inflammatory or autoimmune disorders. For example, the compounds of the invention can be used in combination with: a calcineurin inhibitor, such as cyclosporin A or FK 506; an mTOR inhibitor, such as rapamycin, 40-0-(2-hydroxyethyl)-rapamycin, biolimus-7 or biolimus-9; an ascomycin with immunosuppressive properties, such as ABT-281, ASM981; a corticosteroid; cyclophosphamide; azathioprine; methotrexate; leflunomide; mizoribine; mycophenolic acid or a salt; mycophenolate mofetil; or an IL-1β inhibitor.
[0244] In some embodiments, the compounds described herein are combined with an adjunct agent that is a PI3K inhibitor.
[0245] In some embodiments, the compounds described herein are combined with an adjunct agent that affects BTK (Bruton's tyrosine kinase).
[0246] For the treatment of oncological diseases, the compounds described herein can be used in combination with B cell modulators, such as Rituximab, Ofatumumab, BTK or SYK inhibitors, inhibitors of PKC, PI3K, PDK, PIM, JAK, and mTOR and BH3 mimetics.
[0247] Examples
[0248] The following representative examples are intended to help illustrate the invention and are not intended, and should not be construed, to limit the scope of the invention.
[0249] The compounds provided herein can be prepared from readily available starting materials using the following general methods and procedures. It should be understood that, unless otherwise stated, other process conditions may also be used when typical or preferred process conditions (i.e., reaction temperature, time, molar ratio of reactants, solvent, pressure, etc.) are given. Optimal reaction conditions may vary with the specific reactants or solvents used, but such conditions may be determined by those skilled in the art by routine optimization.
[0250] In addition, as will be apparent to those skilled in the art, conventional blocking groups may be necessary to prevent some functional groups from experiencing undesirable reactions. The selection of suitable blocking groups for specific functional groups and the suitable conditions for protecting and deprotecting are well known in the art. For example, many blocking groups and their introduction and removal are described in TW Greene and PGM Woods, Protecting Groups in Organic Synthesis, second edition, New York Wiley Press (Wiley, New York), 1991 and the references cited therein.
[0251] Compounds provided herein can be separated and purified by known standard procedures. Such procedures include recrystallization, filtration, flash chromatography, grinding, high pressure liquid chromatography (HPLC) or supercritical fluid chromatography (SFC). Note that flash chromatography can be performed manually or by an automated system. Compounds provided herein can be characterized by known standard procedures, such as nuclear magnetic resonance spectroscopy (NMR) or liquid chromatography mass spectrometry (LCMS). NMR chemical shifts are reported in parts per million (ppm) and are produced using methods well known to those skilled in the art.
[0252] List of abbreviations:
[0253] EtOAc, EA Ethyl acetate
[0254] THF Tetrahydrofuran
[0255] PE Petroleum Ether
[0256] MeOH Methanol
[0257] EtOH
[0258] DMF N,N--Dimethylformamide
[0259] FA Formic acid
[0260] DCM Dichloromethane
[0261] MeCN, ACN, CH 3 CN Acetonitrile
[0262] xantphos 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene
[0263] h, hr, hrs hours
[0264] Calcd
[0265] UV
[0266] rt room temperature
[0267] DIEA, DIPEA N,N-Diisopropylethylamine
[0268] Pd 2 (dba) 3 Tris(dibenzylideneacetone)dipalladium(0)
[0269] E 3 N、TEA triethylamine
[0270] Cs 2 CO 3 Cesium carbonate
[0271] INT intermediate
[0272] t-BuOH tert-Butanol
[0273] Boc tert-Butyloxycarbonyl
[0274] LiOH.H 2 O Lithium hydroxide monohydrate
[0275] NH 4 Cl Ammonium chloride
[0276] DPPA Diphenylphosphorylazide
[0277] NaOH Sodium hydroxide
[0278] (COCl) 2 Oxalyl chloride
[0279] NaN 3 Sodium Azide
[0280] CDI 1,1'-Carbonyldiimidazole
[0281] BnOH Benzyl alcohol
[0282] Cbz benzyloxycarbonyl
[0283] SnCl 2 Stannous chloride
[0284] HCl
[0285] NaNO 2 Sodium Nitrite
[0286] KOH Potassium Hydroxide
[0287] BH 3 .DMS Borane dimethyl sulfide complex
[0288] H 2 O 2 Hydrogen Peroxide
[0289] RuCl 3 Ruthenium trichloride
[0290] NaIO 4 Sodium periodate
[0291] NaH Sodium hydride
[0292] KNO 3 Potassium Nitrate
[0293] H 2 SO 4 sulfuric acid
[0294] Pd / C Palladium Carbon
[0295] DMF-DMA, N,N-dimethylformamide dimethyl acetal
[0296] (CH 3 ) 2 NCH(OCH 3 ) 2
[0297] CF 3 CH 2 OH 2,2,2-Trifluoroethanol
[0298] N 2 H 4 Hydrazine
[0299] CH 3 (NH)NH 2 Methylhydrazine
[0300] MeI Methyl iodide
[0301] LiHMDS Lithium bis(trimethylsilyl)amide
[0302] (n-Bu) 4 NOAc Tetrabutylammonium acetate
[0303] TMSCF 3 Trimethyl(trifluoromethyl)silane
[0304] AcOH Acetic acid
[0305] PtO 2 Platinum oxide
[0306] NaBH 3 CN Sodium cyanoborohydride
[0307] CuCN Cuprous Cyanide
[0308] MgCl 2 Magnesium chloride
[0309] K 2 CO 3 Potassium carbonate
[0310] CuI Cuprous iodide
[0311] CH 2 I 2 Diiodomethane
[0312] Pd(PPh 3 ) 2 Cl 2 Bis(triphenylphosphine)palladium(II) dichloride
[0313] NaBH 4 Sodium borohydride
[0314] Example 1. Preparation of compounds
[0315] Methods for preparing the compounds described herein are shown in the following synthetic schemes. These schemes are given for the purpose of illustrating the present invention and should not be considered in any way as limiting the scope or spirit of the present invention. The starting materials shown in the schemes can be obtained from commercial sources or can be prepared from commercially available sources based on procedures described in the literature.
[0316] 1. Compounds prepared using Scheme 1
[0317] Scenario 1:
[0318]
[0319] Make G-1a and R 1 ' is reacted with formamide G-1b to provide a compound of formula (A).
[0320] Exemplary procedures for compounds prepared using Scheme 1:
[0321] (S)-N-methyl-N-(2,2,2-trifluoro-1-(4-((1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)amino Synthesis of tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide (compound 1.1)
[0322]
[0323] To a mixture of 1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-amine [free base of INT 1.1] (50 mg, 302 μmol) and (S)-N-(1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N-methyltetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [INT 5.1] (155 mg, 362 μmol) in dioxane (2 mL) was added Pd 2 (dba) 3 (27.6mg, 30.2μmol), xantphos (34.9mg, 60.4μmol) and Cs 2 CO 3 (295 mg, 906 μmol). The mixture was stirred at N 2 The mixture was stirred at 100 °C for 2 hours under atmosphere, then quenched with water (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were filtered through anhydrous Na 2 SO 4 The crude product was purified by prep-HPLC (column: YMC-Actus Triart C18 150*30mm*5μm, condition: 42%-62% CH 3 CN water (0.05% ammonium hydroxide v / v)-ACN, flow rate: 35 ml / min) to give (S)-N-methyl-N-(2,2,2-trifluoro-1-(4-((1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)tetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [Compound 1.1] (20.6 mg, 40.1 μmol, 13.3% yield) as a white dry powder. m / z: [M+H]+ calculated for C20H23F6N4O3S, 513.1; found, 513.2. 1 H NMR (400MHz, CD 3 OD)δ=7.55(s,1H),7.19(d,J=8.4Hz,2H),6.82(d,J=8.4Hz,2H),6.57-5.9 5(m,1H),4.00(s,3H),3.30-3.09(m,5H),2.98(s,3H),2.39-2.10(m,4H).
[0324] 2. Compounds prepared using Scheme 2
[0325] Scenario 2:
[0326]
[0327] Use alkali (LiOH.H 2The starting material G-2a is treated with 2% O or NaOH to provide the compound of formula (B). 2 is phenyl, pyridyl or pyridazine; R 1 It is CF 3 or (S)-methoxyethane; and m and n are each independently 0 or 1. 3 ' is methyl or benzyl.
[0328] Exemplary procedures for compounds prepared using Scheme 2:
[0329] (1S,4r)-4-(methyl((S)-2,2,2-trifluoro-1-(4-((1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4- Synthesis of 1-(4-(4-amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylic acid (Compound 2.1)
[0330]
[0331] To methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylate [INT 6.1] (280 mg, 480 μmol) in THF (3 mL) and H 2 O (1 mL) was added to the mixture. 2 O (60.4 mg, 1.44 mmol), and the mixture was stirred at 25 ° C for 12 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by Prep-HPLC (column: YMC Actus Triart C18 150*30 mm*5 μm, table: 50-70% B (A = water (0.225% formic acid)-ACN, B = acetonitrile), flow rate: 35 ml / min, UV detector 220 nm) to give (1S, 4r)-4-(methyl ((S)-2,2,2-trifluoro-1-(4-((1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylic acid [Compound 2.1] (30.5 mg, 53.6 μmol, 11.2% yield) as a white dry powder. m / z: [M+H]+ calcd. for C27H27F6N4O3, 569.2; found, 569.1. 1 H NMR (400 MHz, CDCl 3)δ=7.80(s,1H),7.54-7.44(m,5H),7.26-7.24(m,2H),6.94(d,J=8.8Hz,2H),6.60(q,J=9.2 Hz,1H),5.51(s,1H),2.90(s,3H),2.62-2.53(m,1H),2.42(tt,J=3.6,12.0Hz,1H),2.15(br t,J=8.8Hz,2H),2.01-1.82(m,2H),1.67(q,J=12.8Hz,2H),1.56-1.42(m,2H).
[0332] (1r,3r)-3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H- Pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxamide (Compound 2.11) and (1s,3s)-3- {Methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}benzene Synthesis of cyclobutane-1-carboxamide (compound 2.12)
[0333]
[0334] A mixture of 3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxylic acid benzyl ester [INT 6.12] (390 mg, 617 μmol) and sodium hydroxide (98.3 mg, 2.46 mmol) in THF (5 mL) and water (5 mL) was stirred at 25 ° C for 2 hours. The reaction mixture was combined with another mixture of the same type. The mixture was diluted with water (10 mL), adjusted to pH=4 with 1N HCl, and extracted with EtOAc (50 mL x 2). The combined organic phases were concentrated under reduced pressure to give a crude product, which was purified by Prep-HPLC (column: YMC-Triart Prep C18 150*40mm*7μm, table: 9-49% B (A = water (0.1% NH 3 .H 2 O and 10 mM NH 4 HCO 3 ), B = acetonitrile), flow rate: 60 ml / min, UV detector 220 nm) to obtain 120 mg of off-white solid. The material was purified by SFC (column: DAICEL CHIRALPAK AS (250 mm*30 mm, 10 μm, table: 25% B (A = CO 2 (0.1% NH 3 H 2O = EtOH), B = EtOH), flow rate: 60 ml / min, UV detector 220 nm) to obtain (1r, 3r)-3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxamide [Compound 2.11] (41 .0 mg, 73.4 μmol, 11.9% yield) and (1s,3s)-3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxamide [Compound 2.12] (55.1 mg, 98.6 μmol, 16.0% yield).
[0335] Compound 2.11: m / z: [M+H]+ calculated for C24H22F6N5O3, 542.2; found, 542.2. 1 HNMR (400MHz, CDCl 3 )δ=8.58-8.48(m,1H),7.89(dt,J=2.0,8.0Hz,1H),7.84(s,1H),7.75(d,J=8.8Hz,1H),7.34(dd,J=4 .0,6.8Hz,1H),7.31-7.27(m,2H),6.97(d,J=8.4Hz,2H),6.57(q,J=8.4Hz,1H),5.67(s,1H),3.51(br t,J=8.3Hz,1H),3.23(td,J=4.4,9.5Hz,1H),2.78(s,3H),2.74-2.65(m,2H),2.64-2.49(m,2H).
[0336] Compound 2.12: m / z: [M+H]+ calculated for C24H22F6N5O3, 542.2; found, 542.2. 1 HNMR (400MHz, CDCl 3)δ=8.58-8.49(m,1H),7.88(dt,J=1.6,8.0Hz,1H),7.85(s,1H),7.75(d,J =8.8Hz,1H),7.34(dd,J=4.8,7.2Hz,1H),7.31-7.27(m,2H),6.97(d,J=8. 4Hz, 2H), 6.55 (q, J = 8.8Hz, 1H), 5.68 (s, 1H), 3.29 (quin, J = 8.8Hz, 1H), 3.17 (quin, J = 8.8Hz, 1H), 2.80 (s, 3H), 2.75-2.62 (m, 2H), 2.61-2.46 (m, 2H).
[0337] 3. Compounds prepared using Scheme 3
[0338] Scenario 3:
[0339]
[0340] (1r,4S)-N-((S)-1-(4-((4-cyclopropyl-1,5-naphthyridin-3-yl)amino)phenyl)-2,2,2-trifluoroethyl Synthesis of 4-(1H-tetrazolyl-5-yl)-N-methyl-4-(1H-tetrazolyl-5-yl)cyclohexane-1-carboxamide (Compound 3.1)
[0341] To a solution of (1r,4r)-4-cyano-N-methyl-N-[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]cyclohexane-1-carboxamide [INT 6.11] (100 mg, 181 μmol) and ammonium chloride (14.4 mg, 271 μmol) in DMF (5 mL) was added sodium azide (40 mg, 615 μmol). The reaction mixture was stirred at 105 °C under nitrogen for 12 h. H was added. 2 O (10 mL), and the mixture was extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2) and filtered through anhydrous Na 2 SO 4Drying and concentration under reduced pressure gave crude (1r,4S)-N-((S)-1-(4-((4-cyclopropyl-1,5-naphthyridin-3-yl)amino)phenyl)-2,2,2-trifluoroethyl)-N-methyl-4-(1H-tetrazol-5-yl)cyclohexane-1-carboxamide [Compound 3.1] (100 mg, 168 μmol, 93.4% yield). The material was purified by prep-HPLC (column: YMC-Triart Prep C18 150*40mm*7μm, table: 16-56% B (A=water (ammonia hydroxide), B=acetonitrile), flow rate: 60 ml / min, UV detector 220nm) to give (1r,4S)-N-((S)-1-(4-((4-cyclopropyl-1,5-naphthyridin-3-yl)amino)phenyl)-2,2,2-trifluoroethyl)-N-methyl-4-(1H-tetrazolyl-5-yl)cyclohexane-1-carboxamide [Compound 3.1] (3.90 mg, 6.58 μmol, 3.9% yield) as an off-white solid. m / z: [M+H]+ calculated for C27H27F6N8O, 593.2; Found, 593.2. 1 H NMR (400 MHz, CDCl 3 )δ=7.81(s,1H),7.49(br s,5H),7.27(s,2H),6.96(d,J=8.8Hz,2H),6.67-6.51(m,1H),5.60(s,1H),3.22-3.15(m,1H),3.03-2.85(m,3H),2.79(br s,1H),2.28(br s,2H),2.13-1.95(m,2H),1.82(br s,4H).
[0342] Synthesis of Exemplary Intermediates
[0343] The following exemplary intermediates were synthesized and used to synthesize one or more exemplary compounds of the present disclosure.
[0344] Synthesis of 1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.1]:
[0345]
[0346] Synthesis of tert-butyl N-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-b]:
[0347] To a solution of 1-methyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-a] (500 mg, 2.57 mmol), 2-methylpropan-2-ol (285 mg, 3.85 mmol) and triethylamine (780 mg, 7.71 mmol) in toluene (5 mL) was added DPPA (1.05 g, 3.85 mmol). The reaction mixture was stirred at N 2 The mixture was stirred at 100° C. for 1 hour. The reaction solution was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAC / PE=0 / 1 to 1 / 1) to give tert-butyl N-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-b] (540 mg, 2.03 mmol, 79% yield) as a white solid. m / z: [M+H]+ calculated for C10H15F3N3O2, 266.1; found, 266.1.
[0348] 1-Methyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.1]:
[0349] A solution of tert-butyl N-[1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-b] (540 mg, 2.03 mmol) in 4M HCl / dioxane (10 mL) was stirred at 25° C. for 2 hours. The reaction was concentrated under reduced pressure to give 1-methyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.1] (350 mg, 1.73 mmol, 86% yield) as a brown solid. m / z: [M+H]+ calculated for C5H7F3N3, 166.1; found, 166.1.
[0350] Synthesis of 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [Intermediate 1.2]:
[0351]
[0352] Synthesis of 5-hydrazinoquinoline [INT 1-d]:
[0353] To a solution of quinolin-5-amine [INT 1-c] (1 g, 6.93 mmol) in HCl (6 mL) was added NaNO dropwise at 0 °C. 2 (525 mg, 7.62 mmol) in H 2A solution in O (1.5 mL). The mixture was stirred at 0 °C for 30 minutes and warmed to 21 °C over 30 minutes until an orange solution was formed. The mixture was cooled to 0 °C and a solution of tin(II) chloride (3.11 g, 13.8 mmol) dissolved in HCl (3 mL) was added dropwise. A yellow precipitate formed immediately after the addition of the tin salt. The mixture was stirred at 0 °C for 30 minutes and then warmed to 21 °C with vigorous stirring for 12 hours. The reaction mixture was filtered. The cake was washed with cold EtOH (10 mL x 3) and dried under reduced pressure to give crude 5-hydrazinoquinoline [INT 1-d] as a yellow solid (1.10 g, 6.90 mmol). 1 H NMR (400 MHz, DMSO-d6) δ = 10.05 (br s, 1H), 9.28 - 9.18 (m, 2H), 8.05 - 7.96 (m, 2H), 7.92 (d, J = 8.4 Hz, 1H), 7.29 (d, J = 7.6 Hz, 1H).
[0354] Synthesis of 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-e]:
[0355] To a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (668 mg, 2.78 mmol) in EtOH (5 mL) was added 5-hydrazinoquinoline [INT 1-d] (367 mg, 2.31 mmol). The mixture was stirred at 80 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography on silica gel (CH 2 Cl 2 / MeOH = 100 / 0 to 95 / 5) to give ethyl 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-e] as a brown semi-solid (185 mg, 551 μmol, 23.9% yield). m / z: calculated for [M+H]+ of C16H13F3N3O2, 336.1; found, 336.2.
[0356] Synthesis of 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-f]:
[0357] To a solution of ethyl 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-e] (419 mg, 1.24 mmol) in H 2 O (0.5 mL) and THF (3 mL) was added lithium hydroxide monohydrate (104 mg, 2.48 mmol). The mixture was stirred at 21 °C for 2 hours and then the mixture was concentrated under reduced pressure to give a brown solid. Then H 2O (3 mL), and the pH of the reaction mixture was adjusted to 5 with 1 M HCl. The mixture was extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (2 x 30 mL), filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give crude 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-f] (120 mg, 390 μmol, 31.5% yield) as a brown solid. m / z: [M+H]+ calculated for C14H9F3N3O2, 308.1; found, 308.0.
[0358] Synthesis of benzyl (1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT1-g]:
[0359] 1-(Quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-f] (180 mg, 585 μmol), benzyl alcohol (75.9 mg, 702 μmol), Et 3 A solution of N (59.1 mg, 585 μmol) and DPPA (241 mg, 877 μmol) in toluene (2 mL) was stirred at 90 ° C for 12 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 3) to give benzyl (1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-g] (100 mg, 242 μmol, 41.4% yield) as a yellow solid. m / z: [M+H]+ calculated for C21H16F3N4O2, 413.1; Found, 413.1.
[0360] Synthesis of 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.2]:
[0361] To a solution of benzyl (1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-g] (100 mg, 242 μmol) in THF (2 mL) was added NaOH (96.8 mg, 2.42 mmol) and H 2 O (2 mL). The resulting mixture was stirred at 60 ° C for 12 hours. Water (10 mL) was added, and the mixture was extracted with EtOAc (15 mL x 2). The combined organic layers were washed with brine (20 mL) and purified by Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / hexane=0 / 1 to 1 / 1) to give 1-(quinolin-5-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.2] (45.0 mg, 161 μmol, 66.8% yield) as a white solid. m / z: [M+H]+ calculated for C13H10F3N4, 279.1; found, 279.1.
[0362] Synthesis of 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-amine [Intermediate 1.3]:
[0363]
[0364] Synthesis of 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-i]:
[0365] To a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (3 g, 12.4 mmol) in EtOH (30 mL) was added (2-methylphenyl)hydrazine hydrochloride [INT 1-h] (1.96 g, 12.4 mmol) at 25°C, and the reaction mixture was stirred at 60°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EA=1 / 0 to 3 / 1) to give ethyl 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-i] (3.10 g, 10.3 mmol, 84.0% yield) as a yellow oil. m / z: [M+H]+ calculated for C14H14F3N2O2, 299.1; found, 298.9.
[0366] Synthesis of 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-j]:
[0367] To ethyl 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-i] (3.1 g, 10.3 mmol) was added to H 2 To a mixture of 4-nitropropene (10 mL) and THF (20 mL) was added lithium hydroxide monohydrate (1.07 g, 25.7 mmol). The reaction mixture was stirred at 15 °C for 1 hour. The reaction mixture was concentrated under reduced pressure. The mixture was then acidified to pH = 4 with 1M HCl and concentrated under reduced pressure to provide crude 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-j] (2.6 g, 9.62 mmol, 93.5% yield). m / z: [M+H]+ calculated for C12H10F3N2O2, 271.1; Found, 270.8.
[0368] Synthesis of tert-butyl (1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT1-k]:
[0369] DPPA (3.05 g, 11.1 mmol) and triethylamine (1.49 g, 14.8 mmol) were added to a mixture of 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-j] (2 g, 7.40 mmol) in t-BuOH (20 mL). The reaction mixture was stirred at 100 ° C for 3 hours under nitrogen. The reaction mixture was concentrated under reduced pressure to give a solid, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give tert-butyl (1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-k] (400 mg, 1.17 mmol, 15.8% yield) as a white solid. m / z: [M+H]+ calcd. for C16H19F3N3O2, 342.1; found, 342.0.
[0370] Synthesis of 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazole-4-amine [INT 1.3]:
[0371] A mixture of tert-butyl (1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-k] (220 mg, 644 μmol) in 4M HCl / dioxane (6 mL) was stirred at 20° C. for 16 hours. The reaction mixture was concentrated under reduced pressure to give crude 1-(o-tolyl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.3] (100 mg, 414 μmol, 70.9% yield). m / z: [M+H]+ calculated for C11H11F3N3, 242.1; found, 241.9.
[0372] Synthesis of 1-methyl-5-phenyl-1H-pyrazole-4-amine [Intermediate 1.4]:
[0373]
[0374] Synthesis of 2-(2-oxo-2-phenylethyl)isoindoline-1,3-dione [INT 1-m]:
[0375] 2-Bromo-1-phenylethyl-1-one (3.20 g, 16.1 mmol) was added to a solution of 1,3-dioxo-2,3-dihydro-1H-isoindol-2-yl potassium [INT 1-1] (3 g, 16.1 mmol) in DMF (10 mL). The reaction mixture was stirred at 25 ° C for 20 hours. Water (20 mL) was added and the mixture was extracted with DCM (30 mL x 2). The combined organic layers were washed with brine (40 mL x 2) and filtered through anhydrous Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 5 / 1) to give 2-(2-oxo-2-phenylethyl)isoindoline-1,3-dione [INT 1-m] (4.16 g, 15.6 mmol, 97.4% yield) as a white solid. m / z: [M+H]+ calculated for C16H12NO3, 266.1; found, 266.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.05-8.00(m,2H),7.96-7.86(m,2H),7.79-7.74(m,2H),7.67-7.62(m,1H),7.56-7.50(m,2H),5.15(s,2H).
[0376] 2-[1-(Dimethylamino)-3-oxo-3-phenylprop-1-en-2-yl]-2,3-dihydro-1H-isoindole-1,3-dihydro- Synthesis of ketone [INT1-n]:
[0377] A suspension of 2-(2-oxo-2-phenylethyl)-2,3-dihydro-1H-isoindole-1,3-dione [INT 1-m] (1.0 g, 3.76 mmol) in (dimethoxymethyl)dimethylamine (3 mL, 15.0 mmol) was heated at 105 °C for 18 hours and concentrated under reduced pressure. The resulting amber oil was crystallized from isopropanol (10 mL) and washed with isopropanol (2 x 5 mL) to give 2-[1-(dimethylamino)-3-oxo-3-phenylprop-1-en-2-yl]-2,3-dihydro-1H-isoindole-1,3-dione [INT 1-n] (930 mg, 2.90 mmol, 77.5% yield) as a yellow solid. m / z: [M+H]+ calcd. for C19H17N2O3, 321.1; found, 321.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.94-7.89(m,2H),7.78-7.73(m,2H),7.59(d,J=6.8Hz,2H),7.45(s,1H),7.43-7.35(m,3H),2.99(s,6H).
[0378] Synthesis of 1-methyl-5-phenyl-1H-pyrazole-4-amine [INT 1.4]:
[0379] To a solution of 2-[1-(dimethylamino)-3-oxo-3-phenylprop-1-en-2-yl]-2,3-dihydro-1H-isoindole-1,3-dione [INT 1-n] (930 mg, 2.90 mmol) in EtOH (6 mL) was added methylhydrazine (723 mg, 15.7 mmol). The reaction mixture was stirred under N 2The mixture was stirred at 25 ° C for 1 hour. The reaction solution was then heated to 80 ° C for 1 hour. The reaction solution was cooled to 25 ° C and concentrated under reduced pressure to obtain a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 1) to obtain a mixture of 1-methyl-5-phenyl-1H-pyrazole-4-amine [INT 1.4] (152 mg, 877 μmol, 30.2% yield) and 1-methyl-3-phenyl-1H-pyrazole-4-amine (190 mg, 1.09 mmol, 37.8% yield) as a brown solid. The mixture was purified by Prep-HPLC (column: Phenomenex Gemini C18 250*50mm*10μm, table: 1-41% B (A = water (0.05% NH 3 H 2 O + 10 mM NH 4 HCO 3 ), B = acetonitrile), flow rate: 25 ml / min, UV detector 220 nm) to give 1-methyl-5-phenyl-1H-pyrazol-4-amine [INT 1.4] (40.0 mg, 230 μmol) as a white solid. m / z: [M+H]+ calculated for C10H12N3, 174.1; found, 174.1.
[0380] Synthesis of 5-isopropyl-1-methyl-1H-pyrazol-4-amine [Intermediate 1.5]:
[0381]
[0382] 1-Methyl-5-(propan-2-yl)-1H-pyrazole [INT 1-p] and 1-methyl-3-(propan-2-yl)-1H-pyrazole [INT Synthesis of 1-q]:
[0383] To a solution of 5-(propan-2-yl)-1H-pyrazole [INT 1-o] (3 g, 27.2 mmol) in DMF (20 mL) was added sodium hydride (1.63 g, 40.8 mmol) at 0°C, and the reaction mixture was stirred at 0°C under nitrogen for 0.5 hours. Then iodomethane (11.5 g, 81.6 mmol) was added, and the reaction was warmed to 25°C over 2 hours. By adding NH 4 The reaction was quenched with Cl(aq) (30 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 50 mL) and purified by anhydrous Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 1 / 2) to give a mixture of 1-methyl-5-(propan-2-yl)-1H-pyrazole [INT1-p], 1-methyl-3-(propan-2-yl)-1H-pyrazole [INT1-q] as a colorless oil (1.30 g, 5.23 mmol, 19.2% yield). m / z: [M+H]+ calculated for C7H13N2, 125.1; experimental value, 125.3.
[0384] 1-methyl-4-nitro-5-(propan-2-yl)-1H-pyrazole [INT1-r] and 1-methyl-4-nitro-3-(propan-2-yl)- Synthesis of 1H-pyrazole [INT 1-s]:
[0385] To 1-methyl-5-(propan-2-yl)-1H-pyrazole [INT 1-p] and 1-methyl-3-(propan-2-yl)-1H-pyrazole [INT1-q] in H 2 SO 4 KNO (1 mL) was added to the mixture 3 (203 mg, 2.01 mmol) and the reaction mixture was stirred at 60 ° C under nitrogen for 16 hours. The reaction was quenched by adding 1N NaOH (aqueous solution) (10 mL) and extracted with EtOAc (3 x 10 mL). The combined organic layers were washed with brine (2 x 10 mL) and washed with anhydrous Na 2 SO 4 Dry, and concentrate under reduced pressure to give 1-methyl-4-nitro-5-(propan-2-yl)-1H-pyrazole [INT 1-r] and 1-methyl-4-nitro-3-(propan-2-yl)-1H-pyrazole [INT 1-s] (100 mg, 295 μmol, 73.5% yield) as yellow solids. m / z: [M+H]+ calculated for C7H12N3O2, 170.1; Found, 170.1.
[0386] Synthesis of 1-methyl-5-(propan-2-yl)-1H-pyrazole-4-amine [INT1.5]:
[0387] To a solution of 1-methyl-4-nitro-5-(propan-2-yl)-1H-pyrazole [INT 1-r] and 1-methyl-4-nitro-3-(propan-2-yl)-1H-pyrazole [INT 1-s] (1 g, 2.95 mmol) in MeOH (10 mL) was added Pd / C (313 mg, 295 μmol), and the suspension was degassed under vacuum and washed with H 2 Purge several times. 2(15 psi) at 25 ° C. and stirred for 16 hours. The reaction mixture was filtered and the filtrate was concentrated under reduced pressure to give 1-methyl-5-(propan-2-yl)-1H-pyrazol-4-amine [INT 1.5] and 1-methyl-3-(propan-2-yl)-1H-pyrazol-4-amine. The mixture was purified by SFC (column: REGIS (S, S) WHELK-O1 (250 mm * 25 mm, 10 μm), conditions: 15%-15% 0.1% NH 3 H 2 O ETOH, flow rate: 60 mL / min) to give 1-methyl-5-(propan-2-yl)-1H-pyrazol-4-amine [INT 1.5] (100 mg, 718 μmol) as a blue oil (m / z: [M+H]+ calculated for C7H14N3, 140.1; experimental value, 140.3) and 1-methyl-3-(propan-2-yl)-1H-pyrazol-4-amine (200 mg, 1.43 mmol) as a blue oil ([M+H]+ calculated for C7H14N3, 140.1; experimental value, 140.3).
[0388] Synthesis of 1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.6]:
[0389]
[0390] Synthesis of 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-u]:
[0391] A mixture of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (3 g, 12.4 mmol) and phenylhydrazine [INT1-t] (1.47 g, 13.6 mmol) in EtOH (35 mL) was stirred at 80 ° C for 4 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 1 to 1 / 0) to give ethyl 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT1-u] (2.44 g, 8.58 mmol, 69.3% yield) as a yellow oil. m / z: [M+H]+ calculated for C13H12F3N2O2, 285.1; Found, 285.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.13(s,1H),7.56-7.49(m,3H),7.47-7.41(m,2H),4.44-4.35(m,2H),1.40(t,J=7.2Hz,3H)
[0392] Synthesis of 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-v]:
[0393] To ethyl 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-u] (2.34 g, 8.23 mmol) in THF (15 mL) and H 2 O (5 mL) was added to the mixture. 2 O (1.03 g, 24.6 mmol) was added, and the mixture was stirred at 15° C. for 16 hours. The mixture was concentrated under reduced pressure to obtain a crude product. H 2 O (30 mL) and EtOAc (30 mL), and the precipitate was collected by filtration. The aqueous phase was washed with EtOAc (30 mL x 2), acidified to pH = 3 with 1M HCl, and extracted with EtOAc (30 mL x 2). The combined organic layers were filtered through Na 2 SO 4 Dried and filtered. The filtrate was concentrated to give a yellow solid, which was combined with the precipitate to give 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-v] (1.88 g, 7.33 mmol, 89.5% yield) as a yellow solid. m / z: [M+H]+ calculated for C11H8F3N2O2, 257.0; found, 256.9. 1 H NMR (400 MHz, CDCl 3 )δ=8.22(s,1H),7.59-7.50(m,3H),7.49-7.43(m,2H).
[0394] Synthesis of tert-butyl (1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-w]:
[0395] A mixture of 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-v] (400 mg, 1.56 mmol), 2-methylpropan-2-ol (1.73 g, 23.4 mmol), diphenylphosphoryl azide (569 mg, 2.34 mmol) and triethylamine (473 mg, 4.68 mmol) in toluene (4 mL) was stirred at 100 °C for 2 hours. NaHCO was added. 3 (30 mL), and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4Dry, filter and concentrate under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 20 to 1 / 0) to give tert-butyl (1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl)carbamate [INT 1-w] (335 mg, 1.02 mmol, 65.6% yield) as a yellow oil. m / z: [M+H]+ calculated for C15H17F3N3O2, 328.1; found, 328.2. 1 H NMR (CDCl 3 )δ=8.27(br s,1H),7.52-7.46(m,3H),7.46-7.39(m,2H),6.54(br s,1H),1.56-1.54(m,9H).
[0396] Synthesis of 1-phenyl-5-(trifluoromethyl)-1H-pyrazole-4-amine hydrochloride [INT 1.6]:
[0397] A mixture of tert-butyl N-[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-w] (235 mg, 717 μmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 4 hours. The mixture was concentrated under reduced pressure to give 1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.6] (160 mg, 606 μmol, 84.6% yield) as a yellow solid. m / z: [M+H]+ calculated for C10H9F3N3, 228.1; found, 228.0.
[0398] Synthesis of 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.7]:
[0399]
[0400] Synthesis of 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-y]:
[0401] A mixture of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (5 g, 20.8 mmol) and cyclopropylhydrazine hydrochloride [INT 1-x] (2.47 g, 22.8 mmol) in EtOH (50 mL) was stirred at 80 ° C for 16 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 10 to 1 / 0) to give ethyl 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-y] (608 mg, 2.44 mmol, 11.7% yield) as a yellow oil. m / z: [M+H]+ calculated for C10H12F3N2O2, 249.1; Found, 249.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.85(s,1H),4.36-4.30(m,2H),3.73(dtt,J=1.2,3.6,7.2Hz,1H),1.39-1.34(m,3H),1.33-1.29(m,2H),1.17-1.10(m,2H).
[0402] Synthesis of 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-z]:
[0403] To ethyl 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-y] (608 mg, 2.44 mmol) in THF (3 mL) and H 2 O (1 mL) was added to the mixture. 2 O (307 mg, 7.32 mmol), and the mixture was stirred at 15 ° C for 16 hours. The mixture was concentrated under reduced pressure to give a crude product. 1N HCl was added to adjust the pH to 3-4, and the mixture was extracted with EtOAc (50 mL x 2). The combined organic layers were filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-z] (436 mg, 1.98 mmol, 81.1% yield) as a yellow solid. m / z: [M+H]+ calculated for C8H8F3N2O2, 221.0; found, 221.0. 1 H NMR (400 MHz, CDCl 3 )δ=7.95(s,1H),2.17-2.11(m,1H),1.38-1.32(m,2H),1.20-1.14(m,2H).
[0404] Synthesis of tert-butyl N-[1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-aa]:
[0405] A mixture of 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-z] (336 mg, 1.52 mmol), 2-methylpropan-2-ol (1.69 g, 22.8 mmol), diphenylphosphoryl azide (554 mg, 2.28 mmol) and triethylamine (461 mg, 4.56 mmol) in toluene (4 mL) was stirred at 100 °C for 2 hours. NaHCO was added. 3 (30 mL), and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give a crude product, which is purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 10 to 1 / 0) to give tert-butyl N-[1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-aa] (287 mg, 985 μmol, 64.9% yield) as a colorless oil. m / z: [M+H]+ calculated for C12H17F3N3O2, 292.1; Found, 292.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.94(br s,1H),7.43-7.36(m,1H),3.55(tt,J=3.6,7.2Hz,1H),1.51(s,9H),1.30-1.23(m,2H),1.09-1.02(m,2H).
[0406] Synthesis of 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazole-4-amine hydrochloride [INT1.7]:
[0407] A mixture of tert-butyl N-[1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-aa] (187 mg, 642 μmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 4 hours. The mixture was concentrated under reduced pressure to give 1-cyclopropyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT1.7] (100 mg, 439 μmol, 68.4% yield) as a brown solid. m / z: [M+H]+ calculated for C7H9F3N3, 192.1; found, 192.0.
[0408] Synthesis of 1-phenyl-5-(propan-2-yl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.8]:
[0409]
[0410] Synthesis of 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-carboxylic acid methyl ester [INT1-bb]:
[0411] To a mixture of 4-methyl-3-oxopentanoic acid methyl esters (1g, 6.93mmol) and (dimethoxymethyl) dimethylamine (990mg, 8.31mmol) in 2,2,2-trifluoroethanol (5mL), phenylhydrazine [INT 1-t] (898mg, 8.31mmol) 2,2,2-trifluoroethanol (5mL) was added. The reaction mixture was stirred at 15 ° C for 1 hour. The reaction was quenched with water (20mL) and extracted with EtOAc (10mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to obtain a crude product, which was purified by flash chromatography using silica gel (0-6% EtOAc / petroleum ether) to obtain 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-formic acid methyl esters [INT 1-bb] (620mg, 2.53mmol, 36.6% yield) as an orange solid. m / z: [M+H]+ calcd. for C14H17N2O2, 245.1; found, 245.0. 1 HNMR (400MHz, CDCl 3 )δ=8.03(s,1H),7.55-7.48(m,3H),7.40-7.34(m,2H),3.87(s,3H),3.34-3.21(m,1H),1.36(d,J=7.2Hz,6H).
[0412] Synthesis of 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-carboxylic acid [INT1-cc]:
[0413] To 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-carboxylic acid methyl ester [INT 1-bb] (620 mg, 2.53 mmol) in THF (6 mL) and H 2 In the mixture of 1- phenyl -5- (propan-2-yl) -1H- pyrazole -4- carboxylic acid [INT1-cc] (460mg, 1.99mmol, 79.0%) in 5% paraformaldehyde (2% paraformaldehyde) was added. Lithium hydroxide monohydrate (318mg, 7.58mmol) was added to the mixture in 0.5% paraformaldehyde (2% paraformaldehyde) ... 1 H NMR (400 MHz, CDCl 3)δ=8.13(s,1H),7.57-7.48(m,3H),7.43-7.36(m,2H),3.37-3.24(m,1H),1.39(d,J=6.8Hz,6H).
[0414] Synthesis of tert-butyl N-[1-phenyl-5-(propan-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-dd]:
[0415] To a mixture of 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-cc] (410 mg, 1.78 mmol), 2-methylpropan-2-ol (1.97 g, 26.7 mmol) and triethylamine (540 mg, 5.34 mmol) in toluene (5 mL) was added diphenylphosphoryl azide (734 mg, 2.67 mmol). The reaction mixture was stirred at 100 ° C. under nitrogen for 3 hours. The reaction mixture was diluted with EtOAc (20 mL) and washed with saturated NaHCO 3 (20 mL) and brine (20 mL). The organic layer was washed with anhydrous Na 2 SO 4 The filtrate was concentrated to give a crude product, which was purified by flash chromatography on silica gel (0-20% EtOAc / petroleum ether) to give tert-butyl N-[1-phenyl-5-(propan-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-dd] (270 mg, 895 μmol, 50.3% yield) as a colorless oil. m / z: [M+H]+ calculated for C17H24N3O2, 302.2; found, 302.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.82(br s,1H),7.55-7.44(m,3H),7.41-7.36(m,2H),5.81(br s,1H),3.07(spt,J=7.2Hz,1H),1.53(s,9H),1.29(d,J=7.2Hz,6H).
[0416] Synthesis of 1-phenyl-5-(propan-2-yl)-1H-pyrazole-4-amine hydrochloride [INT 1.8]:
[0417] A mixture of tert-butyl N-[1-phenyl-5-(propan-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-dd] (270 mg, 895 μmol) in 4M HCl / dioxane (5 mL, 20 mmol) was stirred at 15° C. for 1 hour. The reaction mixture was concentrated to give 1-phenyl-5-(propan-2-yl)-1H-pyrazol-4-amine hydrochloride [INT 1.8] (210 mg, 883 μmol, 99.0% yield) as a yellow solid. 1H NMR (400MHz, MeOD) δ = 7.71 (s, 1H), 7.63-7.55 (m, 3H), 7.46-7.39 (m, 2H), 3.23-3.09 (m, 1H), 1.27 (d, J = 7.2Hz, 6H).
[0418] Synthesis of 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.9]:
[0419]
[0420] Synthesis of 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-ff]:
[0421] A mixture of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (2 g, 8.32 mmol) and (propan-2-yl)hydrazine hydrochloride [INT 1-ee] (920 mg, 8.32 mmol) in EtOH (20 mL) was stirred at 80 ° C for 16 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 10) to give ethyl 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-ff] (1.40 g, 5.59 mmol, 67.3% yield) as a colorless oil. m / z: [M+H]+ calculated for C10H14F3N2O2, 251.1; Found, 251.1. 1 H NMR (400MHz, DMSO-d6) δ = 8.08 (s, 1H), 4.80 (spt, J = 6.4Hz, 1H), 4.25 (q, J = 7.2Hz, 2H), 1.45 (d, J = 6.4Hz, 6H), 1.26 (t, J = 7.2Hz, 3H).
[0422] Synthesis of 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-gg]:
[0423] To ethyl 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-ff] (900 mg, 3.59 mmol) in THF (9 mL) and H 2 Lithium hydroxide monohydrate (448mg, 10.7mmol) was added to a solution in 4% HCl (3mL). The reaction mixture was stirred at 20°C for 12 hours and then concentrated under reduced pressure. The crude product was quenched with water (20mL) and washed with EtOAc (30mL x 2). The aqueous phase was then acidified to pH=4 with 1M HCl and extracted with EtOAc (20mLx 2). The combined organic layers were washed with brine (50mL x 2) and filtered through anhydrous Na2 SO 4 Dry, filter and concentrate under reduced pressure to give 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-gg] (250 mg, 1.12 mmol, 31.3% yield) as a colorless oil. m / z: [M+H]+ calculated for C8H10F3N2O2, 223.1; found, 223.0.
[0424] Synthesis of tert-butyl N-[1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-hh] become:
[0425] A mixture of 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-gg] (250 mg, 1.12 mmol), 2-methylpropan-2-ol (1.24 g, 16.8 mmol), diphenylphosphoryl azide (408 mg, 1.68 mmol) and triethylamine (340 mg, 3.36 mmol) in toluene (4 mL) was stirred at 100° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 20) to give tert-butyl N-[1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT1-hh] (150 mg, 511 μmol, 45.7% yield) as a yellow oil. m / z: [M+H]+ calcd. for C12H19F3N3O2, 294.1; found, 294.1.
[0426] Synthesis of 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.9]:
[0427] A solution of tert-butyl N-[1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-hh] (150 mg, 511 μmol) in dioxane (3 mL) containing 4M HCl was stirred at 20°C for 2 hours. The reaction mixture was concentrated under reduced pressure to give 1-(propan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.9] (110 mg, 479 μmol, 94.0% yield). m / z: [M+H]+ calculated for C7H11F3N3, 194.1; found, 193.9.
[0428] Synthesis of 1-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol hydrochloride [Intermediate 1.10]:
[0429]
[0430] Synthesis of 1-hydrazino-2-methylpropan-2-ol [INT 1-jj]:
[0431] To a suspension of 2,2-dimethyloxirane [INT 1-ii] (1.0 g, 13.8 mmol) in EtOH (5 mL) was added hydrazine (884 mg, 27.6 mmol). The reaction mixture was stirred at 60 ° C for 4 hours and then concentrated under reduced pressure to give 1-hydrazino-2-methylpropan-2-ol [INT 1-jj] (1.24 g, 11.9 mmol, 86.7% yield) as a colorless oil. 1 H NMR (400 MHz, CDCl 3 )δ=3.52(s,4H),2.71(s,2H),1.21-1.18(m,6H).
[0432] Synthesis of 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-kk] become:
[0433] 1-Hydrazino-2-methylpropan-2-ol [INT 1-jj] (1.03 g, 9.98 mmol) was added to a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (2.0 g, 8.32 mmol) in EtOH (8 mL). The reaction solution was stirred at 80 ° C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give ethyl 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-kk] (1 g, 3.56 mmol, 42.9% yield) as a yellow oil. m / z: [M+H]+ calculated for C11H16F3N2O3, 281.1; Found, 280.9. 1 H NMR (400 MHz, CDCl 3 )δ=8.01(s,1H),4.40-4.30(m,4H),3.85(s,1H),1.37(t,J=7.2Hz,3H),1.19(s,6H).
[0434] Synthesis of 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-11]:
[0435] To a solution of ethyl 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-kk] (1.0 g, 3.56 mmol) in THF (5 mL) was added lithium hydroxide monohydrate (298 mg, 7.12 mmol) in H 2O (5 mL). The reaction solution was stirred at 20 ° C for 3 hours. The reaction mixture was poured into water (10 mL), acidified to pH = 5-6 with 1N HCl, and extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (20 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-11] (710 mg, 2.81 mmol, 79.1% yield) as a yellow solid. m / z: [M+H]+ calculated for C9H12F3N2O3, 253.1; found, 252.9.
[0436] tert-Butyl N-[1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-mm] Synthesis:
[0437] A mixture of 1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-11] (710 mg, 2.81 mmol), diphenylphosphoryl azide (1.54 g, 5.62 mmol) and triethylamine (1.41 g, 14.0 mmol) in t-BuOH (8 mL) was stirred at N 2 The mixture was stirred at 100° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give tert-butyl N-[1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-mm] (600 mg, 1.85 mmol, 66.0% yield) as a yellow oil. m / z: [M+H]+ calculated for C13H21F3N3O3, 324.1; found, 323.9. 1 H NMR (400 MHz, CDCl 3 )δ=8.11(s,1H),6.47(s,1H),4.42(s,1H),4.08(s,2H),1.52(s,9H),1.17(s,6H).
[0438] Synthesis of 1-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol hydrochloride [INT1.10] become:
[0439] A solution of tert-butyl N-[1-(2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-mm] (600 mg, 1.85 mmol) in HCl / dioxane (5 mL) was stirred at 20° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to give 1-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol hydrochloride [INT 1.10] (480 mg, 1.84 mmol) as a yellow oil. m / z: [M+H]+ calculated for C8H13F3N3O, 224.1; found, 223.9.
[0440] Synthesis of 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.11]:
[0441]
[0442] Synthesis of N'-[(2Z)-1-methoxyprop-2-ylidene](tert-butoxy)carbohydrazide [INT1-oo]:
[0443] At 50 ° C, to a mixture of 1-methoxypropan-2-one [INT 1-nn] (10 g, 113 mmol) in heptane (400 mL) was added toluene (30 ml) containing (tert-butoxy) carbohydrazide (19.2 g, 146 mmol). The mixture was stirred at 70 ° C for 2 hours. The mixture was then stirred at 15 ° C for 12 hours. The formed precipitate was collected, washed with heptane and dried to obtain N'-[(2Z)-1-methoxypropan-2-ylidene] (tert-butoxy) carbohydrazide [INT 1-oo] (19.6 g, 96.9 mmol, 85.9% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ=7.59(br d,J=6.8Hz,1H),4.02(d,J=2.4Hz,2H),3.32-3.28(m,3H),1.84(s,3H),1.50(d,J=2.4Hz,9H).
[0444] Synthesis of N'-(1-methoxyprop-2-yl)(tert-butoxy)carbohydrazide [INT1-pp]:
[0445] N'-[(2Z)-1-methoxyprop-2-ylidene](tert-butyloxy)carbohydrazide [INT 1-oo] (5 g, 24.7 mmol) and PtO 2 A mixture of (0.05 g, 220 μmol) in AcOH (50 ml) was stirred at 4 °C for 2 h. 2 The mixture was stirred at 15°C for 12 h under 15 psi. After filtering the mixture through celite, NaHCO3 The solution was added to adjust the pH to 8-9. The mixture was extracted with EtOAc (100 mL x 2). The combined organic layers were passed through Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (CH 2 Cl 2 / MeOH=1 / 20 to 1 / 0) to give N'-(1-methoxypropan-2-yl)(tert-butoxy)carbohydrazide [INT 1-pp] (3.25 g, 15.9 mmol, 64.4% yield) as a yellow oil. m / z: [M-56+H]+ calculated for C9H21N2O3, 149.0; found, 148.9. 1 H NMR (400 MHz, CDCl 3 )δ=6.45-5.99(m,1H),4.25(br s,1H),3.34(s,3H),3.31(t,J=4.4Hz,1H),3.27-3.17(m,2H),1.44(s,9H),0.99(br s,3H).
[0446] Synthesis of (1-methoxyprop-2-yl)hydrazine hydrochloride [INT1-qq]:
[0447] A mixture of N'-(1-methoxypropan-2-yl)(tert-butoxy)carbohydrazide [INT 1-pp] (3.25 g, 15.9 mmol) in 4M HCl / dioxane (30 mL, 120 mmol) was stirred at 25°C for 4 hours. The mixture was concentrated under reduced pressure to give (1-methoxypropan-2-yl)hydrazine hydrochloride [INT 1-qq] (2.00 g, 14.2 mmol, 89.6% yield) as a yellow oil. m / z: [M+H]+ calculated for C4H13N2O, 105.1; found, 104.8.
[0448] Synthesis of 1-(1-methoxyprop-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-rr]:
[0449] A mixture of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (2 g, 8.32 mmol), (1-methoxypropan-2-yl)hydrazine hydrochloride [INT 1-qq] (1.28 g, 9.10 mmol) and triethylamine (841 mg, 8.32 mmol) in EtOH (20 mL) was stirred at 80° C. for 12 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 10 to 1 / 0) to give ethyl 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-rr] (990 mg, 3.55 mmol, 42.8% yield) as a yellow oil. m / z: [M+H]+ calcd. for C11H16F3N2O3, 281.1; found, 281.1. 1 H NMR (400MHz, DMSO-d6) δ = 8.11 (s, 1H), 4.88-4.77 (m, 1H), 4.25 (q, J = 6.8Hz, 2H), 3.74-3.66 (m,1H),3.62-3.55(m,1H),3.19-3.12(m,3H),1.40(d,J=6.8Hz,3H),1.27(t,J=7.2Hz,3H).
[0450] Synthesis of 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ss]:
[0451] To ethyl 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-rr] (890 mg, 3.17 mmol) in THF (6 mL) and H 2 LiOH.H O (2 mL) was added to the mixture 2 O (1.06 g, 25.3 mmol), and the mixture was stirred at 50 ° C for 2 hours. The mixture was concentrated under reduced pressure to give a crude product. 1N HCl was added to adjust the pH to 3-4, and the mixture was extracted with EtOAc (50 mL x 2). The combined organic layers were washed with anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ss] (395 mg, 1.56 mmol, 49.4% yield) as a yellow oil. m / z: [M+H]+ calculated for C9H12F3N2O3, 253.1; found, 253.0. 1 H NMR (400 MHz, CDCl 3)δ=8.07(s,1H),4.88(qd,J=6.8,13.2Hz,1H),3.85(t,J=9.2Hz,1H),3.63(dd,J=5.2,10.0Hz,1H),3.30(s,3H),1.52(d,J=6.8Hz,3H).
[0452] tert-Butyl N-[1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT1- Synthesis of tt]:
[0453] A mixture of 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ss] (295 mg, 1.16 mmol), 2-methylpropan-2-ol (1.28 g, 17.4 mmol), diphenylphosphoryl azide (423 mg, 1.74 mmol) and triethylamine (352 mg, 3.48 mmol) in toluene (3 mL) was stirred at 100 °C for 2 hours. NaHCO was added. 3 (30 mL), and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give a crude product, which is purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 10 to 1 / 0) to give tert-butyl N-[1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-tt] (208 mg, 643 μmol, 55.4% yield) as a yellow oil. m / z: [M+H]+ calculated for C13H21F3N3O3, 324.1; Found, 324.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.07(brs,1H),6.44(br s,1H),4.55(sxt,J=6.8Hz,1H),3.84(dd,J=7.6,9.6Hz,1H),3.60(dd,J=5.6,10.0Hz,1H),3.30(s,3H),1.51(s,9H),1.45(d,J=6.8Hz,3H).
[0454] 1-(1-Methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.11]:
[0455] A mixture of tert-butyl N-[1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT1-tt] (158 mg, 488 μmol) in 4M HCl / dioxane (15 mL, 60.0 mmol) was stirred at 15° C. for 4 hours. The mixture was concentrated under reduced pressure to give 1-(1-methoxypropan-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.11] (150 mg, 577 μmol) as a yellow oil. m / z: [M+H]+ calculated for C8H13F3N3O, 224.1; found, 223.9.
[0456] Synthesis of 1-neopentyl-5-(trifluoromethyl)-1H-pyrazol-4-amine [Intermediate 1.12]:
[0457]
[0458] Synthesis of N'-(2,2-dimethylpropyl)(tert-butoxy)carbohydrazide [INT 1-vv]:
[0459] A mixture of 2,2-dimethylpropanal [INT 1-uu] (5 g, 58.0 mmol) and (tert-butoxy)carbohydrazide (7.66 g, 58.0 mmol) in MeOH (80 mL) was stirred at 20° C. for 2 hours. 10% Pd / C (1 g) was then added. The flask was evacuated and heated with N 2 Backfill three times, then evacuate and rinse with H 2 Backfill three more times. 2 The mixture was stirred at 20 ° C for 12 hours under (15psi). The reaction solution was filtered and the filter cake was washed with MeOH (20mL x 3). The filtrate was cooled to 0 ° C, and then sodium cyanoborohydride (3.64g, 58.0mmol) was added. The mixture was stirred at 20 ° C for 1 hour. The reaction was quenched by adding water (80mL). The mixture was concentrated under reduced pressure to remove MeOH. The residue was diluted with water (100mL) and extracted with EtOAc (2x 150mL). The combined organic layer was washed with brine (2x 80mL), filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give N'-(2,2-dimethylpropyl)(tert-butoxy)carbohydrazide [INT 1-vv] (11.0 g, 54.3 mmol, 94% yield) as a gray solid. m / z: [Mt-Bu+H]+ calculated for C6H15N2O2, 147.2; found, 147.1. 1 H NMR (400 MHz, CDCl 3)δ=2.59(s,2H),1.39(s,9H),0.88(s,9H).
[0460] Synthesis of (2,2-dimethylpropyl)hydrazine [INT1-ww]:
[0461] N'-(2,2-dimethylpropyl)(tert-butoxy)carbohydrazide [INT 1-vv] (6 g, 29.6 mmol) was added to HCl / dioxane (40 mL) at 15° C., and the mixture was stirred for 2 hours. The mixture was concentrated under reduced pressure to give (2,2-dimethylpropyl)hydrazine [INT 1-ww] (3.02 g, 29.5 mmol). 1 H NMR (400MHz, DMSO-d6) δ = 2.67 (s, 2H), 0.91 (s, 9H).
[0462] Synthesis of 1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-xx]:
[0463] To a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (8.50 g, 35.4 mmol) in EtOH (100 mL) at 10°C was added (2,2-dimethylpropyl)hydrazine [INT 1-ww] (3.02 g, 29.5 mmol) and Et 3 N (5.97 g, 59.0 mmol). The mixture was stirred at 80 ° C for 3 hours. The reaction solution was concentrated under reduced pressure, quenched by adding water (50 mL), and extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine (50 mL x 2) and filtered through anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 20 / 1) to give ethyl 1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-xx] (1.81 g, 6.50 mmol, 22.0% yield) as a colorless oil. m / z: [M+H]+ calculated for C12H18F3N2O2, 279.1; found, 278.9. (400 MHz, CDCl 3 )δ=7.97(s,1H),4.34(q,J=8.0Hz,2H),4.19(s,2H),1.37(t,J=8.0Hz,3H),0.99(s,9H).
[0464] 1-(2,2-Dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-yy]:
[0465] At 10°C, ethyl 1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-xx] (1.81 g, 6.50 mmol) was dissolved in THF (10 mL) and H 2 In the solution of 1- (2,2- dimethylpropyl) -5- (trifluoromethyl) -1H- pyrazole -4- carboxylic acid [INT 1-yy] (1.16 g, 4.63 mmol, 71.6% yield) in 5- (trifluoromethyl) -1H- pyrazole -4- carboxylic acid was added to ... 1 H NMR (400MHz, DMSO) δ = 8.04 (s, 1H), 4.16 (s, 2H), 0.91 (s, 9H).
[0466] tert-Butyl N-[1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1- Synthesis of zz]:
[0467] A mixture of 1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-yy] (1.06 g, 4.23 mmol), 2-methylpropan-2-ol (4.69 g, 63.4 mmol), diphenylphosphoryl azide (1.54 g, 6.34 mmol) and triethylamine (2.13 g, 21.1 mmol) in toluene (10 mL) was stirred at 100 ° C for 2 hours. The mixture was post-treated with materials from two identical reactions. Water (40 mL) was added, and the mixture was extracted with EtOAc (40 mL x 2). The combined organic layer was washed with brine (40 mL x 2) and purified by anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 10 to 20 / 1) to give tert-butyl N-[1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-zz] (1.27 g, 3.95 mmol) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ=8.02(s,1H),6.43(s,1H),3.94(s,2H),1.52(s,9H),0.99(s,9H).
[0468] 1-neopentyl-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT1.12]:
[0469] A solution of tert-butyl N-[1-(2,2-dimethylpropyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT1-zz] (500 mg, 1.55 mmol) in HCl / dioxane (10 mL) was stirred at 10 ° C for 1 hour. TLC showed that the starting material was completely consumed and a new spot was formed. The mixture was concentrated under reduced pressure to give 1-neopentyl-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT1.12] (342 mg, 1.54 mmol).
[0470] Synthesis of 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.13]:
[0471]
[0472] Synthesis of 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-bbb]:
[0473] The mixture was prepared from ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (9.39 g, 39.1 mmol), 3-hydrazinopyridine hydrochloride [INT 1-aaa] (5.7 g, 39.1 mmol), Et 3 A solution of N (7.91 g, 78.2 mmol) and EtOH (50 mL) was stirred at 80 ° C for 16 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash column chromatography (petroleum ether: ethyl acetate = 100: 0 to 80: 20) to give 1- (pyridin-3-yl) -5- (trifluoromethyl) -1H- pyrazole-4-carboxylic acid ethyl ester [INT 1-bbb] (3.45 g, 12.0 mmol, 31.0% yield). m / z: [M + H] + calculated for C12H11F3N3O2, 286.1; experimental value, 285.9. 1 H NMR (400 MHz, CDCl 3 )δ=8.78(dd,J=1.2,4.8Hz,1H),8.74(d,J=2.4Hz,1H),8.18(s,1H),7.84-7.76( m, 1H), 7.50 (dd, J = 4.8, 8.0Hz, 1H), 4.40 (q, J = 7.2Hz, 2H), 1.41 (t, J = 7.2Hz, 3H).
[0474] 1-(Pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride [INT1-ccc]:
[0475] To a solution of 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-bbb] (3.45 g, 12.0 mmol) in THF (1 mL) was added lithium hydroxide monohydrate (12.0 mL, 24.0 mmol). The mixture was stirred at 25 ° C for 16 hours. The resulting solution was concentrated to dryness under reduced pressure to give a crude product, which was poured into water (20 mL) and acidified to pH = 5 with 1M HCl. The resulting solution was filtered, and the filter cake was washed with water (20 mL) and then dried under reduced pressure to give 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride [INT1-ccc] (2.30 g, 7.83 mmol, 65.3% yield) as a white solid. m / z: [M+H]+ calcd. for C10H7F3N3O2, 258.0; found, 257.9.
[0476] Tert-butyl N-[1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ddd] Synthesis of:
[0477] A solution of 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid hydrochloride [INT 1-ccc] (500 mg, 1.70 mmol), triethylamine (472 μL, 3.40 mmol) and diphenylphosphoryl azide (701 mg, 2.55 mmol) in tert-butyl alcohol (2 mL, 21.1 mmol) was stirred at N 2 The mixture was stirred at 90 °C for 2 hours. The reaction was quenched by adding water (15 mL) and extracted with EtOAc (2 x 15 mL). The combined organic layers were washed with brine (2 x 30 mL) and purified by anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 4) to give tert-butyl N-[1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ddd] (443 mg, 1.34 mmol, 79.3% yield) as a white solid. m / z: [M+H]+ calculated for C14H16F3N4O2, 329.1; found, 328.9. 1 H NMR (400 MHz, CDCl 3 )δ=8.80-8.69(m,2H),8.35(br s,1H),7.81(br d,J=8.0Hz,1H),7.47(dd,J=4.8,8.0Hz,1H),6.60(br s,1H),1.56(s,9H).
[0478] 1-(Pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.13]:
[0479] A solution of tert-butyl N-[1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ddd] (443 mg, 1.34 mmol) in HCl (4M in dioxane, 5 mL, 20.0 mmol) was stirred at 20° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give 1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.13] (343 mg, 1.29 mmol, 96.8% yield) as a yellow solid. m / z: [M+H]+ calculated for C9H8F3N4, 229.1; found, 228.9. 1 H NMR (400MHz, DMSO-d6) δ = 8.81 (d, J = 2.4Hz, 1H), 8.79 (dd, J = 1.2, 4.8Hz, 1H), 8.12 (br d, J = 8.4Hz, 1H), 7.83 (s, 1H), 7.75 (dd, J = 4.8, 8.4Hz, 1H).
[0480] Synthesis of 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [Intermediate 1.14]:
[0481]
[0482] Synthesis of 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-fff]:
[0483] To a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (7.20 g, 30.0 mmol) in EtOH (50 mL) at 10 °C was added 4-hydrazinopyridine hydrochloride [INT 1-eee] (4.37 g, 30.0 mmol) and Et 3 N (3.03 g, 30.0 mmol), and then the mixture was stirred at 80 ° C for 3 hours. The reaction solution was concentrated under reduced pressure, quenched by adding water (50 mL), and extracted with EtOAc (50 mL x 3). The combined organic layer was washed with brine (50 mL x 2) and washed with anhydrous Na 2 SO 4The reaction mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 3 / 1) to give ethyl 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-fff] (3.00 g, 10.5 mmol, 35.0% yield) as a yellow solid. m / z: [M+H]+ calculated for C12H11F3N3O2, 286.0; found, 285.9.
[0484] Synthesis of 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-ggg]:
[0485] At 10°C, ethyl 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-fff] (2.5 g, 8.76 mmol) was dissolved in THF (15 mL) and H 2 To the solution in 4% paraformaldehyde (2% paraformaldehyde) (4% paraformaldehyde) (5% paraformaldehyde) (6% paraformaldehyde) (7% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (20% paraformaldehyde) (10% paraformaldehyde) (20% paraformaldehyde) (6% paraformaldehyde) (7% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8% paraformaldehyde) (9% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (10% paraformaldehyde) (6% paraformaldehyde) (8 ...
[0486] Tert-butyl N-[1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-hhh] Synthesis of:
[0487] To a mixture of 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ggg] (1 g, 3.88 mmol) in t-BuOH (3 mL) and dioxane (5 mL) was added triethylamine (1.96 g, 19.4 mmol) and diphenylphosphoryl azide (1.88 g, 7.76 mmol) at 10 ° C, and the mixture was stirred at 100 ° C for 2 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layer was washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 10 to 3 / 1) to give tert-butyl N-[1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-hhh] (360 mg, 1.09 mmol, 28.3% yield) as a white solid. 1 H NMR (400 MHz, DMSO) δ = 8.78 (d, J = 4.0 Hz, 2H), 8.58 (s, 1H), 8.00 (s, 1H), 7.56 (d, J = 4.0 Hz, 2H), 1.46 (s, 9H).
[0488] Synthesis of 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT1.14]:
[0489] A solution of tert-butyl N-[1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-hhh] (360 mg, 1.09 mmol) in HCl / dioxane (10 mL) was stirred at 50° C. for 12 hours. The mixture was concentrated under reduced pressure to give 1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.14] (248 mg, 1.08 mmol). m / z: [M+H]+ calculated for C9H8F3N4, 229.1; found, 229.1.
[0490] Synthesis of 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [Intermediate 1.15]:
[0491]
[0492] Synthesis of 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-jjj]:
[0493] To a solution of 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoic acid ethyl ester (5g, 20.8mmol) and 2-hydrazinopyridine [INT 1-iii] (2.26g, 20.8mmol) in EtOH (30mL), triethylamine (2.10g, 20.8mmol) was added. The mixture was stirred at 80°C for 12 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 10 / 1) to give 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-jjj] (5.00g, 17.5mmol, 84.3% yield) as a yellow oil. m / z: [M+H]+ calcd. for C12H11F3N3O2, 286.1; found, 285.9. 1 H NMR (400MHz, DMSO-d6) δ = 8.64-8.59 (m, 1H), 8.34 (s, 1H), 8.19-8.12 (m, 1H), 7.80 (dd ,J=0.8,8.0Hz,1H),7.68-7.63(m,1H),4.33(q,J=7.2Hz,2H),1.31(t,J=7.2Hz,3H).
[0494] Synthesis of 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-kkk]:
[0495] To ethyl 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-jjj] (1 g, 3.50 mmol) in THF (6 mL) and H 2 To the mixture in 4% CO (2 mL), lithium hydroxide monohydrate (440 mg, 10.5 mmol) was added. The reaction mixture was stirred at 15 °C for 12 h. The reaction mixture was concentrated under reduced pressure. The residue was acidified to pH = 4 with 1 M HCl. The reaction mixture was stirred by adding H 2 O (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL) and purified by Na 2 SO 4 Dried, filtered and concentrated under reduced pressure to give 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-kkk] (800 mg, 3.11 mmol, 88.8% yield) as a yellow solid. 1H NMR(400MHz,DMSO-d6)δ=13.43(br s,1H),8.60(td,J=0.8,4.8Hz,1H),8.28(s,1H),8.14(dt,J=2.0,7.6Hz,1H),7.79(d,J=8.0Hz,1H),7.64(ddd,J=0.8,4.8,7.6Hz,1H).
[0496] Tert-butyl N-[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-111] Synthesis of:
[0497] A mixture of 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-kkk] (400 mg, 1.55 mmol), triethylamine (784 mg, 7.75 mmol) and diphenylphosphoryl azide (564 mg, 2.32 mmol) in t-BuOH (3 mL) and dioxane (3 mL) was stirred at 100 ° C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 0 to 1 / 1) to give tert-butyl N-[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-111] (470 mg, 1.43 mmol, 92.5% yield) as a white solid. m / z: [M+H]+ calcd. for C14H16F3N4O2, 329.1; found, 328.9. 1 H NMR(400MHz,DMSO-d6)δ=9.14(br s,1H),8.56-8.51(m,1H),8.06(dt,J=1.8,7.6Hz,1H),7.95(s,1H),7.77(d,J=8.0Hz,1H),7.55-7.46(m,1H),1.46(s,9H).
[0498] Synthesis of 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.15]:
[0499] A solution of tert-butyl N-[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-111] (470 mg, 1.43 mmol) in 4M HCl / dioxane (4 mL) was stirred at 15° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT1.15] (260 mg, 1.13 mmol, 79.7% yield) as a white solid. m / z: [M+H]+ calculated for C9H8F3N4, 229.1; found, 228.9. 1H NMR (400MHz, DMSO-d6) δ = 8.48 (dd, J = 1.2, 4.8Hz, 1H), 8.01 (dt, J = 1.6, 7.6Hz, 1H), 7.76-7.72 (m, 2H), 7.65 (br s, 2H), 7.43 (dd, J = 4.8, 6.8Hz, 1H).
[0500] Synthesis of 2-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile [Intermediate 1.16]:
[0501]
[0502] Synthesis of 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-nnn]:
[0503] To a solution of (2-bromophenyl) hydrazine hydrochloride [INT 1-mmm] (5 g, 22.3 mmol) and ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (4.44 g, 18.5 mmol) in EtOH (6 mL) was added triethylamine (2.81 g, 27.8 mmol). The mixture was stirred at 80 ° C for 12 hours. The reaction was quenched by adding water (50 mL) and extracted with EtOAc (3x50 mL). The combined organic layer was washed with brine (2x 50 mL) and filtered through anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 1 / 10) to give ethyl 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-nnn] (3.00 g, 8.26 mmol, 44.7% yield) as a red oil. m / z: [M+H]+ calculated for C13H11BrF3N2O2, 363.0; found, 362.9.
[0504] Synthesis of 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-ooo]:
[0505] To ethyl 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-nnn] (2 g, 3.30 mmol) in THF (3 mL) and H 2 To the solution in 4% CO (1 mL), lithium hydroxide monohydrate (276 mg, 6.60 mmol) was added. The mixture was stirred at 25 °C for 16 h. The reaction was quenched by adding 1N HCl (10 mL) and H 2 O (20 mL) and extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (2 x 50 mL) and filtered through anhydrous Na2 SO 4 Dry and concentrate under reduced pressure to give 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ooo] (800 mg, 2.38 mmol, 72.7% yield) as a red solid. 1 H NMR (400MHz, DMSO-d6) δ = 13.43 (br s, 1H), 8.31 (s, 1H), 7.88 (dd, J = 1.6, 7.6Hz, 1H), 7.74 (dd, J = 2.0, 7.6Hz, 1H), 7.59 (dquin, J = 1.6, 7.6Hz, 2H).
[0506] Tert-butyl N-[1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ppp] synthesis:
[0507] To a solution of 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ooo] (1.2 g, 3.58 mmol) in toluene (1 mL) was added diphenylphosphoryl azide (1.47 g, 5.37 mmol), triethylamine (1.08 g, 10.7 mmol) and 2-methyl-2-propanol (2.65 g, 35.8 mmol). The reaction mixture was stirred at N 2 The mixture was stirred at 100°C for 16 hours. The reaction solution was diluted with water (50 mL) and extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (50 mL x 2) and purified by anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give tert-butyl N-[1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ppp] (400 mg, 984 μmol, 27.5% yield) as a yellow oil. m / z: [M+H]+ calculated for C15H16BrF3N3O2, 406.0; found, 406.1. 1 H NMR (400MHz, DMSO-d6) δ = 9.04 (br s, 1H), 7.92 (br s, 1H), 7.88-7.85 (m, 1H), 7.65-7.52 (m, 3H), 1.46 (s, 9H).
[0508] Synthesis of 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-amine [INT1-qqq]:
[0509] A mixture of tert-butyl N-[1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-ppp] (400 mg, 1.13 mmol) in HCl / dioxane (4 mL) was stirred at 4 °C for 1 h. 2 The reaction was stirred at 25 °C for 12 h. The reaction was concentrated by adding saturated NaHCO 3 The combined organic layers were washed with brine (2 x 50 mL) and purified by anhydrous Na 2 SO 4 Drying and concentration under reduced pressure gave 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1-qqq] (290 mg, 947 μmol, 96.6% yield) as a yellow oil. m / z: [M+H]+ calculated for C10H8BrF3N3, 306.0; found, 305.8. 1 H NMR (400MHz, DMSO-d6) δ = 7.81 (d, J = 7.6Hz, 1H), 7.56-7.35 (m, 4H), 4.81 (s, 2H).
[0510] Synthesis of 2-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile [INT1.16]:
[0511] A mixture of 1-(2-bromophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1-qqq] (240 mg, 784 μmol) and copper cyanide (351 mg, 3.92 mmol) in DMF (3 mL) was stirred at N 2 The reaction mixture was stirred at 140°C for 2 hours. The reaction mixture was combined with another identical reaction mixture and NH 3 .H 2 O (5 mL) and H 2 O (20 mL), and then the mixture was extracted with EtOAc (3 x 20 mL). The combined organic layers were washed with brine (3 x 20 mL) and filtered through anhydrous Na 2 SO 4 Drying and concentrating under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 0 to 1 / 1) to give 2-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile [INT1.16] (160 mg, 634 μmol, 81.2% yield) as a yellow oil. m / z: [M+H]+ calculated for C11H8F3N4, 253.1; found, 252.9. 1H NMR (400MHz, DMSO-d6) δ = 8.06 (d, J = 7.6Hz, 1H), 7.91-7.84 (m, 1H), 7.77-7.70 (m, 1H), 7.65 (d, J = 8.0Hz, 1H), 7.47 (s, 1H), 5.01 (s, 2H).
[0512] Synthesis of 3-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile hydrochloride [Intermediate 1.17]:
[0513]
[0514] Synthesis of 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-sss]:
[0515] 3-Hydrazinobenzonitrile hydrochloride [INT1-rrr] (2.10 g, 12.4 mmol) and triethylamine (1.37 g, 13.6 mmol) were added to a solution of 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoic acid ethyl ester (3.0 g, 12.4 mmol) in EtOH (5 mL). The reaction solution was stirred at 20 ° C for 16 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-sss] (350 mg, 1.13 mmol, 9.1% yield) as a red solid. m / z: [M+H]+ calcd. for C14H11F3N3O2, 310.1; found, 310.0. 1 H NMR (400 MHz, CDCl 3 )δ=8.17(s,1H),7.87-7.81(m,1H),7.79(s,1H),7.75-7.62(m,2H),4.41(q,J=7.2Hz,2H),1.41(t,J=7.2Hz,3H).
[0516] Synthesis of 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-ttt]:
[0517] To a solution of ethyl 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-sss] (2.35 g, 5.30 mmol) in THF (15 mL) was added lithium hydroxide monohydrate (444 mg, 10.6 mmol) in H 2O (5 mL). The reaction solution was stirred at 20 ° C for 12 hours. The reaction mixture was poured into 10 mL of water, acidified to pH = 3-4 with 1N HCl, and extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (MeOH / DCM=0 / 1 to 1 / 20) to give 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ttt] (1.50 g, 5.33 mmol, 100% yield) as a brown solid. 1 H NMR (400MHz, DMSO-d6) δ = 13.41 (brs, 1H), 8.29 (s, 1H), 8.20 (t, J = 1.6Hz, 1H), 8.12-8.07 (m, 1H), 7.94 (br d, J = 8.8Hz, 1H), 7.83-7.78 (m, 1H).
[0518] Tert-butyl N-[1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT1-uuu] Synthesis of:
[0519] A solution of 1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ttt] (1.45 g, 5.15 mmol), triethylamine (781 mg, 7.72 mmol) and diphenylphosphoryl azide (2.83 g, 10.3 mmol) in t-BuOH (6 mL) was stirred at N 2 The mixture was stirred at 100° C. for 3 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give tert-butyl N-[1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-uuu] (1 g, 2.83 mmol, 55.2% yield) as a white solid. m / z: [M+H]+ calculated for C16H16F3N4O2, 353.1; Found, 353.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.32(br s,1H),7.79-7.73(m,2H),7.71(br d,J=8.0Hz,1H),7.65-7.59(m,1H),6.55(br s,1H),1.55(s,9H).
[0520] Synthesis of 3-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile hydrochloride [INT1.17]:
[0521] A solution of tert-butyl N-[1-(3-cyanophenyl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-uuu] (100 mg, 283 μmol) in HCl / dioxane (1.5 mL) was stirred at 20° C. for 2 hours. The reaction was concentrated under reduced pressure to give 3-[4-amino-5-(trifluoromethyl)-1H-pyrazol-1-yl]benzonitrile hydrochloride [INT 1.17] (82.0 mg, 284 μmol, 100% yield) as an off-white solid. m / z: [M+H]+ calculated for C11H8F3N4, 253.1; found, 253.0. 1 H NMR (400MHz, DMSO-d6) δ = 8.04-7.94 (m, 2H), 7.85-7.71 (m, 2H), 7.61 (s, 1H).
[0522] Synthesis of 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [Intermediate 1.18]:
[0523]
[0524] Synthesis of 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-www]:
[0525] To a solution of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (5.45 g, 22.7 mmol) in EtOH (10 mL) at 10 °C was added 2-hydrazinopyrimidine [INT 1-vvv] (2.5 g, 22.7% mmol) and Et 3 N (2.29 g, 22.7 mmol). The mixture was stirred at 80 ° C for 3 hours. The reaction solution was concentrated under reduced pressure, quenched by adding water (100 mL), and extracted with EtOAc (80 mL x 3). The combined organic layer was washed with brine (80 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 5 / 1) to give ethyl 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-www] (4.72 g, 16.5 mmol, 72.7% yield) as a yellow oil. 1 H NMR (400MHz, DMSO) δ=9.08 (d, J=4.0Hz, 2H), 8.38 (s, 1H), 7.83 (t, J=4.0Hz, 1H), 4.33 (q, J=8.0Hz, 2H), 1.31 (t, J=8.0Hz, 3H).
[0526] Synthesis of 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-xxx]:
[0527] To ethyl 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-www] (4 g, 13.9 mmol) in THF (6 mL) and H 2 Lithium hydroxide monohydrate (2.91 g, 69.5 mmol) was added to the solution in 4% HCl (2 mL). The mixture was then stirred at 50°C for 2 hours. The mixture was post-treated with another identical reaction solution. The mixture was acidified to pH = 5 with 1M HCl and extracted with EtOAc (60 mL x 2). The combined organic layers were washed with brine (40 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, and concentrate under reduced pressure to give 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-xxx] (3.80 g, 14.7 mmol) as a pale yellow solid. 1 H NMR (400MHz, DMSO) δ = 9.07 (d, J = 4.0Hz, 2H), 8.30 (s, 1H), 7.82 (t, J = 6.0Hz, 1H)
[0528] Tert-butyl N-[1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-yyy] Synthesis of:
[0529] To a mixture of 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-xxx] (500 mg, 1.93 mmol) in t-BuOH (2 mL) and dioxane (6 mL) at 10 ° C. triethylamine (781 mg, 7.72 mmol) and diphenylphosphoryl azide (1.40 g, 5.79 mmol) were added. The mixture was then stirred at 100 ° C. for 2 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layer was washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 0 to 3 / 1) to give tert-butyl N-[1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-yyy] (340 mg, 1.03 mmol, 53.5% yield) as a white solid. 1H NMR (400MHz, DMSO) δ = 9.23 (s, 1H), 8.98 (d, J = 4.0Hz, 2H), 7.99 (s, 1H), 7.65 (t, J = 4.0Hz, 1H), 1.47 (s, 9H).
[0530] Synthesis of 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT1.18]:
[0531] A solution of tert-butyl N-[1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-yyy] (340 mg, 1.03 mmol) in HCl / dioxane (10 mL) was stirred at 15° C. for 1 hour. The mixture was concentrated under reduced pressure to give 1-(pyrimidin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.18] (236 mg, 1.02 mmol, 100% yield) as a brown solid. 1 H NMR (400MHz, DMSO) δ = 8.86 (d, J = 4.0 Hz, 2H), 7.56 (s, 1H), 7.49 (t, J = 4.0 Hz, 1H).
[0532] Synthesis of 1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.19]:
[0533]
[0534] Synthesis of 1-(pyrazine-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-aaaa]:
[0535] 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutyric acid ethyl ester (4.34g, 18.1mmol) and triethylamine (2.01g, 19.9mmol) were added to a solution of 2-hydrazinopyrazine [INT 1-zzz] (2.0g, 18.1mmol) in EtOH (15mL). The reaction solution was stirred at 20°C for 16 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give 1-(pyrazine-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-aaaa] (3.00g, 10.4mmol, 57.9% yield) as an oil. m / z: [M+H]+ calcd. for C11H10F3N4O2, 287.1; found, 287.1. 1 H NMR (400 MHz, CDCl 3)δ=9.01(d,J=1.2Hz,1H),8.73(d,J=2.8Hz,1H),8.59-8.54(m,1H),8.18(s,1H),4.40(q,J=6.8Hz,2H),1.40(t,J=7.2Hz,3H).
[0536] Synthesis of 1-(pyrazine-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-bbbb]:
[0537] To a solution of ethyl 1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-aaaa] (2.8 g, 9.78 mmol) in THF (12 mL) was added lithium hydroxide monohydrate (818 mg, 19.5 mmol). 2 O (4 mL). The reaction solution was stirred at 20 ° C for 4 hours. The reaction mixture was poured into 20 mL of water, acidified to pH = 3-4 with 1N HCl, and extracted with EtOAc (30 mL x 2). The combined organic layer was washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give 1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-bbbb] (2.25 g, 8.71 mmol, 89.2% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ=13.57(br s,1H),9.14(s,1H),8.92(d,J=2.4Hz,1H),8.75(d,J=1.2Hz,1H),8.37(s,1H).
[0538] Tert-butyl N-[1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-cccc] Synthesis of:
[0539] A solution of 1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-bbbb] (2.25 g, 8.71 mmol), triethylamine (1.31 g, 13.0 mmol) and diphenylphosphoryl azide (4.78 g, 17.4 mmol) in t-BuOH (20 mL) was stirred at N 2The mixture was stirred at 100° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give tert-butyl N-[1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-cccc] (2.33 g, 7.07 mmol, 81.4% yield) as a white solid. m / z: [M+H]+ calculated for C13H15F3N5O2, 330.1; found, 330.0. 1 H NMR (400 MHz, CDCl 3 )δ=9.15(d,J=0.8Hz,1H),8.56(d,J=2.4Hz,1H),8.51-8.36(m,2H),6.76(br s,1H),1.54(s,9H).
[0540] Synthesis of 1-(pyrazine-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT1.19]:
[0541] A mixture of tert-butyl N-[1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-cccc] (100 mg, 303 μmol) in HCl / dioxane (5 mL) was stirred at 20° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give 1-(pyrazin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.19] (81.0 mg, 304 μmol) as a brown solid. m / z: [M+H]+ calculated for C8H7F3N5, 230.1; found, 229.9. 1 HNMR (400MHz, DMSO-d6) δ = 9.04 (d, J = 1.6Hz, 1H), 8.59 (d, J = 2.4Hz, 1H), 8.53-8.49 (m, 1H), 7.64 (s, 1H).
[0542] Synthesis of 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.20]:
[0543]
[0544] Synthesis of 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-eeee]:
[0545] A mixture of ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (5 g, 20.8 mmol) and 4-hydrazinopyrimidine [INT 1-dddd] (2.74 g, 24.9 mmol) in EtOH (50 mL) was stirred at 80 ° C for 4 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (0-15% EtOAc / petroleum ether) to give ethyl 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT1-eeee] (3.90 g, 13.6 mmol, 65.5% yield) as a white solid. m / z: [M+H]+ calculated for C11H10F3N4O2, 287.1; Found, 287.0. 1 H NMR (400 MHz, CDCl 3 )δ=9.21(s,1H),8.96(dd,J=2.0,5.6Hz,1H),8.14(s,1H),7.80(td,J=1.2,5.6Hz,1H),4.40(tq,J=1.6,7.2Hz,2H),1.44-1.36(m,3H).
[0546] Synthesis of 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ffff]:
[0547] To ethyl 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-eeee] (2.9 g, 10.1 mmol) in THF (15 mL) and H 2 O (5 mL) was added to the mixture. 2 O (1.27 g, 30.3 mmol) was added, and the mixture was stirred at 50° C. for 6 hours. The mixture was concentrated under reduced pressure to obtain a crude product. H 2 O (200 mL) and EtOAc (200 mL), and the precipitate was collected by filtration. The aqueous phase was washed with EtOAc (200 mL x 2), acidified to pH = 3 with 1M HCl, and extracted with EtOAc (200 mL x 2). The combined organic layers were filtered through Na 2 SO 4 The filtrate was concentrated to give a yellow solid, which was combined with the precipitate to give 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ffff] (2.10 g, 8.13 mmol, 80.7% yield) as a yellow solid. 1 H NMR (400 MHz, CDCl 3)δ=9.23(s,1H),8.99(d,J=5.6Hz,1H),8.22(s,1H),7.81(d,J=4.4Hz,1H).
[0548] N-[1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamic acid tert-butyl ester [INT1-gggg] Synthesis of:
[0549] A mixture of 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-ffff] (1.6 g, 6.19 mmol), 2-methylpropan-2-ol (6.87 g, 92.8 mmol), diphenylphosphoryl azide (2.25 g, 9.28 mmol) and triethylamine (1.87 g, 18.5 mmol) in toluene (20 mL) was stirred at 100 °C for 3 hours. NaHCO was added. 3 (100 mL), and the mixture was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (100 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-10% EtOAc / petroleum ether) to give tert-butyl N-[1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-gggg] (1.80 g, 5.46 mmol, 88.6% yield) as a white solid. m / z: [M+H]+ calculated for C13H15F3N5O2, 330.1; found, 330.1. 1 H NMR (400 MHz, CDCl 3 )δ=9.06(s,1H),8.79(d,J=5.6Hz,1H),8.49(br s,1H),7.88(d,J=5.6Hz,1H),6.82(br s,1H),1.54(s,9H).
[0550] Synthesis of 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT1.20]:
[0551] A mixture of tert-butyl N-[1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-gggg] (150 mg, 455 μmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 6 hours. The mixture was concentrated under reduced pressure to give 1-(pyrimidin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.20] (120 mg, 451 μmol) as a brown solid. m / z: [M+H]+ calculated for C8H7F3N5, 230.1; found, 230.0.
[0552] Synthesis of 1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.21]:
[0553]
[0554] Synthesis of 1-(pyridazine-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-iiii]:
[0555] 3-Hydrazinopyridazine [INT 1-hhhh] (800 mg, 7.26 mmol), Et 3 A solution of N (1.46 g, 14.5 mmol), ethyl 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoate (1.74 g, 7.26 mmol) and EtOH (50 mL) was stirred at 80 ° C for 16 hours. The mixture was concentrated under reduced pressure to give a brown oil, which was purified by flash column chromatography (petroleum ether: ethyl acetate = 0: 1 to 85: 15) to give 1-(pyridazine-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-iiii] (1 g, 3.49 mmol, 48.3% yield) as a white solid. m / z: [M+H]+ calculated for C11H10F3N4O2, 287.1; Found, 286.9. 1 H NMR (400 MHz, CDCl 3 )δ=9.36(dd,J=1.2,4.8Hz,1H),8.23(s,1H),7.95(dd,J=1.6,8.8Hz,1H),7.80(dd,J=4.8,8.8Hz,1H),4.46-4.41(m,2H),1.45-1.41(m,3H).
[0556] Synthesis of 1-(pyridazine-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT1-jjjj]:
[0557] Ethyl 1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-iiii] (800 mg, 2.79 mmol) was dissolved in THF (9 mL) and H 2 The mixture in 4% paraformaldehyde (2% paraformaldehyde) (2% paraformaldehyde) (3 ... 1 H NMR (400 MHz, DMSO-d6) δ = 9.46 (dd, J = 1.2, 4.8 Hz, 1H), 8.41 (s, 1H), 8.21 (dd, J = 1.2, 8.8 Hz, 1H), 8.10 (dd, J = 4.8, 8.8 Hz, 1H).
[0558] Tert-butyl N-[1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-kkkk] Synthesis of:
[0559] To a solution of 1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-jjjj] (200 mg, 774 μmol) in t-BuOH (3 mL) was added diphenylphosphoryl azide (319 mg, 1.16 mmol) and Et 3 The reaction mixture was stirred at 4 ℃ for 2 h under N 2 The mixture was stirred at 100 °C for 2 hours, then quenched by adding water (15 mL) and extracted with EtOAc (2 x 10 mL). The combined organic layers were washed with brine (2 x 20 mL) and purified by anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 4) to give tert-butyl N-[1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-kkkk] (142 mg, 431 μmol, 55.9% yield) as a colorless oil. m / z: [M+H]+ calculated for C13H15F3N5O2, 330.1; found, 330.0.1 H NMR (400 MHz, CDCl 3 )δ=9.20(d,J=4.4Hz,1H),8.51(brs,1H),8.07(br d,J=8.8Hz,1H),7.68(dd,J=4.8,8.8Hz,1H),6.79(br s,1H),1.57(s,9H).
[0560] Synthesis of 1-(pyridazine-3-yl)-5-(trifluoromethyl)-1H-pyrazole-4-amine hydrochloride [INT1.21]:
[0561] A solution of tert-butyl N-[1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-kkkk] (142 mg, 431 μmol) in HCl (4M in dioxane, 5 mL, 20.0 mmol) was stirred at 20° C. for 12 hours. The mixture was concentrated under reduced pressure to give 1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.21] (114 mg, 429 μmol) as a yellow solid. m / z: [M+H]+ calculated for C8H7F3N5, 230.1; found, 230.0.
[0562] Synthesis of 1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.22]:
[0563]
[0564] Synthesis of 4-hydrazinopyridazine [INT1-mmmm]:
[0565] To a mixture of 4-chloropyridazine hydrochloride [INT 1-111] (900 mg, 5.96 mmol) in EtOH (10 mL) was added NH 2 NH 2 ·H 2 O (3.50 g, 59.6 mmol). The reaction mixture was stirred at 80° C. for 12 hours. The reaction mixture was concentrated to give 4-hydrazinopyridazine [INT 1-mmmm] (656 mg, 5.95 mmol) as a brown oil. 1 HNMR (400MHz, DMSO-d6) δ = 8.59 (d, J = 2.4 Hz, 1H), 8.47 (dd, J = 0.8, 6.0 Hz, 1H), 6.73 (dd, J = 2.8, 6.0 Hz, 1H).
[0566] Synthesis of 1-(pyridazine-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-nnnn]:
[0567] To a mixture of 4-hydrazinopyridazine [INT 1-mmmm] (656mg, 5.95mmol) and 2-(ethoxymethylene)-4,4,4-trifluoro-3-oxobutanoic acid ethyl ester (7.13g, 29.7mmol) in EtOH (10mL), triethylamine (6.02g, 59.5mmol) is added. The reaction mixture is stirred at 80 ° C for 3 hours. The reaction mixture is concentrated, diluted with water (100mL), and extracted with EtOAc (50mL x 3). The combined organic layer is washed with brine (100mL), dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by flash chromatography using silica gel (20-25% EtOAc / petroleum ether) to give ethyl 1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-nnnn] (1 g, 3.49 mmol, 58.8% yield) as a brown oil. m / z: [M+H]+ calculated for C11H10F3N4O2, 287.1; found, 287.0. 1 H NMR (400 MHz, CDCl 3 )δ=9.55-9.42(m,2H),8.25(s,1H),7.71(br s,1H),4.42(q,J=7.2Hz,2H),1.41(t,J=7.2Hz,3H).
[0568] Synthesis of 1-(pyridazine-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-oooo]:
[0569] To ethyl 1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylate [INT 1-nnnn] (950 mg, 3.31 mmol) in THF (10 mL) and H 2 O (3mL) in the mixture was added lithium hydroxide monohydrate (416mg, 9.93mmol). The reaction mixture was stirred at 25 ° C for 2 hours. The reaction mixture was concentrated, diluted with water (50mL), and washed with EtOAc (50mL x 2). The aqueous phase was acidified to pH = 3 with 1M HCl and extracted with EtOAc (50mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give 1- (pyridazine-4-yl) -5- (trifluoromethyl) -1H- pyrazole -4- carboxylic acid [INT 1-oooo] (530mg, 2.05mmol, 62.0% yield) as a yellow solid. m / z: [M + H] + calculated for C9H6F3N4O2, 259.0; experimental value, 258.9. 1H NMR (400MHz, DMSO-d6) δ = 9.58 (d, J = 2.4 Hz, 1H), 9.56 (dd, J = 1.2, 5.6 Hz, 1H), 8.42 (s, 1H), 8.06 (dd, J = 2.4, 5.6 Hz, 1H).
[0570] N-[1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamic acid tert-butyl ester [INT1-pppp] Synthesis of:
[0571] To a mixture of 1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-carboxylic acid [INT 1-oooo] (500 mg, 1.93 mmol) and 2-methylpropan-2-ol (2.14 g, 28.9 mmol) in toluene (5 mL) was added diphenylphosphoryl azide (795 mg, 2.89 mmol) and triethylamine (585 mg, 5.79 mmol). The reaction mixture was stirred at 100 ° C. for 2 hours under nitrogen. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give tert-butyl N-[1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-pppp] (250 mg, 759 μmol, 39.3% yield) as a white solid. m / z: [M+H]+ calcd. for C13H15F3N5O2, 330.1; found, 330.1. 1 H NMR (400 MHz, CDCl 3 )δ=9.51(d,J=2.4Hz,1H),9.32(dd,J=0.8,5.6Hz,1H),8.48(br s,1H),7.66-7.59(m,1H),6.69(br s,1H),1.58-1.51(m,9H).
[0572] Synthesis of 1-(pyridazine-4-yl)-5-(trifluoromethyl)-1H-pyrazole-4-amine hydrochloride [INT1.22]:
[0573] A solution of tert-butyl N-[1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]carbamate [INT 1-pppp] (230 mg, 698 μmol) in HCl / dioxane (5 mL) was stirred at 25° C. for 12 h. The reaction mixture was concentrated under reduced pressure to give 1-(pyridazin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.22] (185 mg, 696 μmol) as a white solid. 1H NMR (400MHz, DMSO-d6) δ = 9.47 (d, J = 2.4Hz, 1H), 9.35 (dd, J = 0.8, 6.0Hz, 1H), 7.76-7.71 (m, 1H), 7.68 (s, 1H).
[0574] Synthesis of 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine [Intermediate 1.23]:
[0575]
[0576] Synthesis of ethyl 4-methoxy-3-oxopentanoate [INT 1-rrrr]:
[0577] To a solution of 2-methoxypropionic acid [INT 1-qqqq] (5 g, 48.0 mmol) in THF (50 mL) was added CDI (9.32 g, 57.5 mmol) at 0 ° C, and the mixture was stirred at 20 ° C for 2 hours. Magnesium chloride (4.57 g, 48.0 mmol) and ethyl potassium malonate (12.2 g, 72.0 mmol) were added to the reaction solution, and the mixture was stirred at 20 ° C for 6 hours. Then 1N HCl (200 mL) was added, and the mixture was extracted with EtOAc (2 x 200 mL). The combined organic layer was washed with brine (2 x 200 mL), filtered through anhydrous Na 2 SO 4 Drying and concentration under reduced pressure gave the crude product ethyl 4-methoxy-3-oxopentanoate [INT 1-rrrr] (6.15 g, 35.3 mmol, 73.5% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ=4.24-4.10(m,2H),3.79(q,J=6.8Hz,1H),3.60-3.47(m,2H),3.40-3.29(m,3H),1.37-1.17(m,6H).
[0578] Synthesis of ethyl 2-((dimethylamino)methylene)-4-methoxy-3-oxopentanoate [INT1-ssss]:
[0579] A mixture of ethyl 4-methoxy-3-oxopentanoate [INT 1-rrrr] (6.15 g, 35.3 mmol) and (dimethoxymethyl)dimethylamine (8.41 g, 70.6 mmol) in 2,2,2-trifluoroethanol (60 mL) was stirred at 50° C. for 4 hours. The mixture was concentrated under reduced pressure to give a crude product of ethyl 2-((dimethylamino)methylene)-4-methoxy-3-oxopentanoate [INT1-ssss].
[0580] Synthesis of 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-tttt]:
[0581] To a mixture of ethyl 2-((dimethylamino)methylene)-4-methoxy-3-oxopentanoate [INT 1-ssss] (5.38 g, 23.4 mmol) and triethylamine (11.8 g, 117 mmol) in 2,2,2-trifluoroethanol (50 mL) was added 3-hydrazinopyridine hydrochloride (11.9 g, 81.9 mmol). The reaction mixture was stirred at 80 ° C for 12 hours. The mixture was concentrated under reduced pressure to obtain a crude product. Brine (200 mL) was added, and the mixture was extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (200 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-40% EtOAc / petroleum ether) to give ethyl 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-tttt] (4.40 g, 15.9 mmol, 68.3% yield) as a yellow oil. m / z: [M+H]+ calculated for C14H18N3O3, 276.1; found, 276.1. 1 HNMR (400MHz, CDCl 3 )δ=8.80(d,J=2.4Hz,1H),8.70(d,J=4.4Hz,1H),8.08(s,1H),7.91-7.87(m,1H),7.43(dd,J=4.8,8.4Hz,1H ),5.44(q,J=6.8Hz,1H),4.39-4.31(m,2H),3.27-3.21(m,3H),1.39(t,J=7.2Hz,3H),1.34(d,J=6.8Hz,3H).
[0582] Synthesis of 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-uuuu]:
[0583] To ethyl 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-tttt] (4.4 g, 15.9 mmol) in THF (30 mL) and H 2 LiOH·H O (10 mL) was added to the mixture 2 O (2.00 g, 47.7 mmol) was added, and the mixture was stirred at 50° C. for 8 hours. The mixture was concentrated under reduced pressure to obtain a crude product. H 2O (200 mL) and EtOAc (200 mL), and the precipitate was collected by filtration. The aqueous phase was washed with EtOAc (100 mL x 2), acidified to pH = 3 with 1M HCl, and extracted with EtOAc (100 mL x 2). The combined organic layers were filtered through Na 2 SO 4 Dried and filtered. The filtrate was concentrated and combined with the precipitate to give 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT1-uuuu] (2.80 g, 11.3 mmol, 71.2% yield) as a white solid. m / z: [M+H]+ calculated for C12H14N3O3, 248.1; found, 248.1. 1 H NMR (400MHz, DMSO-d6) δ = 8.80-8.66 (m, 2H), 8.06 (s, 1H), 8.02-7.96 (m, 1H), 7.59 (dd, J=4.8, 8.0Hz, 1H), 5.30 (q, J=6.8Hz, 1H), 3.08 (s, 3H), 1.28 (d, J=6.8Hz, 3H).
[0584] tert-Butyl N-[5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT 1- Synthesis of vvvv]:
[0585] A mixture of 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-uuuu] (2.8 g, 11.3 mmol), 2-methylpropan-2-ol (12.5 g, 169 mmol), diphenylphosphoryl azide (4.11 g, 16.9 mmol) and triethylamine (3.43 g, 33.9 mmol) in toluene (20 mL) was stirred at 100 °C for 2 h. Saturated NaHCO 3 The solution (200 mL) was added and the mixture was extracted with EtOAc (100 mL x 2). The combined organic layers were washed with brine (100 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-10% EtOAc / petroleum ether) to give tert-butyl N-[5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT 1-vvvv] (2.50 g, 7.85 mmol, 69.6% yield) as a white solid. m / z: [M+H]+ calculated for C16H23N4O3, 319.2; found, 319.2. 1 H NMR (400 MHz, CDCl 3)δ=8.66(brs,2H),8.20(br s,1H),7.82-7.74(m,1H),7.45(dd,J=5.2,8.0Hz,1H),6.88(br s, 1H), 4.48 (q, J = 6.8Hz, 1H), 3.28 (s, 3H), 1.54 (s, 9H), 1.50 (d, J = 6.8Hz, 3H).
[0586] Synthesis of 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine [INT1.23]:
[0587] A mixture of tert-butyl N-[5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT1-vvvv] (500 mg, 1.57 mmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 12 hours. The mixture was concentrated under reduced pressure to give a yellow solid, which was purified by Prep-HPLC (column: Boston Prime C18 150*30mm*5μm, table: 0-30% B (A = water (ammonia hydroxide v / v)-ACN), B = acetonitrile), flow rate: 20 ml / min, UV detector 220nm) to give 5-(1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-amine [INT 1.23] (185 mg, 847μmol, 53.9% yield) as a white solid. [M+H]+ calculated for C11H15N4O, 219.1; experimental value, 219.0. 1 H NMR (400 MHz, CDCl 3 )δ=8.68(d,J=2.3Hz,1H),8.63(d,J=4.8Hz,1H),7.78(dd,J=1.5,8.0Hz,1H),7.47-7.42(m,1H),7.42 -7.39(m,1H),4.49(q,J=6.5Hz,1H),3.27(d,J=1.3Hz,3H),3.13-2.80(m,2H),1.53(d,J=6.5Hz,3H).
[0588] Synthesis of 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-ol [Intermediate 1.24]:
[0589]
[0590] Synthesis of 5-amino-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-xxxx]:
[0591] 5-amino-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-wwww] (18.5 g, 119 mmol), 3-bromopyridine (15.6 g, 99.1 mmol), CuI (942 mg, 4.95 mmol), K 2 CO 3 A suspension of 1,2-diaminocyclohexane (27.3 g, 198 mmol) and trans-1,2-diaminocyclohexane (1.13 g, 9.91 mmol) in DMF (100 mL) was heated at 120 °C under N 2 The reaction mixture was filtered. The filtrate was diluted with water (30 mL) and extracted with EtOAc (2 x 20 mL). The combined organic layers were washed with brine (2 x 50 mL) and purified by anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 4 to 1 / 1) to give a mixture of 5-amino-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-xxxx] (10.1 g, 43.4 mmol, 43.9% yield) and 3-amino-1-(pyrazol-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester (5.20 g, 22.3 mmol, 22.6% yield) as a yellow oil. m / z: [M+H]+ calculated for C11H13N4O2, 233.1; found, 233.2.
[0592] Synthesis of 5-iodo-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-yyyy]:
[0593] 5-amino-1-(pyridin-3-yl)-1H-pyrazole-4-formic acid ethyl ester [INT 1-xxxx] (6.78g, 29.2mmol) is suspended in acetonitrile (100mL) at ambient temperature.Add diiodomethane (46.8g, 175mmol), then add isoamyl nitrite (10.2g, 87.6mmol).The reaction solution is heated at 50 ℃ for 12 hours, then it is merged with another kind of reaction solution of the same type, and distributed between water (500mL) and ethyl acetate (300mL).Extract the aqueous layer with ethyl acetate (300mL x 2).The organic layer merged is passed through anhydrous sodium sulfate drying.After removing the solvent under reduced pressure, use silica gel column chromatography to purify the crude material (10-25% ethyl acetate / petroleum ether). The compound 5-iodo-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-yyyy] (2.25 g, 6.55 mmol) was obtained as a yellow solid. m / z: [M+H]+ calculated for C11H11IN3O2, 344.0; found, 343.9. 1H NMR (400 MHz, CDCl 3 )δ=8.76(d,J=2.4Hz,1H),8.68(d,J=4.8Hz,1H),8.14(s,1H),7.86-7.78(m ,1H),7.43(dd,J=4.8,8.0Hz,1H),4.35-4.29(m,2H),1.33(t,J=7.2Hz,3H).
[0594] Synthesis of 5-iodo-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-zzzz]:
[0595] Ethyl 5-iodo-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-yyyy] (156 mg, 454 μmol) and lithium hydroxide monohydrate (28.5 mg, 681 μmol) were dissolved in THF (3 mL) and H 2 O (1mL) in a mixture of 2-nitro-1H-pyrazole-4-carboxylic acid (INT 1-zzzz) was stirred at 20 ° C for 12 hours. The mixture was adjusted to pH = 4 with 1N HCl. The resulting suspension was filtered and washed with water (5mL x2). The filter cake was dried to obtain 5-iodo-1- (pyridin-3-yl) -1H-pyrazole-4-carboxylic acid [INT 1-zzzz] (56.0 mg, 177 μmol, 39.1% yield) as a yellow solid. m / z: [M + H] + calculated for C9H7IN3O2, 316.0; experimental value, 315.9. 1 HNMR (400MHz, DMSO-d6) δ = 12.81 (br s, 1H), 8.83-8.70 (m, 2H), 8.20 (s, 1H), 8.11-8.01 (m, 1H), 7.66 (dd, J = 4.8, 8.0Hz, 1H).
[0596] Synthesis of tert-butyl N-[5-iodo-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT1-aaaaa]:
[0597] To a solution of 5-iodo-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-zzzz] (2.2 g, 6.98 mmol) in t-BuOH (20 mL) was added diphenylphosphoryl azide (2.86 g, 10.4 mmol) and Et 3 The reaction mixture was stirred at 4 ℃ for 2 h under N 2 The mixture was stirred at 100 °C for 2 hours. The reaction was quenched by adding water (100 mL) and extracted with EtOAc (2 x 30 mL). The combined organic layers were washed with brine (2 x 50 mL) and purified by anhydrous Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=0 / 1 to 1 / 1) to give tert-butyl N-[5-iodo-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT 1-aaaaa] (1.80 g, 4.66 mmol, 66.9% yield) as a white solid. m / z: [M+H]+ calculated for C13H16IN4O2, 387.0; found, 387.0. 1 H NMR (400 MHz, CDCl 3 )δ=8.89(d,J=1.6Hz,1H),8.68(br d,J=4.4Hz,1H),8.20(br s,1H),7.96(br d,J=8.0Hz,1H),7.49(dd,J=4.8,8.0Hz,1H),6.15(br s,1H),1.56(s,9H).
[0598] tert-Butyl N-[5-(1-ethoxyvinyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT Synthesis of 1-bbbbb]:
[0599] Tert-butyl N-[5-iodo-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT 1-aaaaa] (500 mg, 1.29 mmol), Pd(PPh 3 ) 2 Cl 2 A mixture of (90.5 mg, 129 μmol), tributyl(1-ethoxyvinyl)stannane (1 g, 2.76 mmol) and dioxane (10 mL) was stirred at N 2 The mixture was stirred at 60 ° C for 12 hours. The mixture was quenched with saturated KF solution (100mL) and stirred at 25 ° C for 1 hour. The aqueous layer was extracted with ethyl acetate (20mL x 3). The combined organic layer was dried over sodium sulfate, filtered and concentrated. The residue was purified by flash column chromatography using silica gel (30% ethyl acetate / PE) to obtain tert-butyl N-[5-(1-ethoxyvinyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT 1-bbbbb] (400mg, 1.21mmol, 93.8% yield) as a brown gum. m / z: [M+H]+ calculated for C17H23N4O3, 331.2; Exp., 331.1. 1H NMR (400MHz, DMSO-d6) δ = 8.64 (d, J = 2.4Hz, 1H), 8.57 (dd, J = 1.3, 4.7Hz, 1H), 8.49 (br s, 1H), 7.88-7.84 (m, 1H), 7.81 (br s,1H),7.54(dd,J=4.8,8.2Hz,1H),4.66(d,J=2.6Hz,1H),4.62(d,J=2.6Hz,1H),3.68(q,J=7.1Hz,2H),1.45(s,9H),0.86(t,J=7.0Hz,3H).
[0600] Synthesis of 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-one hydrochloride [INT 1-ccccc] become:
[0601] Tert-butyl N-[5-(1-ethoxyvinyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl]carbamate [INT1-bbbbb] (400 mg, 1.21 mmol) was dissolved in 1 M HCl (10 mL), and the mixture was stirred at 25° C. for 3 h. The mixture was heated to 40° C. with saturated NaHCO 3 The mixture was adjusted to pH 8 with aqueous solution and extracted with ethyl acetate (20 mL x 2). The combined organic layers were passed through Na 2 SO 4 The mixture was concentrated to give 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-one hydrochloride [INT 1-ccccc] (280 mg, 1.17 mmol, 97.2% yield) as a brown solid. m / z: [M+H]+ calculated for C10H11N4O, 203.1; found, 203.0.
[0602] Synthesis of 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-ol [INT1.24]:
[0603] A solution of 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-one [free base of INT 1-ccccc] (180 mg, 0.8901 mmol) in methanol (5 mL) was cooled to 0°C. Sodium borohydride (101 mg, 2.67 mmol) was added and the reaction mixture was stirred at 0-25°C for 12 hours. MeOH was removed and the residue was diluted with water (10 mL). The residue was washed with saturated NaHCO 3 The pH of the reaction mixture was adjusted to 8-9 with aqueous solution, and the resulting mixture was extracted with ethyl acetate (15 mL x 3). The combined organic layers were passed through Na 2 SO 4Dried, filtered and concentrated to give crude 1-[4-amino-1-(pyridin-3-yl)-1H-pyrazol-5-yl]ethan-1-ol [INT 1.24] (180 mg, 0.8813 mmol, 99.4% yield) as a brown gum. m / z: [M+H]+ Calcd. for C10H13N4O, 205.1; Found, 204.8. 1 H NMR (400MHz, DMSO-d6) δ = 8.78 (d, J = 2.4Hz, 1H), 8.61 (dd, J = 1.3, 4.7Hz, 1H), 8.01-7.97 (m, 1H), 7.58 (dd, J = 4.7, 7.8Hz, 1H), 7.30 (s, 1H), 5.47 (br s,1H),4.94-4.80(m,1H),4.45-4.02(m,2H),1.41(d,J=6.8Hz,3H).
[0604] Synthesis of (S)-3-(4-amino-5-(1-methoxyethyl)-1H-pyrazol-1-yl)benzonitrile [Intermediate 1.25]:
[0605]
[0606] Synthesis of ethyl (4S)-4-methoxy-3-oxopentanoate [INT1-eeeeee]:
[0607] To a solution of (2S)-2-methoxypropionic acid [INT 1-ddddd] (5 g, 48.0 mmol) in THF (50 mL) was added 1,1'-carbonyldiimidazole (9.32 g, 57.5 mmol) at 0 ° C, and the mixture was stirred at 20 ° C for 2 hours. Magnesium chloride (4.57 g, 48.0 mmol) and potassium 1-ethyl 3-malonate (12.2 g, 72.0 mmol) were added to the reaction solution, and the mixture was stirred at 20 ° C for 6 hours. The reaction was quenched by adding 1N HCl aqueous solution (200 mL) and extracted with EtOAc (3 x 200 mL). The combined organic layer was washed with brine (2 x 100 mL) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give (4S)-4-methoxy-3-oxopentanoic acid ethyl ester [INT 1-eeeee] (8.00 g, 45.9 mmol, 95.6% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ=4.24-4.06(m,2H),3.86-3.70(m,1H),3.62-3.47(m,2H),3.39-3.32(m,3H),1.32-1.23(m,6H).
[0608] 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-fffff] synthesis:
[0609] To a mixture of ethyl (4S)-4-methoxy-3-oxopentanoate [INT 1-eeeee] (1.5 g, 8.61 mmol) in 2,2,2-trifluoroethanol (15 mL) was added N,N-dimethylformamide dimethyl acetal (1.22 g, 10.3 mmol). The mixture was stirred at 20° C. for 30 minutes. 3-Hydrazinobenzonitrile hydrochloride [INT 1-rrr] (1.74 g, 10.3 mmol) was added, and the mixture was stirred at 20° C. for 12 hours. The mixture was concentrated to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give ethyl 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylate [INT 1-fffff] (1.95 g, 6.51 mmol, 75.8% yield) as an orange solid. m / z: [M+H]+ calculated for C16H18N3O3, 300.1; found, 300.0. 1 H NMR (400 MHz, CDCl 3 )δ=8.06(s,1H),7.90(t,J=1.6Hz,1H),7.87-7.82(m,1H),7.74(td,J=1.6,8.0Hz,1H),7.62-7.57(m, 1H), 5.47 (q, J = 6.8Hz, 1H), 4.40-4.29 (m, 2H), 3.27 (s, 3H), 1.39 (t, J = 7.2Hz, 3H), 1.33-1.30 (m, 3H).
[0610] Synthesis of 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylic acid [INT1-ggggg] become:
[0611] To a solution of ethyl 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylate [INT 1-fffff] (1.8 g, 6.01 mmol) in THF (15 mL) was added lithium hydroxide monohydrate (302 mg, 7.21 mmol) in H 2 O (5 mL). The reaction solution was stirred at 20 ° C for 12 hours. The reaction mixture was poured into 10 mL of water, acidified to pH = 5-6 with 1N HCl, and extracted with EtOAc (30 mL x 2). The combined organic layer was washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4Dry and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (MeOH / DCM=0 / 1 to 1 / 20) to give 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylic acid [INT 1-ggggg] (1.20 g, 4.42 mmol, 73.6% yield) as a yellow solid. 1 H NMR(400MHz,DMSO-d6)δ=12.76(br s,1H),8.07-8.03(m,2H),8.00(d,J=8.0Hz,1H),7.90-7.86(m,1H),7.77 -7.71(m,1H),5.29(q,J=6.8Hz,1H),3.08(s,3H),1.28(d,J=6.8Hz,3H).
[0612] tert-Butyl N-[1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazol-4-yl]carbamate [INT Synthesis of 1-hhhhh]:
[0613] A solution of 1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazole-4-carboxylic acid [INT 1-ggggg] (1.2 g, 4.42 mmol), triethylamine (670 mg, 6.63 mmol) and diphenylphosphoryl azide (2.43 g, 8.84 mmol) in t-BuOH (15 mL) was stirred at N 2 The mixture was stirred at 100° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give tert-butyl N-[1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazol-4-yl]carbamate [INT 1-hhhhh] (1 g, 2.92 mmol, 66.2% yield) as a yellow oil. m / z: [M+H]+ calculated for C18H23N4O3, 343.2; found, 343.2. 1 H NMR (400 MHz, CDCl 3 )δ=8.18(br s,1H),7.73-7.67(m,2H),7.67-7.57(m,2H),6.86(br s, 1H), 4.49 (q, J = 6.8Hz, 1H), 3.28 (s, 3H), 1.54 (s, 9H), 1.50 (d, J = 6.8Hz, 3H).
[0614] Synthesis of (S)-3-(4-amino-5-(1-methoxyethyl)-1H-pyrazol-1-yl)benzonitrile [INT1.25]:
[0615] A mixture of tert-butyl N-[1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazol-4-yl]carbamate [INT 1-hhhhh] (500 mg, 1.46 mmol) in 4M HCl / dioxane (8 mL) was stirred at 20°C for 12 hours. The reaction mixture was poured into 10 mL of water and washed with NH 3 ·H 2 O was basified to pH = 9-10 and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Drying and concentrating under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give (S)-3-(4-amino-5-(1-methoxyethyl)-1H-pyrazol-1-yl)benzonitrile [INT 1.25] (100 mg, 412 μmol, 28.3% yield) as a yellow solid. m / z: [M-OCH3]+ calculated for C12H11N4, 211.1; found, 210.9. 1 H NMR (400 MHz, CDCl 3 )δ=7.76-7.73(m,1H),7.69-7.64(m,2H),7.62-7.55(m,1H),7.39(s,1H),4.50(q,J=6.8Hz,1H),3.28(s,3H),1.53(d,J=6.4Hz,3H).
[0616] Synthesis of 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-amine hydrochloride [Intermediate 1.26]:
[0617]
[0618] Synthesis of 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-iiiii]:
[0619] To a mixture of phenylhydrazine [INT 1-t] (1.5 g, 13.8 mmol) and N, N-dimethylformamide dimethyl acetal (1.96 g, 16.5 mmol) in 2,2,2-trifluoroethanol (20 mL) was added 2,2,2-trifluoroethanol (10 mL) containing (4S)-4-methoxy-3-oxopentanoic acid ethyl ester [INT 1-eeeee] (2.87 g, 16.5 mmol). The reaction mixture was stirred at 25 ° C for 12 hours. The reaction was quenched with water (100 mL) and extracted with EtOAc (100 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by flash chromatography using silica gel (0-15% EtOAc / petroleum ether) to give ethyl 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylate [INT 1-iiiiii] (2.00 g, 7.29 mmol, 52.9% yield) as a brown oil. m / z: [M+H]+ calculated for C15H19N2O3, 275.1; found, 275.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.05(s,1H),7.53-7.43(m,5H),5.34(q,J=6.8Hz,1H),4.40-4.29(m,2H),3.25(s,3H),1.39(t,J=7.2Hz,3H),1.35(d,J=6.8Hz,3H).
[0620] Synthesis of 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylic acid [INT 1-jjjjj]:
[0621] To ethyl 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylate [INT 1-iiiiii] (1.8 g, 6.56 mmol) in THF (5 mL), MeOH (5 mL) and H 2 Lithium hydroxide monohydrate (822 mg, 19.6 mmol) was added to the mixture in 4% paraformaldehyde (5 mL). The reaction mixture was stirred at 50 ° C for 2 hours, then concentrated, diluted with water (50 mL), and washed with EtOAc (100 mL x 2). The aqueous phase was acidified to pH = 3 with 1M HCl aqueous solution and extracted with EtOAc (100 mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylic acid [INT 1-jjjjj] (950 mg, 3.85 mmol, 59.0% yield) as an orange solid. [M+H]+ calculated for C13H15N2O3, 247.1; experimental value, 247.2.1 H NMR (400 MHz, CDCl 3 )δ=8.18(d,J=1.2Hz,1H),7.51(br d,J=2.0Hz,3H),7.48-7.42(m,2H),5.13-5.00(m,1H),3.32(d,J=3.6Hz,3H),1.46(t,J=5.6Hz,3H).
[0622] N-{5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-yl}carbamic acid tert-butyl ester [INT1- Synthesis of kkkkk]:
[0623] To a mixture of 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-carboxylic acid [INT 1-jjjjj] (850 mg, 3.45 mmol), 2-methylpropan-2-ol (3.83 g, 51.7 mmol) and triethylamine (1.04 g, 10.3 mmol) in toluene (10 mL) was added diphenylphosphoryl azide (1.42 g, 5.17 mmol). The reaction mixture was stirred at 100 ° C under nitrogen for 2 hours. The reaction mixture was diluted with EtOAc (100 mL x 3) and washed with saturated NaHCO 3 Aqueous solution (100mL) and brine (100mL) are washed. The organic layer is dried over anhydrous sodium sulfate and filtered. The filtrate is concentrated to obtain a crude product, which is purified by flash chromatography using silica gel (0-13% EtOAc / petroleum ether) to obtain tert-butyl N-{5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-yl}carbamate [INT 1-kkkkk] (770mg, 2.42mmol, 70.6% yield) as a yellow solid. m / z: [M+H]+ calculated for C17H24N3O3, 318.2; Exp., 318.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.15(br s,1H),7.52-7.33(m,5H),6.90(br s,1H),4.48(q,J=6.4Hz,1H),3.27(s,3H),1.54(br s,9H),1.48(d,J=6.4Hz,3H).
[0624] Synthesis of 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazole-4-amine hydrochloride [INT1.26]:
[0625] A mixture of tert-butyl N-{5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-yl}carbamate [INT 1-kkkkk] (150 mg, 472 μmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 12 hours. The mixture was concentrated under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-amine hydrochloride [INT 1.26] (119 mg, 469 μmol) as a brown oil. m / z: [M+H]+ calculated for C12H16N3O, 218.1; found, 217.9.
[0626] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.27]:
[0627]
[0628] 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-lllll] synthesis:
[0629] To a mixture of (4S)-4-methoxy-3-oxopentanoic acid ethyl ester [INT 1-eeeee] (3 g, 17.2 mmol) and triethylamine (2.08 g, 20.6 mmol) in 2,2,2-trifluoroethanol (50 mL) at 15 ° C, N- dimethylformamide dimethyl acetal (10.2 g, 85.9 mmol) and 2- hydrazine pyridine [INT 1-iii] (2.24 g, 20.6 mmol) were added. The reaction mixture was stirred at 80 ° C for 12 hours. The mixture was concentrated, and the resulting residue was quenched with water (60 mL) and extracted with EtOAc (50 mL x3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 5 / 1) to give ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate [INT 1-lllll] (1.30 g, 4.72 mmol, 27.4% yield) as a yellow oil. 1 H NMR (400MHz, DMSO) δ = 8.59-8.53 (m, 1H), 8.10-8.01 (m, 2H), 7.67-7.61 (m, 1H), 7.58-7.52 (m, 1H), 5. 19(q,J=8.0Hz,1H), 4.26(q,J=8.0Hz,2H), 2.91(s,3H), 1.61(d,J=8.0Hz,3H), 1.30(t,J=8.0Hz,3H).
[0630] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT1-mmmmm]:
[0631] Ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate [INT 1-1111] (1.3 g, 4.72 mmol) and lithium hydroxide monohydrate (990 mg, 23.6 mmol) were dissolved in EtOH (10 mL) and H 2 O (3mL) in the solution was stirred at 50 ° C for 3 hours. The reaction solution was acidified to pH = 4 with 1M HCl aqueous solution and extracted with EtOAc (25mL x2). The combined organic layer was concentrated under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-mmmmm] (946 mg, 3.82 mmol, 81.5% yield) as a light yellow solid. 1 H NMR (400MHz, DMSO) δ = 8.59-8.50 (m, 1H), 8.10-7.96 (m, 2H), 7.65-7.58 (m, 1H) ,7.57-7.51(m,1H),5.22(q,J=8.0Hz,1H),2.90(s,3H),1.59(d,J=8.0Hz,3H).
[0632] tert-Butyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-yl}carbamate [INT Synthesis of 1-nnnnn]:
[0633] To a mixture of 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-mmmmm] (946 mg, 3.82 mmol) in t-BuOH (3 mL) and dioxane (9 mL) was added triethylamine (1.92 g, 19.0 mmol) and diphenylphosphoryl azide (2.77 g, 11.4 mmol) at 10 °C. The mixture was then stirred at 100 °C for 2 hours. Water (30 mL) was added, and the mixture was extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and purified by anhydrous Na 2 SO 4Dry, filter and concentrate under reduced pressure to give a crude product, which is purified by flash chromatography using silica gel (petroleum ether / EtOAc=1 / 0 to 17 / 3) to give tert-butyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-yl}carbamate [INT 1-nnnnn] (265 mg, 832 μmol, 21.9% yield) as a white solid. m / z: [M+H]+ calculated for C16H23N4O3, 319.2; found, 319.3. 1 H NMR (400MHz, DMSO) δ = 8.49-8.45 (m, 1H), 7.99-7.81 (m, 4H), 7.40-7.35 (m, 1 H), 5.35 (q, J = 8.0Hz, 1H), 3.15 (s, 3H), 1.52 (d, J = 8.0Hz, 3H), 1.46 (s, 9H).
[0634] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-amine hydrochloride [INT 1.27] become:
[0635] A solution of tert-butyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-yl}carbamate [INT 1-nnnnn] (265 mg, 832 μmol) in HCl / dioxane (10 mL) was stirred at 20° C. for 1 hour. The mixture was concentrated under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-amine hydrochloride [INT 1.27] (211 mg, 828 μmol) as a black solid. 1 H NMR (400 MHz, CDCl 3 )δ=8.41-8.32(m,1H),7.86(d,J=8.0Hz,1H),7.80-7.71(m,1H),7.35(s, 1H),7.15-7.08(m,1H),5.62(q,J=8.0Hz,1H),3.35(s,3H),1.62(s,3H).
[0636] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-amine [Intermediate 1.28]:
[0637]
[0638] 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-ooooo] synthesis:
[0639] To a mixture of (4S)-4-methoxy-3-oxopentanoic acid ethyl ester [INT 1-eeeee] (1.7 g, 9.75 mmol) and N, N-dimethylformamide dimethyl acetal (1.39 g, 11.7 mmol) in 2,2,2-trifluoroethanol (30 mL), 4-hydrazinopyridine hydrochloride [INT 1-eee] (1.70 g, 11.7 mmol) and triethylamine (1.18 g, 11.7 mmol) were added. The reaction mixture was stirred at 15 ° C for 12 hours. The mixture was concentrated to obtain a crude product. The mixture was post-processed with another mixture of the same type. The residue was quenched with water (30 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give the crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 5 / 1) to give ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylate [INT 1-ooooo] (1.80 g, 6.53 mmol, 67.1% yield) as a yellow oil. 1 H NMR (400MHz, DMSO) δ=8.80-8.71(m,2H),8.14(s,1H),7.67-7.64(m,2H),5.29(q,J=8.0H z, 1H), 4.28 (q, J = 8.0Hz, 2H), 3.10 (s, 3H), 1.36 (d, J = 8.0Hz, 3H), 1.31 (t, J = 8.0Hz, 3H).
[0640] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid [INT1-ppppp]:
[0641] To ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylate [INT1-ooooo] (1.76 g, 6.39 mmol) in THF (20 mL) and H 2 Lithium hydroxide monohydrate (1.33 g, 31.9 mmol) was added to a solution of 4% HCl (4 mL). The mixture was stirred at 40 °C for 2 hours. The mixture was acidified to pH = 5 with 1M HCl aqueous solution and extracted with EtOAc (60 mL x 2). The combined organic layers were washed with brine (30 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry and concentrate under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid [INT 1-ppppp] (1.57 g, 6.34 mmol) as a pale yellow solid. 1H NMR (400 MHz, DMSO) δ = 8.66 (d, J = 4.0 Hz, 2H), 7.89 (s, 1H), 7.74 (d, J = 4.0 Hz, 2H), 6.04 (q, J = 4.0 Hz, 1H), 3.19 (s, 3H), 1.21 (d, J = 8.0 Hz, 3H).
[0642] N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-yl}benzyl carbamate [INT Synthesis of 1-qqqqq]:
[0643] To a mixture of 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazole-4-carboxylic acid [INT 1-ppppp] (1.25 g, 5.05 mmol) in BnOH (3 mL) and dioxane (12 mL) at 20° C., diphenylphosphoryl azide (3.67 g, 15.1 mmol) and triethylamine (2.55 g, 25.2 mmol) were added. The mixture was then stirred under N 2 The mixture was stirred at 100 °C for 3 hours. The reaction was quenched by adding water (40 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (40 mL x 2) and purified by anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 5 / 1) to give benzyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-yl}carbamate [INT 1-qqqqq] (390 mg, 1.10 mmol, 22.0% yield) as a light yellow oil. m / z: [M+H]+ calculated for C19H21N4O3, 353.2; found, 353.2.
[0644] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-amine [INT1.28]:
[0645] To a mixture of 10% Pd / C (40 mg) in EtOH (40 mL) at 20°C was added benzyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-yl}carbamate [INT 1-qqqqq] (390 mg, 1.10 mmol). 2 The mixture was stirred at 400 psi for 4 h. The mixture was filtered and the filtrate was concentrated under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-amine [INT 1.28] (200 mg, 916 μmol, 83.3% yield) as a white solid. 1H NMR (400MHz, DMSO) δ=8.60 (d, J=8.0Hz, 2H), 7.60 (d, J=8.0Hz, 2H), 7.36 (s, 1H), 4.71 (q, J=8.0Hz, 1H), 4.24 (s, 2H), 3.18 (s, 3H), 1.37 (d, J=8.0Hz, 3H).
[0646] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.29]:
[0647]
[0648] 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-rrrrr] synthesis:
[0649] A mixture of (4S)-4-methoxy-3-oxopentanoic acid ethyl ester [INT 1-eeeee] (3 g, 17.2 mmol) and N,N-dimethylformamide dimethyl acetal (3.07 g, 25.8 mmol) in 2,2,2-trifluoroethanol (20 mL) was stirred at 25° C. for 12 hours. The mixture was concentrated under reduced pressure to give crude (2Z,4S)-2-[(dimethylamino)methylene]-4-methoxy-3-oxopentanoic acid ethyl ester, which was used directly in the next step.
[0650] To a mixture of (2Z, 4S)-2-[(dimethylamino)methylene]-4-methoxy-3-oxopentanoic acid ethyl ester (3.94 g, 17.1 mmol) and triethylamine (8.65 g, 85.5 mmol) in 2,2,2-trifluoroethanol (20 mL) was added 3-hydrazinopyridine hydrochloride [INT 1-aaa] (7.46 g, 51.3 mmol). The reaction mixture was stirred at 80 ° C for 2 hours. The mixture was concentrated under reduced pressure to obtain a crude product. Brine (200 mL) was added, and the mixture was extracted with EtOAc (200 mL x 2). The combined organic layer was washed with brine (200 mL x 2) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-40% EtOAc / petroleum ether) to give ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-rrrrr] (2.20 g, 7.99 mmol, 46.8% yield) as a yellow oil. m / z: [M+H]+ calculated for C14H18N3O3, 276.1; found, 276.1. 1H NMR (400 MHz, CDCl 3 )δ=8.80(br s,1H),8.70(br d,J=3.6Hz,1H),8.11-8.05(m,1H),7.94-7.86(m,1H),7.44(dd,J=4.8,8.0Hz,1H),5.49- 5.39(m,1H),4.42-4.29(m,2H),3.30-3.20(m,3H),1.42-1.36(m,3H),1.36-1.31(m,3H).
[0651] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT1-sssss]:
[0652] To ethyl 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-rrrrr] (2.2 g, 7.99 mmol) in THF (15 mL) and H 2 O (5mL) in the mixture was added lithium hydroxide monohydrate (1g, 23.9mmol). The reaction mixture was stirred at 50 ° C for 12 hours, then concentrated, diluted with water (100mL), and washed with EtOAc (200mL x 2). The aqueous phase was acidified to pH = 3 with 1M HCl aqueous solution and extracted with EtOAc (200mL x 2). The combined organic layer was dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-sssss] (1.30g, 5.25mmol, 65.9% yield) as a white solid. [M+H]+ calculated for C12H14N3O3, 248.1; experimental value, 248.2. 1 H NMR (400 MHz, CDCl 3 )δ=8.83(d,J=1.6Hz,1H),8.76(br d,J=4.0Hz,1H),8.20(s,1H),7.94(td,J=1.6,8.0Hz,1H),7.51(dd,J=4.8,8.0Hz,1H),5.30(q,J=6.8Hz,1H),3.30(s,3H),1.43(d,J=6.8Hz,3H).
[0653] tert-Butyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-yl}carbamate Synthesis of [INT1-ttttt]:
[0654] To a mixture of 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-sssss] (1.2 g, 4.85 mmol), 2-methylpropan-2-ol (5.38 g, 72.7 mmol) and diphenylphosphoryl azide (2.00 g, 7.27 mmol) in toluene (10 mL) was added triethylamine (1.46 g, 14.5 mmol). The reaction mixture was stirred at 100 ° C under nitrogen for 2 hours. The reaction mixture was diluted with EtOAc (100 mL x 3) and washed with saturated NaHCO 3 The mixture was stirred for 2 hours at 4 ℃ for 10 minutes.Then the mixture was stirred for 2 hours at 4 ℃ for 3 hours ... 1 H NMR (400 MHz, CDCl 3 )δ=8.76-8.65(m,2H),8.21(br s,1H),7.99-7.78(m,1H),7.59-7.43(m,1H),6.86(br d,J=12.8Hz,1H),4.56-4.45(m,1H),3.29(d,J=6.8Hz,3H),1.55(s,9H),1.52-1.48(m,3H).
[0655] Synthesis of 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-amine hydrochloride [INT 1.29] become:
[0656] A mixture of tert-butyl N-{5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-yl}carbamate [INT 1-ttttt] (490 mg, 1.53 mmol) in 4M HCl / dioxane (10 mL, 40.0 mmol) was stirred at 25° C. for 12 hours. The mixture was concentrated under reduced pressure to give 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-amine hydrochloride [INT 1.29] (389 mg, 1.52 mmol) as a yellow solid. m / z: [M+H]+ calculated for C11H15N4O, 219.1; found, 219.1.
[0657] Synthesis of 3-(4-amino-5-cyclopropyl-1H-pyrazol-1-yl)benzonitrile hydrochloride [Intermediate 1.30]:
[0658]
[0659] Synthesis of 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid ethyl ester [INT1-uuuuu]:
[0660] To a mixture of ethyl 3-cyclopropyl-3-oxopropanoate (2.0 g, 12.8 mmol) in 2,2,2-trifluoroethanol (15 mL) was added N,N-dimethylformamide dimethyl acetal (1.82 g, 15.3 mmol). The mixture was stirred at 20 ° C for 30 minutes. 3-Hydrazinobenzonitrile hydrochloride [INT 1-rrr] (2.59 g, 15.3 mmol) was added and the mixture was stirred at 20 ° C for 12 hours. The mixture was concentrated to give a crude product. The residue was quenched with water (40 mL) and extracted with EtOAc (30 mL x 3). The combined organic layer was washed with brine (40 mL x 2) and filtered through anhydrous Na 2 SO 4 The reaction mixture was dried and concentrated under reduced pressure to give a crude product which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give ethyl 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylate [INT 1-uuuuu] (2.00 g, 7.10 mmol, 55.5% yield) as an orange solid. m / z: [M+H]+ calculated for C16H16N3O2, 282.1; found, 282.0. 1 H NMR (400 MHz, CDCl 3 )δ=8.04(s,1H),7.90(s,1H),7.85(d,J=8.0Hz,1H),7.75-7.70(m,1H),7.67-7.59(m,1H),4.34(q,J=7.2Hz,2H),1.66(br s, 1H), 1.39 (t, J = 7.2Hz, 3H), 1.05-0.98 (m, 2H), 0.59 (q, J = 5.6Hz, 2H).
[0661] Synthesis of 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid [INT 1-vvvvv]:
[0662] To a solution of ethyl 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylate [INT 1-uuuuu] (1.5 g, 5.33 mmol) in MeOH (6 mL) was added lithium hydroxide monohydrate (335 mg, 7.99 mmol) in H 2O (2 mL). The reaction solution was stirred at 80 ° C for 2 hours. The reaction mixture was poured into 10 mL of water, acidified to pH = 3-4 with 1N HCl aqueous solution, and extracted with EtOAc (20 mL x 2). The combined organic layer was washed with brine (20 mL x 2) and filtered through anhydrous Na 2 SO 4 Drying and concentration under reduced pressure gave the crude product, which was purified by flash chromatography using silica gel (MeOH / DCM=0 / 1 to 1 / 10) to give 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid [INT 1-vvvvv] (740 mg, 2.92 mmol, 55.2% yield) as an off-white solid. 1 H NMR (400MHz, DMSO-d6) δ = 12.38 (s, 1H), 8.18-8.15 (m, 1H), 7.99 (s, 1H), 7.98-7.92 ( m,2H),7.79-7.73(m,1H),2.22-2.12(m,1H),0.86-0.81(m,2H),0.47-0.41(m,2H).
[0663] Tert-butyl N-[1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazol-4-yl]carbamate [INT 1-wwwww] synthesis:
[0664] A solution of 1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazole-4-carboxylic acid [INT 1-vvvvv] (640 mg, 2.52 mmol), triethylamine (382 mg, 3.78 mmol) and diphenylphosphoryl azide (1.38 g, 5.04 mmol) in t-BuOH (8 mL) was stirred at N 2 The mixture was stirred at 100° C. for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography (EtOAc / PE=0 / 1 to 1 / 5) and Prep HPLC (column: YMC Triart 30*150mm*7μm, table: 30-70% B (A=water (ammonia hydroxide v / v)-(ACN-THF 50 / 50), B=acetonitrile), flow rate: 50 ml / min, UV detector 220nm) using silica gel to give tert-butyl N-[1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazol-4-yl]carbamate [INT 1-wwwww] (110 mg, 339 μmol, 13.4% yield) as a white solid. m / z: [M+H]+ calculated for C18H21N4O2, 325.2; experimental value, 325.1. 1 H NMR (400 MHz, CDCl 3)δ=8.00-7.91(m,2H),7.91-7.86(m,1H),7.66-7.60(m,1H),7.60-7.54(m,1H),6 .19(s,1H),1.88-1.76(m,1H),1.54(s,9H),1.00-0.93(m,2H),0.52-0.46(m,2H).
[0665] Synthesis of 3-(4-amino-5-cyclopropyl-1H-pyrazol-1-yl)benzonitrile hydrochloride [INT 1.30]:
[0666] A solution of tert-butyl N-[1-(3-cyanophenyl)-5-cyclopropyl-1H-pyrazol-4-yl]carbamate [INT 1-wwwww] (110 mg, 339 μmol) in HCl / dioxane (3 mL) was stirred at 20° C. for 12 hours. The reaction mixture was concentrated under reduced pressure to give 3-(4-amino-5-cyclopropyl-1H-pyrazol-1-yl)benzonitrile hydrochloride [INT1.30] (89.0 mg, 341 μmol) as an off-white solid. m / z: [M+H]+ calculated for C13H13N4, 225.1; found, 225.0. 1 H NMR (400MHz, DMSO-d6) δ = 10.22 (br s, 2H), 8.18 (s, 1H), 8.02 (br d,J=8.0Hz,1H),7.94(brd,J=7.6Hz,1H),7.79(s,1H),7.78-7.72(m,1H),2.15-2.03(m,1H),0.91-0.80(m,2H),0.61-0.47(m,2H).
[0667] Synthesis of 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.31]:
[0668]
[0669] Synthesis of (2Z)-2-[(Z)-cyclopropanecarbonyl]-3-(dimethylamino)prop-2-enoic acid ethyl ester [INT1-xxxxx]:
[0670] A mixture of ethyl 3-cyclopropyl-3-oxopropanoate (20 g, 128 mmol) and N,N-dimethylformamide dimethyl acetal (30.5 g, 256 mmol) was stirred at 100°C for 4 hours. The mixture was concentrated under reduced pressure to give ethyl (2Z)-2-[(Z)-cyclopropanecarbonyl]-3-(dimethylamino)prop-2-enoate [INT 1-xxxxx] (27.0 g, 127 mmol). m / z: [M+H]+ calculated for C11H18NO3, 212.1; Found, 212.1.
[0671] Synthesis of ethyl 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate [INT1-yyyyy]:
[0672] Ethyl (2Z)-2-[(Z)-cyclopropanecarbonyl]-3-(dimethylamino)prop-2-enoate [INT 1-xxxxx] (5 g, 21.3 mmol), 2-hydrazinopyridine hydrochloride [HCl salt of INT 1-iii] (3.71 g, 25.5 mmol) and Et 3 A solution of N (4.30 g, 42.6 mmol) in EtOH (50 mL) was stirred at 25 ° C for 16 hours. The reaction solution was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-yyyyy] (2.80 g, 10.8 mmol, 51.0% yield) as a yellow oil. m / z: [M+H]+ calculated for C14H16N3O2, 258.1; found, 258.0. 1 HNMR (400MHz, CDCl 3 )δ=8.57(dd,J=1.0,4.8Hz,1H),8.02(s,1H),7.87(dt,J=1.8,7.8Hz,1H),7.64(d,J=8.1Hz,1H),7.41-7.30(m,1H ), 4.32 (q, J = 7.1Hz, 2H), 2.29 (tt, J = 5.6, 8.6Hz, 1H), 1.37 (t, J = 7.1Hz, 3H), 1.02-0.85 (m, 2H), 0.68-0.50 (m, 2H).
[0673] Synthesis of 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-zzzzzz]:
[0674] Ethyl 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylate [INT 1-yyyyy] (2.5 g, 9.71 mmol) and lithium hydroxide monohydrate (1.01 g, 24.2 mmol) were dissolved in THF (10 mL), H 2 O (10 mL) and CH 3 The solution in 1H-2-pyridine-2-ol (1H-pyridine-2-ol)-1H-pyrazole-4-carboxylic acid [INT 1-zzzzz] (1.90 g, 8.28 mmol, 85.5% yield) was stirred at 25 °C for 16 hours. The reaction solution was concentrated under reduced pressure, and the resulting solution was acidified to pH = 6 with 1M aqueous HCl. The resulting suspension was filtered, and the filter cake was concentrated under reduced pressure to give 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-zzzzz] (1.90 g, 8.28 mmol, 85.5% yield) as a white solid. m / z: [M+H]+ calculated for C12H12N3O2, 230.1; found, 230.0. 1H NMR(400MHz,DMSO-d6)δ=12.41(br s,1H),8.67-8.52(m,1H),8.06(dt,J=2.0,7.8Hz,1H),7.96(s,1H),7.69(d,J=8.1Hz,1H),7.53 (ddd,J=1.0,4.9,7.5Hz,1H),2.25(tt,J=5.6,8.7Hz,1H),0.86-0.78(m,2H),0.60-0.53(m,2H).
[0675] Tert-butyl N-[5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-aaaaaa] synthesis:
[0676] 5-Cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylic acid [INT 1-zzzzz] (1.8 g, 7.85 mmol), DPPA (3.21 g, 11.7 mmol) and Et 3 A solution of N (2.37 g, 23.5 mmol) in toluene (20 mL) was stirred at 25 ° C for 15 minutes. 2-Methylpropan-2-ol (581 mg, 7.84 mmol) was added and the reaction mixture was stirred at 100 ° C for 1 hour. The reaction was quenched by adding water (30 mL) and extracted with EtOAc (2 x 50 mL). The combined organic layer was washed with brine (2 x 50 mL) and filtered through anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give tert-butyl N-[5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-aaaaaa] (800 mg, 2.66 mmol, 34.0% yield) as a colorless oil. m / z: [M+H]+ calculated for C16H21N4O2, 301.2; found, 301.2. 1 H NMR (400 MHz, CDCl 3 )δ=8.47(dd,J=1.0,4.8Hz,1H),7.97(br s,1H),7.84-7.76(m,1H),7.75-7.66(m,1H),7.21(ddd,J=1.0,4.9,7.2Hz,1H),6.28(br s,1H),2.14(ddd,J=2.7,5.5,8.2Hz,1H),1.53(s,9H),0.96-0.81(m,2H),0.54-0.39(m,2H).
[0677] Synthesis of 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazole-4-amine hydrochloride [INT1.31]:
[0678] A solution of tert-butyl N-[5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazol-4-yl]carbamate [INT 1-aaaaaa] (700 mg, 2.33 mmol) in dioxane (10 mL) containing 4M HCl was stirred at 25°C for 1 hour. The reaction was concentrated under reduced pressure to give 5-cyclopropyl-1-(pyridin-2-yl)-1H-pyrazol-4-amine hydrochloride [INT1.31] (550 mg, 2.32 mmol, 99.8% yield) as a yellow solid. m / z: [M+H]+ calculated for C11H13N4, 201.1; found, 201.1.
[0679] Synthesis of 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine hydrochloride [Intermediate 1.32]:
[0680]
[0681] Synthesis of 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-bbbbbb]:
[0682] Ethyl (2Z)-2-[(Z)-cyclopropanecarbonyl]-3-(dimethylamino)prop-2-enoate [INT 1-xxxxx] (5 g, 23.6 mmol), 3-hydrazinopyridine hydrochloride [INT 1-aaa] (4.12 g, 28.3 mmol) and Et 3 A solution of N (4.76 g, 47.2 mmol) in EtOH (50 mL) was stirred at 25 ° C for 16 hours. The reaction solution was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 1) to give 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid ethyl ester [INT 1-bbbbbb] (1.70 g, 6.60 mmol, 28.0% yield) as a yellow oil. m / z: [M+H]+ calculated for C14H16N3O2, 258.1; found, 258.1. 1 H NMR (400 MHz, CDCl 3 )δ=8.85(d,J=2.2Hz,1H),8.65(dd,J=1.2,4.7Hz,1H),8.04(s,1H),7.94-7.83(m,1H),7.45(dd,J=4.8,8.2H z, 1H), 4.32 (q, J = 7.2Hz, 2H), 2.01-1.88 (m, 1H), 1.37 (t, J = 7.2Hz, 3H), 1.05-0.90 (m, 2H), 0.66-0.48 (m, 2H).
[0683] Synthesis of 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-cccccc]:
[0684] To ethyl 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylate [INT 1-bbbbbb] (1.7 g, 6.60 mmol) in THF (6 mL) and H 2 To the mixture in 4% CO (2 mL), lithium hydroxide monohydrate (826 mg, 19.7 mmol) was added. The reaction mixture was stirred at 60° C. for 2 hours. The reaction mixture was concentrated under reduced pressure. The resulting residue was acidified to pH=4 with 1M HCl aqueous solution. The reaction mixture was stirred by adding H 2 O (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL) and purified by Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-cccccc] (1 g, 4.36 mmol, 66.2% yield) as a yellow solid. m / z: [M+H]+ calculated for C12H12N3O2, 230.1; found, 230.1.
[0685] Synthesis of tert-butyl (5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate [INT1-dddddd] become:
[0686] To a mixture of 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-carboxylic acid [INT 1-cccccc] (500 mg, 2.18 mmol) in toluene (3 mL) and t-BuOH (2 mL) was added diphenylphosphoryl azide (899 mg, 3.27 mmol) and triethylamine (661 mg, 6.54 mmol). The reaction mixture was stirred at 100 ° C for 3 hours under nitrogen. The reaction mixture was concentrated to give a residue, which was purified by flash chromatography using silica gel (0-50% EtOAc / petroleum ether) to give tert-butyl (5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate [INT 1-dddddd] (500 mg, 1.66 mmol, 76.4% yield) as a yellow oil. m / z: [M+H]+ calcd. for C16H21N4O2, 301.2; found, 301.2.
[0687] Synthesis of 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazole-4-amine hydrochloride [INT1.32]:
[0688] A solution of tert-butyl (5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-yl)carbamate [INT 1-dddddd] (500 mg, 1.66 mmol) in 4M HCl / dioxane (5 mL) was stirred at 20° C. for 16 hours. The reaction mixture was concentrated under reduced pressure to give 5-cyclopropyl-1-(pyridin-3-yl)-1H-pyrazol-4-amine hydrochloride [INT1.32] (250 mg, 1.24 mmol, 75.3% yield) as a yellow solid. m / z: [M+H]+ calculated for C11H13N4, 201.1; found, 201.0.
[0689] Synthesis of (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfenamide [Intermediate 2.1]:
[0690]
[0691] Synthesis of (R,E)-N-(4-bromobenzylidene)-2-methylpropane-2-sulfenamide [INT2-b]:
[0692] To a solution of 4-bromobenzaldehyde [INT 2-a] (100 g, 541 mmol, 1.0 eq) in toluene (500 mL) was added (R)-2-methylpropane-2-sulfenamide (72.1 g, 595 mmol, 1.1 eq) at 25°C. The mixture was stirred at 25°C for 15 minutes. NaOH (21.6 g, 541 mmol, 1.0 eq) was then added to the reaction solution, and the mixture was stirred at 25°C for 12 hours. 2 SO 4 The mixture was stirred for 20 minutes at room temperature. (50g) was added to the mixture and stirred for 20 minutes. Four kinds of reaction mixtures were merged, and filtered through Celite diatomite to obtain a filtrate, which was concentrated in vacuo to obtain a crude product in an oily state. The crude product was dissolved in petroleum ether (1.0L), and stirred for 1.0 hours at -50 °C, filtered to obtain (R, E)-N-(4-bromobenzylidene)-2-methylpropane-2-sulfinamide [INT 2-b] (620g, 2.15mol, 99.5% yield) in a solid state.
[0693] (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfenamide [INT 2.1] Synthesis:
[0694] To a solution of (R,E)-N-(4-bromobenzylidene)-2-methylpropane-2-sulfenamide [INT 2-b] (206 g, 715 mmol, 1.0 eq) and tetrabutylammonium acetate (216 g, 715 mmol, 218 mL, 1.0 eq) in DMF (1.4 L) was added TMSCF at 0 °C. 3(259 g, 1.82 mol, 2.5 eq). The mixture was stirred at 5 °C for 1.5 h. This process was repeated twice and the three reaction mixtures were combined for post-processing. The mixture was poured into saturated NH 4 Cl solution (13.0L), and stirred for 10 minutes, to obtain a suspension. The suspension is filtered, and the filter cake is washed with water (5.0L). The filter cake is ground with MTBE / petroleum ether (v / v=1:4, 2.0L), to obtain a solid product, and the mother liquor is concentrated in a vacuum, to obtain a crude product in an oily state, the crude product is purified by column chromatography using petroleum ether / ethyl acetate (10 / 1-1 / 1) using silica gel, to obtain (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfinamide [INT 2.1] (389g, 1.09mol, 50.6% yield) in a solid state. 1 H NMR (400 MHz, CDCl 3 )δ=1.25(s,9H),3.64(d,J=6.40Hz,1H),4.79-4.83(m,1H),7.32(d,J=8.40Hz,2H),7.56(d,J=6.40Hz,2H).
[0695] Synthesis of (S)-1-(4-bromophenyl)-2,2,2-trifluoro-N-methylethan-1-amine [Intermediate 3.1]:
[0696]
[0697] (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfenamide Synthesis of [INT3-b]:
[0698] To a solution of LiHMDS (1.0 M, 838 mL, 3.0 eq) was added (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-2-methylpropane-2-sulfenamide [INT 2.1] (100 g, 279 mmol, 1.0 eq) at 0-10°C, and the resulting mixture was stirred at 0-10°C for 0.5 hours. To the above mixture was added MeI (119 g, 838 mmol, 52.1 mL, 3.0 eq) at 0-10°C, and the reaction mixture was stirred at 25°C for 1 hour. This process was repeated twice, and the three combined reaction mixtures were poured into saturated NH 4 Cl aqueous solution (3.0 L) and diluted with EtOAc (1.0 L). The mixture was separated to give an organic layer, and the aqueous layer was extracted with EtOAc (500 mL). The combined organic layers were washed with saturated NaCl (1.0 L) and washed with Na 2 SO 4The mixture was dried, filtered and concentrated in vacuo to give a crude product as an oil. The crude product was purified by column chromatography using silica gel with petroleum ether / ethyl acetate (15 / 1-1 / 1) to give (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfenamide [INT 3-b] (161 g, 432.5 mmol, 51.6% yield) as an oil.
[0699] Synthesis of (S)-1-(4-bromophenyl)-2,2,2-trifluoro-N-methylethyl-1-amine hydrochloride [INT 3.1]:
[0700] To a mixture of (R)-N-((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N,2-dimethylpropane-2-sulfinamide [INT 3-b] (202 g, 543 mmol, 1.0 eq) in EtOAc (600 mL) was slowly added HCl / EtOAc (4.0 M, 2.02 L, 14.9 eq). The above mixture was stirred at 20 °C for 1 hour. The reaction mixture was filtered to give a solid and eluted with EtOAc (200 mL), and the mother liquor was concentrated in vacuo to give a solid. The solid was purified by column chromatography using silica gel with petroleum ether / ethyl acetate (10 / 1-1 / 0), combined with the filter cake, and concentrated with an oil pump at 45° C. for 1 hour to remove solvent residues to give (S)-1-(4-bromophenyl)-2,2,2-trifluoro-N-methylethan-1-amine hydrochloride [INT3.1] (115 g, 378 mmol, 69.6% yield, 100% purity, HCl) as a solid. 1 H NMR (400 MHz, DMSO-d 6 )δ=2.45(s,3H),5.51(s,1H),7.62(d,J=8.4Hz,2H),7.78(d,J=8.40Hz,2H),10.59(s,2H).
[0701] SFC: Rt = 0.776 min, 99.98% ee; column: Chiralpak AD-3, 100 × 4.6 mm, ID, 3 μm; mobile phase: A: CO 2 , B: MeOH (0.05% IPAm); gradient: A:B = 97:3; flow rate: 3 ml / min; column temperature: 35°C.
[0702] LCMS: Rt = 1.755 min, purity 100.0%, m / z = 268.0, 270.0 (M+1)+. The gradient was 0.40 min 5% B, 0.4-3.0 min 5-95% B, hold 95% B for 1.00 min, then 0.01 min 95-5% B, flow rate was 1.0 ml / min. Mobile phase A was water with 0.037% trifluoroacetic acid, and mobile phase B was acetonitrile with 0.018% trifluoroacetic acid. The column used for chromatography was a Kinetex C18 50*2.1 mm column (5 μm particles). The detection method was diode array (DAD) with positive electrospray ionization. The MS range was 100-1000.
[0703] Synthesis of tetrahydro-2H-thiopyran-4-carbonyl chloride 1,1-dioxide [Intermediate 4.1]:
[0704]
[0705] At 0°C in N 2 To a solution of tetrahydro-2H-thiopyran-4-carboxylic acid 1,1-dioxide [INT 4-a] (41.0 g, 230 mmol, 1.0 eq) in DCM (410 mL) was added (COCl) 2 (58.4 g, 460 mmol, 40.3 mL, 2.0 eq) and DMF (168 mg, 2.30 mmol, 177 μL, 0.01 eq). The mixture was warmed to 20 ° C and stirred at 20 ° C for 2 hours. The reaction mixture was concentrated in vacuo to give a crude product tetrahydro-2H-thiopyran-4-carbonyl chloride 1,1-dioxide [INT4.1] (46.5 g, crude) as a solid.
[0706] Synthesis of 1-acetylpiperidine-4-carbonyl chloride [Intermediate 4.2]:
[0707]
[0708] To a mixture of 1-acetylpiperidine-4-carboxylic acid [INT 4-b] (1 g, 5.84 mmol) in dichloromethane (10 mL) was slowly added oxalyl chloride (2.20 g, 17.5 mmol) and DMF (42.6 mg, 584 μmol), and the mixture was stirred for 2 hours at 40° C. The mixture was concentrated under reduced pressure to give crude 1-acetylpiperidine-4-carbonyl chloride [INT 4.2] (1.10 g, 5.80 mmol) as a green oil.
[0709] Synthesis of 1-acetylazetidine-3-carbonyl chloride (Intermediate 4.3):
[0710]
[0711] To a solution of 1-acetylazetidine-3-carboxylic acid [INT 4-c] (300 mg, 2.09 mmol) in DCM (4 mL) was added oxalyl chloride (397 mg, 3.13 mmol) at 0° C. The mixture was stirred at 20° C. for 1.5 hours. The reaction was concentrated under reduced pressure to give 1-acetylazetidine-3-carbonyl chloride [INT 4.3] (337 mg, 2.08 mmol).
[0712] Synthesis of methyl (1r,4r)-4-(chlorocarbonyl)cyclohexane-1-carboxylate (Intermediate 4.4):
[0713]
[0714] To a mixture of (1r,4r)-4-(methoxycarbonyl)cyclohexane-1-carboxylic acid [INT 4-d] (1.45 g, 7.78 mmol) in dichloromethane (10 mL) were slowly added oxalyl chloride (2.93 g, 23.3 mmol) and DMF (56.8 mg, 778 μmol), and the mixture was stirred at 40° C. for 2 hours. The mixture was concentrated under reduced pressure to give crude methyl (1r,4r)-4-(chlorocarbonyl)cyclohexane-1-carboxylate [INT 4.4] (1.59 g, 7.76 mmol) as a yellow gum.
[0715] Synthesis of methyl (1r,3r)-3-(chloroformyl)cyclobutane-1-carboxylate (Intermediate 4.5):
[0716]
[0717] To (1r,3r)-3-(methoxycarbonyl)cyclobutane-1-carboxylic acid [INT 4-e] (100 mg, 632 μmol) was added to CH 2 Cl 2 To the mixture in 4% paraformaldehyde (2 mL) was added DMF (one drop) and oxalic acid dichloride (239 mg, 1.89 mmol). The mixture was stirred at 20 °C for 1 hour. The reaction solution was concentrated under reduced pressure to give crude (1r, 3r)-3-(chlorocarbonyl)cyclobutane-1-carboxylic acid methyl ester [INT 4.5] (111 mg, 628 μmol) as a light yellow oil.
[0718] Synthesis of benzyl 3-(chlorocarbonyl)cyclobutane-1-carboxylate (Intermediate 4.6):
[0719]
[0720] Synthesis of 3-methylenecyclobutane-1-carboxylic acid [INT4-g]:
[0721] To a mixture of 3-methylenecyclobutane-1-carbonitrile [INT 4-f] (20 g, 214 mmol) in EtOH (100 mL) and water (100 mL) was added potassium hydroxide (48.0 g, 856 mmol). The mixture was stirred at 100 ° C for 2 hours. Ethanol was removed under reduced pressure, and the solution was then cooled to below 10 ° C and acidified to pH = 1 with concentrated HCl. The mixture was extracted with EtOAc (300 mL x 2), and the combined organic extracts were dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain 3-methylenecyclobutane-1-carboxylic acid [INT 4-g] (23.0 g, 205 mmol, 96.2% yield) as a yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ=9.51(br s,1H),4.82(quin,J=2.4Hz,2H),3.25-3.12(m,1H),3.08-2.89(m,4H).
[0722] Synthesis of 3-methylenecyclobutane-1-carboxylic acid benzyl ester [INT 4-h]:
[0723] Potassium carbonate (23.7 g, 172 mmol) and (bromomethyl) benzene (21.5 g, 126 mmol) were added to a mixture of 3-methylenecyclobutane-1-carboxylic acid [INT 4-g] (13 g, 115 mmol) in DMF (120 mL). The mixture was stirred at 25 ° C for 12 hours and then combined with another mixture of the same type. The mixture was diluted with water (200 mL) and extracted with ethyl acetate (250 mL x 2). The combined organic phases were washed with saturated brine (100 mL x 3) and purified by anhydrous Na 2 SO 4 Drying and concentration under reduced pressure gave a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 10 / 1) to give benzyl 3-methylenecyclobutane-1-carboxylate [INT 4-h] (33.0 g, 163 mmol) as a light yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ=7.43-7.31(m,5H),5.16(s,2H),4.83(quin,J=2.4Hz,2H),3.26-3.13(m,1H),3.10-2.86(m,4H).
[0724] Synthesis of 3-(hydroxymethyl)cyclobutane-1-carboxylic acid benzyl ester [INT 4-i]:
[0725] Borane dimethyl sulfide (29.5mL, 296mmol) was added dropwise to a mixture of 3-methylenecyclobutane-1-formic acid benzyl ester [INT 4-h] (20g, 98.8mmol) in THF (200mL) under an ice-salt bath. The mixture was stirred at 25 ° C for 1 hour. Then sodium hydroxide (20mL, 60.0mmol) and hydrogen peroxide (18mL, 98.8mmol) were added under an ice-salt bath. The mixture was stirred for another 2 hours at 25 ° C. The reaction was quenched with saturated sodium sulfite solution (100mL), diluted with water (50mL), and extracted with ethyl acetate (2x 200mL). The organic phase was washed with saturated brine (2x 100mL), filtered through anhydrous Na 2 SO 4 Drying and concentration under reduced pressure gave a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1:0 to 1 / 3) to give benzyl 3-(hydroxymethyl)cyclobutane-1-carboxylate [INT 4-i] (6.50 g, 29.5 mmol, 29.9% yield) as a pale yellow oil. 1 H NMR (400 MHz, CDCl 3 )δ=7.41-7.30(m,5H),5.14(d,J=9.2Hz,2H),3.67(d,J=6.4Hz,1H),3.60( d,J=6.0Hz,1H),3.22-3.05(m,1H),2.64-2.28(m,3H),2.14-2.01(m,2H).
[0726] Synthesis of 3-[(Benzyloxy)carbonyl]cyclobutane-1-carboxylic acid [INT 4-j]:
[0727] Benzyl 3-(hydroxymethyl)cyclobutane-1-carboxylate [INT 4-i] (4.5 g, 20.4 mmol) was added to CH 3 CN (30 mL), water (30 mL) and CH 2 Cl 2 (30mL) was added with sodium periodate (13.0g, 61.1mmol) and ruthenium (III) chloride (421mg, 2.03mmol). The mixture was warmed to 25°C and reacted for 12 hours. The reaction solution was poured into 1N HCl (100mL). The mixture was concentrated under reduced pressure to obtain a residue. The residue was diluted with water (50mL) and extracted with EtOAc (100mL x2). The combined organic phase was washed with brine (80mL) and filtered through anhydrous Na 2 SO 4The reaction mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give 3-[(benzyloxy)carbonyl]cyclobutane-1-carboxylic acid [INT 4-j] (3.36 g, 14.3 mmol, 70.4% yield) as a brown oil. m / z: [M+H]+ calculated for C13H15O4, 235.1; found, 235.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.44-7.30(m,5H),5.15(d,J=8.0Hz,2H),3.37-3.04(m,2H),2.69-2.44(m,4H).
[0728] Synthesis of 3-(chlorocarbonyl)cyclobutane-1-carboxylic acid benzyl ester [INT 4.6]:
[0729] 3-[(Benzyloxy)carbonyl]cyclobutane-1-carboxylic acid [INT 4-j] (3.36 g, 14.3 mmol) was added to CH 2 Cl 2 To the mixture in 4% paraformaldehyde (5% paraformaldehyde) (80 mL) was added DMF (one drop) and oxalyl chloride (3.62 g, 28.6 mmol). The mixture was stirred at 25 °C for 1 hour. The reaction was concentrated under reduced pressure to give crude 3-(chlorocarbonyl)cyclobutane-1-carboxylic acid benzyl ester [INT 4.6] (3.61 g, 14.2 mmol) as a black oil.
[0730] Synthesis of (S)-N-(1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N-methyltetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [Intermediate 5.1]:
[0731]
[0732] To a solution of (S)-1-(4-bromophenyl)-2,2,2-trifluoro-N-methylethyl-1-amine hydrochloride [INT 3.1] (39.0 g, 128 mmol, 1.0 eq, HCl) and TEA (45.7 g, 451 mmol, 62.8 mL, 3.5 eq) in DCM (200 mL) at 0-10 ° C., tetrahydro-2H-thiopyran-4-carbonyl chloride 1,1-dioxide [INT 4.1] (45.3 g, 231 mmol, 1.8 eq) was added. The mixture was stirred at 20 ° C for 12 hours. The mixture was separated to obtain an organic layer, and the aqueous layer was extracted with DCM (100 mL). The combined organic layers were concentrated in vacuo to obtain a crude product as an oil. The crude product was purified by column chromatography using silica gel with petroleum ether / ethyl acetate (15 / 1-3 / 1) to give (S)—N-(1-(4-bromophenyl)-2,2,2-trifluoroethyl)-N-methyltetrahydro-2H-thiopyran-4-carboxamide 1,1-dioxide [INT 5.1] (26.0 g, 60.7 mmol, 47.4% yield, 100% purity) as a solid. 1 H NMR (400MHz, CDCl3) δ=2.25-2.37(m,1H),2.38-2.40(m,3H),2.88-3.00(m,6H),3.30-3.31( m,1H),3.22-3.45(m,1H),6.56-6.63(m,1H),7.23(d,J=8.00Hz,2H),7.55(d,J=8.40Hz,2H).
[0733] SFC: Rt = 1.21 min, 100.0% ee; column: Chiralpak AD-3, 50×4.6 mm ID, 3 μm; mobile phase: A: CO 2 , B: MeOH (0.05% IPAm, v / v); flow rate: 3.4 ml / min; column temperature: 35°C.
[0734] LCMS: Rt = 2.431 min, purity 100%, m / z = 428.0, 430.0 (M+1)+. The gradient was 0.40 min 5% B, 0.4-3.0 min 5-95% B, hold 95% B for 1.00 min, then 0.01 min 95-5% B, flow rate was 1.0 ml / min. Mobile phase A was water with 0.037% trifluoroacetic acid, and mobile phase B was acetonitrile with 0.018% trifluoroacetic acid. The column used for chromatography was a Kinetex C18 50*2.1 mm column (5 μm particles). The detection method was diode array (DAD) with positive electrospray ionization. The MS range was 100-1000.
[0735] Synthesis of 1-acetyl-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-N-methylpiperidine-4-carboxamide [Intermediate 5.2]:
[0736]
[0737] [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)amine hydrochloride [INT 3.1] (500 mg, 1.64 mmol) and Et 3 To a mixture of N (829 mg, 8.20 mmol) in dichloromethane (10 mL) was added 1-acetylpiperidine-4-carbonyl chloride [INT 4.2] (550 mg, 2.90 mmol), and the mixture was stirred at 25° C. for 3 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (methanol / dichloromethane=0 / 1 to 1 / 20) to give 1-acetyl-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-N-methylpiperidine-4-carboxamide [INT 5.2] (680 mg, 1.61 mmol, 98.5% yield) as a yellow solid. m / z: [M+H]+ calculated for C17H21BrF3N2O2, 421.1, 423.1; Found, 423.1. 1 H NMR (400 MHz, CDCl 3 )δ=7.55(d,J=8.4Hz,2H),7.24(d,J=8.4Hz,2H),6.62(q,J=8.8Hz,1H),4.05-3.82(m,1H),3.23- 3.04(m,1H),2.90(s,3H),2.87-2.71(m,2H),2.70-2.43(m,1H),2.13(s,3H),1.92-1.63(m,4H).
[0738] Synthesis of 1-acetyl-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-N-methylazetidine-3-carboxamide (Intermediate 5.3):
[0739]
[0740] 1-Acetylazetidine-3-carbonyl chloride [INT 4.3] (300 mg, 1.85 mmol) and [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)amine hydrochloride [INT 3.1] (563 mg, 1.85 mmol) were stirred in CH 2 Cl 2(3mL) in the solution of 4-nitropropene (50mL) and 4-nitropropene (50mL) were added triethylamine (561mg, 5.55mmol). The mixture was stirred at 20°C for 4 hours. The reaction solution was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 5) to give 1-acetyl-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-N-methylazetidine-3-carboxamide [INT 5.3] (250mg, 635μmol, 34.3% yield) as a yellow oil. m / z: [M+H]+ calculated for C15H17BrF3N2O2, 393.0, 395.0; experimental value, 394.8.
[0741] Synthesis of methyl (1S,4r)-4-(((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)cyclohexane-1-carboxylate (Intermediate 5.4):
[0742]
[0743] To (1r,4r)-4-(chlorocarbonyl)cyclohexane-1-carboxylic acid methyl ester [INT 4.4] (1.59 g, 7.76 mmol) and Et 3 To a mixture of N (2.65 g, 26.2 mmol) in dichloromethane (6 mL) was added a solution of [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)amine hydrochloride [INT 3.1] (1.6 g, 5.25 mmol) in dichloromethane (6 mL), and the mixture was stirred at 25 ° C for 16 hours. Water (30 mL) was added, and the mixture was extracted with dichloromethane (30 mL x 2). The combined organic layers were washed with brine (30 mL) and filtered through anhydrous Na 2 SO 4 Dry, filter and concentrate under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / petroleum ether=1 / 10 to 1 / 5) to give (1S,4r)-methyl 4-(((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)cyclohexane-1-carboxylate [INT 5.4] (1.10 g, 2.52 mmol, 32.5% yield) as a yellow oil. m / z: [M+H]+ calculated for C18H22BrF3NO3, 436.1, 438.1; found, 438.0.
[0744] Synthesis of methyl (1S,3r)-3-(((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)cyclobutane-1-carboxylate (Intermediate 5.5):
[0745]
[0746] To (1r,3r)-3-(chlorocarbonyl)cyclobutane-1-carboxylic acid methyl ester [INT 4.5] (111 mg, 628 μmol) and [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl] (methyl)amine hydrochloride [INT 3.1] (120 mg, 394 μmol) was added to CH 2 Cl 2 N,N-diisopropylethylamine (254 mg, 1.97 mmol) was added to the mixture in 4% paraformaldehyde (2 mL). The mixture was stirred at 0°C for 1 hour and then at 20°C for 12 hours. 2 Cl 2 The reaction solution was diluted with 1N HCl (50 mL) and 1N HCl (20 mL). The organic phase was separated and washed with brine (20 mL) and then filtered through anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography on silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give (1S,3r)-3-(((S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl)(methyl)carbamoyl)cyclobutane-1-carboxylic acid methyl ester [INT 5.5] (84.8 mg, 207 μmol, 53.0% yield (53% purity)) as a yellow oil. m / z: [M+H]+ calculated for C16H18BrF3NO3, 408.0; found, 408.0.
[0747] Synthesis of benzyl 3-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclobutane-1-carboxylate (Intermediate 5.6):
[0748]
[0749] Benzyl 3-(chloroformyl)cyclobutane-1-carboxylate [INT 4.6] (3.61 g, 14.2 mmol) and [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)amine hydrochloride [INT 3.1] (2.5 g, 8.20 mmol) were added to CH 2 Cl 2 N,N-diisopropylethylamine (5.28 g, 40.9 mmol) was added to the mixture in 4% paraformaldehyde (100 mL). The mixture was stirred at 0°C for 1 hour and at 20°C for 12 hours. 2 Cl 2The reaction solution was diluted with 1N HCl (100 mL) and 1N HCl (50 mL). The organic phase was separated and washed with brine (50 mL) and then filtered through anhydrous Na 2 SO 4 The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3). The resulting product was further purified by Prep-HPLC (column: YMC-Triart Prep C18 150*40mm*7μm, table: 48-68% B (A=water (0.025% FA), B=acetonitrile), flow rate: 60 ml / min, UV detector 220nm) to give 3-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclobutane-1-carboxylic acid benzyl ester [INT 5.6] (760mg, 1.56mmol, 19.1% yield) as a yellow oil. m / z: [M+H]+ calculated for C22H22BrF3NO3, 484.1; found, 484.0. 1 HNMR (400MHz, CDCl 3 )δ=7.60-7.51(m,2H),7.41-7.31(m,5H),7.29-7.19(m,2H),6.66-6.34(m,1H ),5.18-5.11(m,2H),3.57-3.07(m,2H),2.77-2.73(m,3H),2.70-2.43(m,4H).
[0750] Synthesis of (1r,4r)-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-4-cyano-N-methylcyclohexane-1-carboxamide (Intermediate 5.7):
[0751]
[0752] [(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)amine hydrochloride [INT 3.1] (350 mg, 1.14 mmol) and triethylamine (576 mg, 5.70 mmol) were dissolved in CH 2 Cl 2 The mixture in 4% paraformaldehyde (5 mL) was stirred at 25° C. for 20 minutes. (1r,4r)-4-cyanocyclohexane-1-carbonyl chloride [INT 4.7] (391 mg, 2.28 mmol) was added to CH 2 Cl 2(5 mL) was added and the reaction was stirred at 25° C. for 3 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography on silica gel (0-30% EtOAc / petroleum ether) to give (1r, 4r)-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-4-cyano-N-methylcyclohexane-1-carboxamide [INT 5.7] (300 mg, 743 μmol, 65.3% yield) as a white solid. 1 H NMR (400 MHz, CDCl 3 )δ=7.57-7.51(m,2H),7.23(d,J=8.4Hz,2H),6.60(q,J=8.8Hz,1H),2.87(s,3H),2.68-2.59(m,1H ),2.58-2.48(m,1H),2.32-2.19(m,2H),2.01-1.93(m,1H),1.92-1.84(m,1H),1.72-1.62(m,4H).
[0753] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.1]:
[0754]
[0755] 1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.6] (140 mg, 531 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (231 mg, 531 μmol), xantphos (30.7 mg, 53.1 μmol), Pd 2 (dba) 3 (48.6 mg, 53.1 μmol) and Cs 2 CO 3 A mixture of (518 mg, 1.59 mmol) in dioxane (3 mL) was stirred at 100 °C under N 2 Stir for 3 hours under atmosphere. Add brine (50 mL), and extract the mixture with EtOAc (50 mL x 2). Wash the combined organic layers with brine (50 mL x 2), 2 SO 4Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-8% EtOAc / petroleum ether) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.1] (152 mg, 260 μmol, 49.1% yield) as a brown solid. m / z: [M+H]+ calculated for C28H29F6N4O3, 583.2; found, 583.2.
[0756] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.2]:
[0757]
[0758] 1-(Pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.14] (80 mg, 350 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (152 mg, 350 μmol), Pd 2 (dba) 3 (32.0mg, 35.0μmol), xantphos (40.5mg, 70.0μmol) and Cs 2 CO 3 A mixture of 1,2-dioxane (228 mg, 700 μmol) and 1,2-dioxane (3 mL) was stirred at 100 °C under N 2 The reaction mixture was quenched by adding water (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2) and purified by anhydrous Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 1 / 1) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-4-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT6.2] (115 mg, 197 μmol) as a pale yellow oil. m / z: [M+H]+ calculated for C27H28F6N5O3, 584.2; found, 584.1.
[0759] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.3]:
[0760]
[0761] 1-(Pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.13] (150 mg, 566 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (246 mg, 566 μmol), Cs 2 CO 3 (550 mg, 1.69 mmol), Pd 2 (dba) 3 A suspension of 2-nitropropene (25.9 mg, 28.3 μmol) and xantphos (32.7 mg, 56.6 μmol) in dioxane (2 mL) was heated at 100 °C under N 2 The mixture was stirred for 1.5 hours at 40 °C. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (MeOH / dichloromethane=0 / 1 to 1 / 99) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.3] (231 mg, 396 μmol, 70.0% yield) as a yellow oil. m / z: [M+H]+ calculated for C27H28F6N5O3, 584.2; Found, 584.1. 1 H NMR (400 MHz, CDCl3 )δ=8.80(d,J=2.8Hz,1H),8.74(dd,J=1.2,4.8Hz,1H),7.91-7.81(m,2H),7.49(dd,J=4.8,8.0Hz,1H),7.30(s,1H),6.97(d,J=8. 8Hz,2H),6.61(q,J=8.8Hz,1H),5.59(s,1H),3.71(s,3H),2.91(s,3H),2.63-2.51(m,1H),2.39(tt,J=3.6,12.0Hz,1H),2.11(br t,J=8.8Hz,2H),1.96-1.83(m,2H),1.70-1.61(m,2H),1.56-1.45(m,2H).
[0762] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.4]:
[0763]
[0764] 1-(Pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine [INT 1.15] (100 mg, 438 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (191 mg, 438 μmol), Cs 2 CO 3 (426 mg, 1.31 mmol) and xantphos (50.6 mg, 87.6 μmol) in dioxane (3 mL) were added Pd 2 (dba) 3 (40.1 mg, 43.8 μmol), and the reaction mixture was heated under N 2The mixture was stirred at 100 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.4] (170 mg, 291 μmol, 66.6% yield) as a yellow oil. m / z: [M+H]+ calculated for C27H28F6N5O3, 584.2; found, 584.1.
[0765] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.5]:
[0766]
[0767] 5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-amine [INT 1.27 free base] (75 mg, 343 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (149 mg, 343 μmol), Pd 2 (dba) 3 (31.3mg, 34.3μmol), xantphos (39.6mg, 68.6μmol) and Cs 2 CO 3 A mixture of (223 mg, 686 μmol) in dioxane (3 mL) was stirred at 100 °C under N 2 The reaction was quenched by adding water (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2) and purified by anhydrous Na 2 SO 4The reaction mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 5 / 1) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-(pyridin-2-yl)-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.5] (85.0 mg, 148 μmol, 43.3% yield) as a light yellow oil. 1 H NMR (400MHz, DMSO) δ = 8.50 (d, J = 4.0Hz, 1H), 8.05-7.97 (m, 1H), 7.84-7.77 (m, 1H) ,7.45-7.36(m,1H),7.20(s,1H),7.10(d,J=8.0Hz,2H),6.86(d,J=8.0Hz,2H),6. 41(q,J=8.0Hz,1H),5.29(q,J=8.0Hz,1H),3.58(s,3H),3.06(s,3H),2.87(s,3H) ,2.73-2.65(m,1H),1.96-1.64(m,5H),1.52(d,J=6.0Hz,3H),1.48-1.37(m,4H).
[0768] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.6]:
[0769]
[0770] 5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-amine [INT 1.26 free base] (100 mg, 460 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (200 mg, 460 μmol), xantphos (26.6 mg, 46.0 μmol), Pd 2 (dba) 3 (42.1 mg, 46.0 μmol) and Cs 2 CO 3 A mixture of (449 mg, 1.38 mmol) in dioxane (1 mL) was stirred at 100 °C under N 2Stir for 3 hours under atmosphere. Add brine (20 mL), and extract the mixture with EtOAc (50 mL x 2). Wash the combined organic layers with brine (20 mL x 2), and 2 SO 4 Dry, filter and concentrate under reduced pressure to give the crude product, which was purified by flash chromatography using silica gel (0-20% EtOAc / petroleum ether) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-phenyl-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.6] (230 mg, 401 μmol, 87.4% yield) as a white solid. m / z: [M+H]+ calculated for C30H36F3N4O4, 573.3; found, 573.3.
[0771] Synthesis of methyl (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.7]:
[0772]
[0773] 5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-amine [INT 1.28] (100 mg, 458 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (199 mg, 458 μmol), Pd 2 (dba) 3 (41.9mg, 45.8μmol), xantphos (53.0mg, 91.6μmol) and Cs 2 CO 3 A mixture of (298 mg, 916 μmol) in dioxane (3 mL) was stirred at 100 °C under N 2 The reaction was quenched by adding water (20 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (20 mL x 2) and purified by anhydrous Na 2 SO 4The mixture was dried and concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (PE / EtOAc=1 / 0 to 1 / 1) to give (1r,4r)-4-{methyl[(1S)-2,2,2-trifluoro-1-[4-({5-[(1S)-1-methoxyethyl]-1-(pyridin-4-yl)-1H-pyrazol-4-yl}amino)phenyl]ethyl]carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.7] (230 mg, 400 μmol, 87.7% yield) as a pale yellow oil. m / z: [M+H]+ calculated for C29H35F3N5O4, 574.3; found, 574.3. 1 H NMR (400MHz, DMSO) δ = 8.71 (d, J = 8.0Hz, 2H), 7.85 (s, 1H), 7.78-7.73 (m, 2H), 7.55 (s, 1H) ,7.11(d,J=8.0Hz,2H),6.78(d,J=8.0Hz,2H),6.41(q,J=8.0Hz,1H),4.65(q,J=8.0Hz,1H ),3.59(s,3H),3.17(s,3H),2.86(s,2.5H),2.74-2.67(m,1H),2.62(s,0.5H),2.33-2.2 9(m,1H),1.96-1.87(m,2H),1.83-1.69(m,2H),1.47-1.36(m,4H),1.33(d,J=4.0Hz,3H).
[0774] Synthesis of methyl (1S,4r)-4-(methyl((S)-2,2,2-trifluoro-1-(4-((5-((S)-1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylate [Intermediate 6.8]:
[0775]
[0776] 5-[(1S)-1-methoxyethyl]-1-(pyridin-3-yl)-1H-pyrazol-4-amine [INT 1.29 free base] (20 mg, 91.6 μmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (39.9 mg, 91.6 μmol), xantphos (5.30 mg, 9.16 μmol), Pd 2 (dba) 3 (8.38 mg, 9.16 μmol) and Cs 2 CO3 A mixture of (89.2 mg, 274 μmol) in dioxane (1 mL) was stirred at 100 °C under N 2 The mixture was stirred for 3 hours under a nitrogen atmosphere. The mixture was concentrated under reduced pressure to give (1S,4r)-4-(methyl((S)-2,2,2-trifluoro-1-(4-((5-((S)-1-methoxyethyl)-1-(pyridin-3-yl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylic acid methyl ester [INT 6.8] (50.0 mg, 87.1 μmol, 95.2% yield). m / z: [M+H]+ calculated for C29H35F3N5O4, 574.3; found, 574.2.
[0777] Synthesis of methyl (1S,4r)-4-(methyl((S)-2,2,2-trifluoro-1-(4-((1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylate [Intermediate 6.9]:
[0778]
[0779] 1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.21] (500 mg, 1.88 mmol), (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (820 mg, 1.88 mmol), Cs 2 CO 3 (1.83 g, 5.64 mmol), Pd 2 (dba) 3 A suspension of 1,4-dioxane (86.0 mg, 94.0 μmol) and xantphos (108 mg, 188 μmol) in dioxane (10 mL) was heated at 100 °C under N 2 The reaction mixture was concentrated to provide methyl (1S,4r)-4-(methyl((S)-2,2,2-trifluoro-1-(4-((1-(pyridazin-3-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl)amino)phenyl)ethyl)carbamoyl)cyclohexane-1-carboxylate [INT 6.9]. m / z: [M+H]+ calculated for C26H27F6N6O3, 585.2; found, 585.1.
[0780] Synthesis of methyl (1r,4r)-4-{[(1S)-1-(4-{[1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazol-4-yl]amino}phenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylate [Intermediate 6.10]:
[0781]
[0782] To a mixture of 3-{4-amino-5-[(1S)-1-methoxyethyl]-1H-pyrazol-1-yl}benzonitrile [INT 1.25] (160 mg, 660 μmol) in dioxane (5 mL) was added (1r,4r)-4-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 5.4] (316 mg, 726 μmol), xantphos (114 mg, 198 μmol), Cs 2 CO 3 (645 mg, 1.98 mmol) and Pd 2 (dba) 3 (60.4 mg, 66.0 μmol). 2 The mixture was stirred at 100° C. for 2 hours. The mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 1) to give (1r,4r)-4-{[(1S)-1-(4-{[1-(3-cyanophenyl)-5-[(1S)-1-methoxyethyl]-1H-pyrazol-4-yl]amino}phenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclohexane-1-carboxylic acid methyl ester [INT 6.10] (250 mg, 418 μmol, 63.4% yield) as a yellow solid. m / z: [M+H]+ calculated for C31H35F3N5O4, 598.3; found, 598.1.
[0783] Synthesis of (1r,4r)-4-cyano-N-methyl-N-[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]cyclohexane-1-carboxamide [Intermediate 6.11]:
[0784]
[0785] To a mixture of 1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-amine [free base of INT 1.6] (100 mg, 440 μmol) in dioxane (5 mL) were added (1r,4r)-N-[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl]-4-cyano-N-methylcyclohexane-1-carboxamide [INT 5.6] (195 mg, 484 μmol), xantphos (76.3 mg, 132 μmol), Cs 2 CO 3 (430 mg, 1.32 mmol) and Pd 2 (dba) 3 (40.2 mg, 44.0 μmol). 2 The mixture was stirred at 100 °C for 2 hours. The reaction mixture was concentrated under reduced pressure to give a crude product, which was purified by flash chromatography using silica gel (EtOAc / PE=0 / 1 to 1 / 3) to give (1r,4r)-4-cyano-N-methyl-N-[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]cyclohexane-1-carboxamide [INT 6.11] (100 mg, 181 μmol, 41.4% yield) as a yellow solid. m / z: [M+H]+ calculated for C27H26F6N5O, 550.2; found, 550.4.
[0786] Synthesis of benzyl 3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxylate [Intermediate 6.12]:
[0787]
[0788] Benzyl 3-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclobutane-1-carboxylate [INT 5.6] (300 mg, 619 μmol), 1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [HCl salt of INT 1.15] (163 mg, 619 μmol), Pd 2 (dba) 3 (56.6mg, 61.9μmol), xantphos (71.1mg, 123μmol) and Cs 2 CO 3 A mixture of (602 mg, 1.85 mmol) in dioxane (10 mL) was stirred at 100 °C under N2 The reaction was quenched by adding water (40 mL) and extracted with EtOAc (2 x 80 mL). The combined organic layers were washed with brine (2 x 50 mL) and purified by anhydrous Na 2 SO 4 The reaction mixture was dried and concentrated under reduced pressure to give benzyl 3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-(pyridin-2-yl)-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxylate [INT 6.12] (390 mg, 617 μmol) as a black oil. m / z: [M+H]+ calculated for C31H28F6N5O3, 632.2; found, 632.3.
[0789] Synthesis of benzyl 3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxylate [Intermediate 6.13]:
[0790]
[0791] 3-{[(1S)-1-(4-bromophenyl)-2,2,2-trifluoroethyl](methyl)carbamoyl}cyclobutane-1-carboxylic acid benzyl ester [INT 5.6] (650 mg, 805 μmol), 1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-amine hydrochloride [INT 1.6] (150 mg, 568 μmol), Pd 2 (dba) 3 (52.0 mg, 56.8 μmol), xantphos (65.3 mg, 113 μmol) and Cs 2 CO 3 A mixture of (553 mg, 1.70 mmol) in dioxane (10 mL) was stirred at 100 °C under N 2 Stir for 2 hours under atmosphere. The reaction was quenched by adding water (50 mL) and extracted with EtOAc (2 x 80 mL). The combined organic layers were washed with brine (60 mL) and purified by anhydrous Na 2 SO 4The reaction mixture was dried and concentrated under reduced pressure to give benzyl 3-{methyl[(1S)-2,2,2-trifluoro-1-(4-{[1-phenyl-5-(trifluoromethyl)-1H-pyrazol-4-yl]amino}phenyl)ethyl]carbamoyl}cyclobutane-1-carboxylate [INT 6.13] (330 mg, 523 μmol, 92.1% yield) as a brown oil. m / z: [M+H]+ calculated for C32H29F6N4O3, 631.2; found, 631.2.
[0792] Exemplary compounds of formula (I)
[0793] The following compounds in Table 2 were synthesized according to Schemes 1-3 above using the identified intermediates.
[0794] Table 2.
[0795]
[0796]
[0797]
[0798]
[0799]
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806]
[0807]
[0808]
[0809]
[0810]
[0811]
[0812]
[0813] Example 2. MALT1 biochemical assay
[0814] Inhibitor potency was assessed by measuring the enzymatic activity of full-length MALT1 at varying concentrations of compound. The enzymatic assay consisted of a single substrate reaction that monitored the release of a fluorescent dye upon cleavage of a peptide substrate. The peptide substrate had the following sequence: Ac-Leu-Arg-Ser-Arg-Rh110-dPro (custom synthesis from WuXi AppTec, Shanghai, China). The assay buffer consisted of 50 mM Hepes (pH 7.5), 0.8 M sodium citrate, 1 mM DTT, 0.004% Tween-20, and 0.005% bovine serum albumin (BSA). Steady-state kinetic analysis of peptide substrate binding yielded a Michaelis-Menten constant (K) of 150 μM. M ). The assay was performed at 15 nM enzyme and 30 μM peptide substrate in a 384-well F-bottom polypropylene black microplate (Greiner Bio-One, catalog number 781209). After 60 minutes, iodoacetate was added to a final concentration of 10 mM to quench the reaction. Total fluorescence was measured using Envision (PerkinElmer) with fluorescence excitation at 485 nm and emission at 520 nm.
[0815] To determine potency, 1 μL of serially diluted compound (in 100% DMSO) was preincubated with 40 μL enzyme for 30 minutes. The reaction was initiated by adding 10 μL of peptide substrate. Relative fluorescence units were converted to percent inhibition by using 0% and 100% inhibition controls as reference. The 100% inhibition control consisted of 1 μM final concentration of (S)-1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea (IC 50 =15 nM), while the 0% inhibition control consisted of 2% DMSO. 50 Values were calculated by fitting concentration-response curves to a four-parameter logistic equation in GraphPad Prism.
[0816] The results of this assay are summarized in Table 3 below. In this table, "A" indicates an IC of less than 0.1 μM 50 ; "B" indicates IC of 0.1 μM to 1 μM 50 ; and "C" indicates an IC greater than 1 μM 50 "N / A" means not tested. For compounds tested in more than one experiment, the results shown represent the average.
[0817] Table 3.
[0818]
[0819]
[0820] Example 3. Jurkat IL-2 assay
[0821] Inhibition was determined in a cell-based assay using Jurkat (ATCC, clone E6.1), an immortalized T cell line, which was exposed to a dose response of the compound and assessed for viability and IL-2 inhibition by ELISA. Cells were cultured in RPMI / 10% FBS (Invitrogen 11875093, Atlanta Biologics S12450H), kept below 3E6 / mL, and only used for assays below the 25th generation. Compounds were stamped onto 384w plates (PerkinElmer Culturplate, 6007680) by ECHO. Cells were plated on top of the compound in fresh culture medium and incubated for 30 minutes, then stimulated for 24 hours with soluble anti-CD3 / 28 / 2 (Stemcell, 10970). Supernatants were collected and IL-2 was assessed (MSD, 384w, L21SA-1). To assess the viability of cells treated with compounds, cells were lysed with CTG reagent (Promega, G7570) and measured photometrically. IL-2 curves were calculated as a percentage of DMSO (100%) and signal inhibition (0%, (S)-1-(5-chloro-6-(2H-1,2,3-triazol-2-yl)pyridin-3-yl)-3-(2-chloro-7-(1-methoxyethyl)pyrazolo[1,5-a]pyrimidin-6-yl)urea) controls. IC was calculated using a 4-parameter fit in GraphPad Prism. 50 .
[0822] The results of this assay are summarized in Table 4 below. In this table, "A" indicates an IC of less than 0.1 μM 50 ; "B" indicates IC of 0.1 μM to 1 μM 50 ; and "C" indicates an IC greater than 1 μM 50 "N / A" means not tested. For compounds tested in more than one experiment, the results shown represent the average.
[0823] Table 4.
[0824]
[0825]
[0826] Equivalents and scope
[0827] In the claims, articles such as "a," "an," and "the" may mean one or more, unless indicated to the contrary or otherwise obvious from the context. Claims or descriptions containing "or" between one or more members of a group are deemed satisfied if one, more than one, or all of the members of the group are present in, used in, or otherwise related to a specified product or process, unless indicated to the contrary or otherwise obvious from the context. The invention includes embodiments in which exactly one member of the group is present in, used in, or otherwise related to a given product or process. The invention includes embodiments in which more than one or all of the members of the group are present in, used in, or otherwise related to a given product or process.
[0828] In addition, the present invention encompasses all variations, combinations and arrangements, wherein one or more limitations, elements, clauses and descriptive terms from one or more listed claims are introduced into another claim. For example, any claim subordinate to another claim can be modified to be included in one or more limitations found in any other claim subordinate to the same basic claim. In the case where the element is presented in a list form such as a Markush group format, each subgroup of the element is also disclosed, and any one or more elements can be removed from the group. It should be understood that, in general, in the case where the present invention or aspects of the present invention are referred to as including specific elements and / or features, some embodiments of the present invention or aspects of the present invention are composed of such elements and / or features, or are substantially composed of such elements and / or features. For simplicity, those embodiments are not specifically described herein. It should also be noted that the terms "include" and "contain" are intended to be open and allow the inclusion of additional elements or steps. In the case of giving a range, endpoints are included. In addition, unless otherwise indicated or otherwise apparent from the context and understanding of one of ordinary skill in the art, values expressed as ranges may be assumed in different embodiments of the present invention to be any specific value or sub-range within the range, to the tenth of the unit of the lower limit of the range, unless the context clearly indicates otherwise.
[0829] This application relates to various issued patents, published patent applications, journal articles, and other publications, all of which are incorporated herein by reference. If there is a conflict between any incorporated reference and this specification, the present specification shall prevail. In addition, any specific embodiment of the present invention that falls within the prior art may be explicitly excluded from any one or more claims. Because such embodiments are considered to be known to those of ordinary skill in the art, even if such exclusion is not explicitly proposed herein, it may be excluded. Any specific embodiment of the present invention may be excluded from any claim for any reason, whether or not related to the existence of the prior art.
[0830] Using only routine experimentation, those skilled in the art will recognize or be able to ascertain many equivalents to the specific embodiments described herein. The scope of the embodiments of the invention described herein is not intended to be limited to the above description, but is as set forth in the appended claims. Those of ordinary skill in the art will appreciate that various modifications and changes may be made to the description without departing from the spirit or scope of the invention as defined in the appended claims.
Claims
1. A compound represented by formula (I) or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein: R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, where R 1 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ; R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ; R 3 is hydrogen or C 1-3 alkyl; R 1a is independently hydroxyl or -OC 1-3 alkyl; R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl; Z is -C(H)(R A )-, -SO2- or -NR A -; R A Yes-C(O)C 1-6 Alkyl, -C(O)OH or 5-6 membered heteroaryl; m is 0 or 1; and n is 0 or 1.
2. The compound according to claim 1, wherein R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, wherein the C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -OC 1-3 Alkyl substitution.
3. The compound according to claim 1 or 2, wherein R 1 Select from the group consisting of: C 1-6 Alkyl, C 1-3 Haloalkyl, C 3-6 Cycloalkyl and aryl, wherein the C 1-6 The alkyl group may be optionally substituted with hydroxy or -O-CH3.
4. The compound according to any one of claims 1 to 3, wherein R 1 Selected from the group consisting of: -CH(CH3)2, CF3, cyclopropyl, phenyl, 5. The compound according to any one of claims 1 to 4, wherein R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein the C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, C 1-6 Alkyl or -OC 1-3 Alkyl substitution.
6. The compound according to any one of claims 1 to 5, wherein R 2 Select from the group consisting of: C 1-6 Alkyl, C3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein the C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxy, cyano, CH3 or -O-CH3.
7. The compound according to any one of claims 1 to 6, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 8. The compound according to any one of claims 1 to 7, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 9. The compound according to any one of claims 1 to 6, wherein R 2 It is C 1-6 Alkyl or aryl, wherein the C 1-6 The alkyl and aryl groups are substituted with hydroxy, cyano, CH3 or -O-CH3.
10. The compound according to any one of claims 1 to 6 and 9, wherein R 2 It is C 1-6 Alkyl or phenyl, wherein the C 1-6 The alkyl group or phenyl group is substituted with a hydroxyl group, a cyano group, CH3 or -O-CH3.
11. The compound according to any one of claims 1 to 6, 9 and 10, wherein R 2 Select from the group consisting of:
12. The compound according to any one of claims 1 to 6 and 9 to 11, wherein R 2 Select from the group consisting of:
13. The compound according to any one of claims 1 to 6, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 14. The compound according to any one of claims 1 to 13, wherein R 3 It is hydrogen or CH3.
15. The compound according to any one of claims 1 to 14, wherein R 3 It is CH3.
16. The compound according to any one of claims 1 to 15, wherein Z is -SO2-.
17. The compound of claim 16, wherein m is 1, and n is 1.
18. A compound according to any one of claims 1 to 15, wherein Z is -NR A -. The compound according to claim 18 , wherein m is 0 and n is 0.
20. The compound of claim 18, wherein m is 1 and n is 1.
21. The compound according to any one of claims 18 to 20, wherein R A Yes-C(O)C 1-6 alkyl.
22. The compound according to any one of claims 18 to 21, wherein R A It is -C(O)CH3.
23. A compound according to any one of claims 1 to 15, wherein Z is -C(H)(R A )-.
24. The compound of claim 23, wherein m is 0 and n is 0.
25. The compound according to claim 24, wherein R A It is -C(O)OH.
26. The compound of claim 23, wherein m is 1 and n is 1.
27. The compound according to claim 26, wherein R A It is -C(O)OH or a 5-6 membered heteroaryl group.
28. The compound according to claim 26 or 27, wherein R A is -C(O)OH or 29. A compound represented by formula (Ia), or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein: R 1 Selected from C 1-6 Alkyl, C 1-3 A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 1a ; R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein R 2 may be optionally substituted on one or more available carbon atoms with one, two, three or more substituents each independently selected from R 2a ; R 1a is independently hydroxyl or -OC 1-3 Alkyl; and R 2a independently selected at each occurrence from the group consisting of: hydroxy, cyano, C 1-6 Alkyl and -OC 1-3 alkyl.
30. The compound according to claim 29, wherein R 1 It is C 1-6 Alkyl, C 1-3A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally replaced by a hydroxyl group or an -OC 1-3 Alkyl substitution.
31. The compound according to claim 29 or 30, wherein R 1 It is C 1-6 Alkyl, C 1-3 A haloalkyl or aryl group, wherein the C 1-6 The alkyl group may be optionally substituted with hydroxy or -O-CH3.
32. The compound according to any one of claims 29 to 31, wherein R 1 Selected from the group consisting of: -CH(CH3)2, CF3, phenyl, 33. A compound according to any one of claims 29 to 32, wherein R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein the C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxyl, cyano, C 1-6 Alkyl or -OC 1-3 Alkyl substitution.
34. A compound according to any one of claims 29 to 33, wherein R 2 Select from the group consisting of: C 1-6 Alkyl, C 3-6 Cycloalkyl, aryl and 5-10 membered heteroaryl, wherein the C 1-6 The alkyl and aryl groups may be optionally substituted with hydroxy, cyano, CH3 or -O-CH3.
35. A compound according to any one of claims 29 to 34, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 36. The compound according to any one of claims 29 to 35, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 37. A compound according to any one of claims 29 to 34, wherein R 2 It is C 1-6 Alkyl or aryl, wherein the C 1-6The alkyl and aryl groups are substituted with hydroxy, cyano, CH3 or -O-CH3.
38. A compound according to any one of claims 29 to 34 and 37, wherein R 2 It is C 1-6 Alkyl or phenyl, wherein the C 1-6 The alkyl group or phenyl group is substituted with a hydroxyl group, a cyano group, CH3 or -O-CH3.
39. The compound according to any one of claims 29 to 34, 37 and 38, wherein R 2 Select from the group consisting of:
40. The compound according to any one of claims 29 to 34 and 37 to 39, wherein R 2 Select from the group consisting of:
41. The compound according to any one of claims 29 to 34, wherein R 2 Selected from the group consisting of: CH3, cyclopropyl, -C(H)(CH3)2, -CH2C(CH3)3, phenyl, 42. A compound represented by formula (Ib), or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein: R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution; R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano; m is 0 or 1; and n is 0 or 1.
43. The compound according to claim 42, wherein R 1 It is C 1-6 Alkyl, C 1-3 Haloalkyl or C 3-6 Cycloalkyl, wherein the C 1-6 The alkyl group may be optionally substituted with -O-CH3.
44. The compound according to claim 42 or 43, wherein R 1 Selected from the group consisting of: -CH(CH3)2, CF3, cyclopropyl and 45. A compound according to any one of claims 42 to 44, wherein R 2 is phenyl or wherein the phenyl group is optionally substituted with a cyano group.
46. A compound according to any one of claims 42 to 45, wherein R 2 Selected from the group consisting of: phenyl, 47. A compound according to any one of claims 42 to 45, wherein R 2 yes 48. The compound according to any one of claims 42 to 45 and 47, wherein R 2 yes 49. The compound according to any one of claims 42 to 45, wherein R 2 Selected from the group consisting of: phenyl, 50. The compound of any one of claims 42 to 49, wherein m is 0 and n is 0.
51. The compound of any one of claims 42 to 49, wherein m is 1 and n is 1.
52. A compound represented by formula (Ic), or a stereoisomer thereof and / or a pharmaceutically acceptable salt thereof, wherein: R 1 It is C 1-6 Alkyl or C 1-3 haloalkyl, wherein the C 1-6 The alkyl group may be optionally replaced by -OC 1-3 Alkyl substitution; R 2 is aryl or 5-6 membered heteroaryl, wherein the aryl may be optionally substituted with cyano; R 4 is -C(O)OH or a 5-6 membered heteroaryl; m is 0 or 1; and n is 0 or 1.
53. The compound according to claim 52, wherein R 1 It is C 1-6 Alkyl or C 1-3 haloalkyl, wherein the C 1-6 The alkyl group may be optionally substituted with -O-CH3.
54. The compound according to claim 52 or 53, wherein R 1 CF3 or 55. The compound according to any one of claims 52 to 54, wherein R 2 It is phenyl, wherein the phenyl group is optionally substituted with a cyano group.
56. The compound according to any one of claims 52 to 55, wherein R 2 Selected from the group consisting of: phenyl, 57. A compound according to any one of claims 52 to 55, wherein R 2 yes 58. The compound according to any one of claims 52 to 55 and 57, wherein R 2 yes 59. The compound according to any one of claims 52 to 55, wherein R 2 Selected from the group consisting of: phenyl, 60. The compound of any one of claims 52 to 59, wherein m is 0 and n is 0.
61. The compound according to claim 60, wherein R 4 It is -C(O)OH.
62. The compound of any one of claims 52 to 59, wherein m is 1 and n is 1.
63. The compound according to claim 62, wherein R 4 is -C(O)OH or 64. A compound selected from any of the compounds shown in Table 1 or a pharmaceutically acceptable salt thereof.
65. A pharmaceutical composition comprising a compound according to any one of claims 1 to 64 and a pharmaceutically acceptable carrier.
66. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 64 or a pharmaceutical composition according to claim 65.
67. A method of treating an autoimmune or inflammatory disorder or disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a compound according to any one of claims 1 to 64 or a pharmaceutical composition according to claim 65.
68. The method of claim 67, wherein the autoimmune or inflammatory disorder or disease is selected from the group consisting of acute graft versus host disease, chronic graft versus host disease, lupus, scleroderma, psoriatic arthritis, primary sclerosing cholangitis, rheumatoid arthritis, and inflammatory bowel disease.
